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ABSTRACT 
 
Genetic and Epigenetic Targets in Liver Cancer 
 
Haluk Yüzügüllü 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August, 2010, 143 Pages 
 
     
     
Hepatocellular carcinoma (HCC) kills nearly 600.000 people each year and the 
only effective therapy for this cancer is liver transplantation or tumor ablation only when 
the tumor is small enough. These tumors are surprisingly resistant to conventional 
therapies such as chemotherapy and radiotherapy. Moreover, as HCC is almost always 
associated with cirrhosis, the treatment with cytotoxic agents is dangerous as they will 
also affect hepatic functions of the diseased liver. Therefore, there is urgent need to find 
novel therapeutic approaches against HCC in order to diminish death toll. Our overall 
goal is to discover “druggable target genes” in HCC. In other words, we wish to identify 
novel genes and novel mechanisms involved in these cancers in order to use them as 
potential therapeutic targets.  
During my thesis work, I developed different approaches to find new mechanisms 
and novel targets:   
1- Deciphering the role of canonical Wnt signaling in HCC:  We classified human HCC 
cell lines into "well-differentiated" and "poorly differentiated" subtypes, based on the 
expression of hepatocyte lineage, epithelial and mesenchymal markers. Poorly 
differentiated cell lines lost epithelial and hepatocyte lineage markers, and overexpressed 
mesenchymal markers. Also, they were highly motile and invasive. We compared the 
expression of 45 Wnt pathway genes between two subtypes. Likewise, six Frizzled 
receptors, and canonical Wnt3 ligand were expressed in both subtypes. In contrast, 
canonical ligand Wnt8b and noncanonical ligands Wnt4, Wnt5a, Wnt5b and Wnt7b were 
expressed selectively in well- and poorly differentiated cell lines, respectively. Canonical 
Wnt signaling activity, as tested by a TCF reporter assay was detected in 80% of well-
differentiated, contrary to 14% of poorly differentiated cell lines. TCF activity generated 
by ectopic mutant β-catenin was weak in poorly differentiated SNU449 cell line, 
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suggesting a repressive mechanism. We tested Wnt5a as a candidate antagonist. It 
strongly inhibited canonical Wnt signaling that is activated by mutant β-catenin in HCC 
cell lines. 
2. Systematic screening of protein kinases and phosphatases as potential therapeutic 
targets: There is evidence of aberrant activation of several signaling cascades in HCC, 
and a multikinase inhibitor, sorafenib, has shown survival benefits in patients with 
advanced HCC. We used siRNAs to screen a large number of kinases and phosphatases 
to identify related genes involved in HCC cell survival. A total of 7 kinases and 5 
phosphatases were identified as strong candidate targets. 
3-Screening of a set of selected epigenetic regulators as potential therapeutic targets: 
Recent studies have indicated that senescence arrest or senescence escape could be 
regulated by epigenetic changes on chromatin. We wanted to identify key histone 
methylation and acetylation changes associated with senescence or senescence escape, 
and select key histone modifying enzymes, as potential targets for “pro-senescence” 
interventions (therapeutic interventions that allow senescence induction in cancer cells). 
We identified ATAD2 as an epigenetic target, and found ATAD2 gene overexpressed in 
HCC compared to normal liver.  We also found a stepwise increase of ATAD2 protein 
expression in late stages with respect to pre-neoplastic and early stage during 
hepatocellular carcinogenesis. ATAD2 knockdown using siRNAs in cancer cells leads to 
increase in global histone acetylation and inhibit cell proliferation and induce caspase-3 
dependent apoptosis in HCC and induce senescence in MRC5 cells. Its potentiator role 
(coactivator role with estrogen, androgen and myc targets) indicates ATAD2 as a 
potential therepeutic target for HCC. 
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ÖZET 
 
Karaciğer kanserinde Genetik ve Epigenetik Hedefler 
Haluk Yüzügüllü 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos, 2010, 143 sayfa 
 
 
Karaciğer kanseri en sık rastlanan birincil kanserlerden olup, yılda 600.000 
civarında ölüme sebep olmaktadır. Şu andaki en etkili tedavi yöntemi karaciğer 
transplantasyonudur ve tümör ablasyon yöntemi sadece tümör yeterince küçük ise 
uygulanabilmektedir. Kanserli hücreler kemoterapi ve radyoterapi gibi yöntemlere 
oldukça dayanıklıdırlar. Dahası, karaciğer kanseri sürekli siroz üzerine geliştiği için 
karaciğerin diğer hepatik fonksiyonlarını yerine getirmesini de engellediği için, sitotoksik 
ajanlar kullanmak oldukça tehlikelidir. Bu nedenle karaciğer kanserini yenmek için daha 
yeni ve geçerli terapatik yöntemlere ihtiyac duyulmaktadır.  
Bizim amacımiz karaciğer kanserinde yeni hedeflenebilir genleri keşfetmektir. 
Başka bir değişle, biz bu çalışma ile karaciğer kanserinde yeni hedefler ve yeni 
mekanizmalar keşfederek bunları potansiyel terapötik hedefler olarak kullanmayı 
amaçladık. 
Tez çalışmalarım sırasında, yeni hedefler ve yeni mekanizmalar keşfetmek için 
değişik yöntemler kullanmaya çalıştım:  
1- Karaciğer kanserinde kanonik Wnt sinyallenme yolağının rolü: karaciğer kanserı 
hücrelerini hepatosit spesifik, epitel ve mezenkimal markörler kullanarak “iyi 
diferansiye” ve “kötü diferansiye” hücre hatları olarak iki gruba ayırdık. Kötü 
diferansiye hücre hatlarında epitel ve hepatosit spesifik markörlerin negatif hale 
geldiğini, mezenkimal markörleri anlatmaya başladığını gösterdik. Wnt sinyal 
yolağında görev alan 45 genin, gen anlatım seviyelerini iki grupta inceledik. 6 
Frizzled almaç geninin ve wnt3 ligandının her iki grupta da anlatıldığını 
gösterdik. Kanonik Wnt ligandı wnt8b`nin sadece iyi diferansiye grupta 
anlatıldığını ve Wnt4, Wnt5a, Wnt5b and Wnt7b gibi kanonik olmayan 
ligandların kötü diferansiye gruba spesifik olduğunu gösterdik. Kanonik Wnt 
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sinyallenmesinin sadece iyi diferansiye hücrelerde seçici olarak aktif olduğunu 
değil, aynı zamanda kötü diferansiye tümörlerde de baskılandığını gösterdik. 
Kanonik olmayan hücre hattı, Snu449 da mutant beta-kateninin ektopik 
anlatımının TCF aktivitesini arttıramaması bu gruptaki hücrelerde baskılayıcı bir 
mekanizma olduğuna işaret etti. Kanonik olmayan wnt5a genini aday olarak test 
ettik. Wnt5a geninin mutant beta-kateninin aktive ettiği TCF aktivitesini 
baskıladığını gösterdik. Bazı kanser tiplerinde, APC, Axin ve beta-katenin gibi 
genlerde oluşan mutasyonlarla Wnt-beta-katenin sinyallenmesinin, Wnt 
ligandlarının olmadığı ortamda anormal olarak aktifleşip, beta-kateninin 
sitoplazma ve çekirdekte birikmesine sebep olup hedef genlerin aktivasyonuna 
yol açtığı biliniyor. Bu nedenle beta-kateninin hücre zarı, sitoplazma ve 
çekirdekteki fraksiyonlarını tanıyabilen monoklonal antikorlar üretip, bu 
antikorları kanserli dokularda test ederek klinik değerlerini karakterize ettik.  
2- Kinaz ve fosfataz genlerini potansiyel terapatik hedef olarak sistematik olarak 
taranması: Karaciğer kanserinde değişik sinyallenme yolaklarının aktif hale 
geldiği ve bu hastalarda multikinaz inhibitorü olan sorafenib ilacının, ileri derece 
hastaların ömürlerini uzattığı biliniyor. Bu amaçla yeni hedefler bulmak ve hücre 
yaşlanması indüklenmesi yönünde terapatik hedef gösterebilmek için çok fazla 
sayıda kinaz ve fosfatazları hedef alan RNA müdehalesi yöntemi ile tarama 
gerçekleştirdik. Toplamda 7 kinaz ve 5 fosfataz genini güçlü adaylar olarak 
gösterildi. 
3- Seçilen epigenetik hedeflerin potansiyel terapötik hedef olarak taranması: Yakın 
dönemde yapılan çalışmalar, hücre yaşlanması ve bundan kaçışın kromatin 
üzerindeki epigenetik değişiklikler ile düzenlendiğini gösterdi. Bu amaçla hücre 
yaşlanması ve bundan kaçış ile uyumlu histon asetillenmesi ve metillenmesi 
değişiklikleri tanımladık, bundan sorumlu histon enzimlerini bulup, bunları 
“hücre yaşlanması öncüleyici” hedefler (kanserli hücreleri hücre yaşlanmasına 
götüren) olarak göstermeyi hedefledik. ATAD2 genini epigenetik hedef olarak 
tanımlayıp, karaciğer kanserinde normal hepatositlere göre daha fazla gen ifadesi 
olduğunu gösterdik. ATAD2 proteinin öncü-neoplastik ve ilk aşama karaciğer 
kanserlerine göre ileri aşama kanserlerde kademeli artış olduğu gösterildi. 
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Kanserli hücrelerde siRNA tekniği kullanarak, ATAD2 proteinini azaltıp ve buna 
bağlı global histon asetillenmesinin arttığını, hücre çoğalmasının azaldığını, 
hücreleri apoptoza götürdüğünü ve MRC5 akciğer fibroblastlarında ise hücre 
yaşlanmasını indüklediğini gösterdik. ATAD2 geninin potansiyel artırıcı 
(östrojen, androjen ve myc hedefleri üzerinde) etkisinden dolayı karaciğer 
kanserinde aday terapötik hedef olduğunu işaret etmektedir. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Hepatocellular malignancy 
Hepatocellular carcinoma (HCC) is believed to be originated from either hepatocytes or 
their progenitors. It is the one of the most frequent neoplasms worldwide and causes around 
600,000 deaths per year, and the incidence is steadily increasing in Europe  [1]. More than 80% 
of HCC occur in sub-Saharan Africa and Eastern Asia. The disease incidence is decreasing in 
these areas due to massive Hepatitis B virus (HBV) vaccination and the control of dietary 
aflatoxin intake, whereas it is still increasing in low-rate area including Europe. The increase has 
been associated with hepatitis C virus (HCV) infection. Hepatocellular carcinoma is classified 
into 4 different groups; well, moderately, poorly differentiated and undifferentiated tumors, 
respectively. HCC arises as a well differentiated cancer and continues with a stepwise 
dedifferentiation process. 
Indeed, well-differentiated histology is generally seen in early stage and advanced HCC is 
associated with dedifferentiation. Well-differentiated and moderately differentiated cells are alike 
hepatocytes, and they are smaller in size and they have irregular trabecular or pseudoglandular 
architechtural patterns. Poorly differentiated and undifferentiated HCC cells have scanty 
cytoplasms and pleomorphism [2]. The progenitor cells in HCC like other epithelial tumors 
evolve during tumor progression and become autonomous later. This is observed with changes in 
their morphology and behavior; cuboidal shape and polarity is lost, and become more 
autonomous. Finally, they invade the underlying tissue and form distant metastases. The 
progressive loss phenotypic and biochemical of hepatocytes is defined as "dedifferentiation" [3]. 
Poorly differentiated and undifferentiated HCCs are associated with portal veneous invasion and 
the tumor invasiveness is a crucial factor in determining the long-term clinical outcome for the 
patient [4-5]. 
 
1.2  Aetiological factors of Hepatocellular Carcinoma  
HCC occurs after years of damage to liver with inflammatory conditions resulting with 
chronic hepatitis and/or cirrhosis. This leads to death of hepatocytes and attack of inflammatory 
cells to hepatocytes and connective tissue [6]. The major causes for HCC are: hepatitis B virus 
(HBV), hepatitis C virus (HCV) and chronic exposure to aflatoxinB1 (AFB1) and nearly all 
 2 
cirrhosis inducing factors together are responsible for about 70% - 90% of all HCCs [7-8]. Apart 
from these factors, there are other aetiological factors including long term use of oral 
contraceptives, hereditary haemochromatosis diseases, Non-alcoholic fatty liver disorders 
(NAFLD) and diabetes  [6, 9-11].  
HCC is a slow process, and usually requires between 10-30 years from the initiation step 
to the fully malignant phenotype. This process is co-occurring with damage and death of 
hepatocytes with structurally aberrant chromosomes and genes often as a result of telomerase 
reactivation with marked genomic instability. The alteration of genes and chromosomes are 
irreversible and leads to heterogeneous malignant phenotype. [6]. Chronic inflammation, massive 
cell death and necrosis, fibrosis and cirrhosis, cycles of regeneration, and finally dysplasia and 
HCC occurs [12]. Recent studies indicate that cirrhosis is associated with senescence arrest of 
hepatocytes, from which HCC cells must emerge through the bypass of senescence control [13]. 
 
1.2.1 Viral induced Hepatocarcinogenesis 
The two main hepatitis viruses are hepatitis B virus (HBV) and hepatitis C virus (HCV). 
HBV infects each year around 2 billions individuals, causes 320,000 deaths each year, and 30-
50% of each attributable to HCC. Hepatitis C virus (HCV) infects each year 170,000 individuals, 
20% of which develops cirrhosis [14-15]. HBV is a double stranded DNA virus and a member of 
hepadnaviridae family. HBV can integrate into the host genome and may lead to chromosomal 
instabilities and DNA microdeletions, may target telomerase reverse transcriptase enzyme 
(hTERT) and also encodes a protein so called protein x (HBx) [16-20]. The role of this protein is 
not fully characterized yet. HCV is a positive stranded RNA virus, a member flaviviridae family, 
thus cannot integrate into the genome. HCV is different from the HBV that it may yield a higher 
chronic infection rates and may cause high rates of cirrhosis (5-20%) [21-22].  HCV infected 
hepatocytes can escape from apoptosis by immune cells via using their HCV core protein and non 
structural protein NS5A interacting with TNF-α and IFN-α [23-25]. 
 
1.2.2 Alcohol and cirrhosis 
Chronic alcohol intake or ethanol exposure affect hepatocyte cell signalling pathways that 
regulate chronic hepatocyte destruction–regeneration, stellate cell activation, cirrhosis and 
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eventually HCC [26]. Alcohol damages liver cells and induces oxidative stress which contributes 
to development of fibrosis and cirrhosis and further on HCC itself.  
 
1.2.3 Aflatoxin B1-induced hepatocarcinogenesis 
 AflatoxinB1 (AFB1) was shown to have a well-defined genotoxic effect in 
hepatocarcinogenesis. Consumption of food contaminated with aflatoxins, toxic metabolites of 
some species of Aspergillus fungi, is a specific mutagen. Aflatoxin is metabolized specifically in 
liver to aflatoxin B1-8,9-epoxide, a toxic product that induces a G to T mutation of the p53 gene 
at codon 249 [27-28]. Aflatoxin B1 exposure coexisting with HBV infection, increases the risk of 
HCC to a 5–10-fold compared with exposure to only one of these factors [29]. 
 
1.3 Genetic and epigenetic events in HCC 
HCC is a multistep process going through rounds of hepatocyte turnover due to damage 
and regeneration because of the aetiological factors as stated earlier [5]. This multistep process 
includes chronic liver injury that produces inflammation, cell death, cirrhosis and regeneration, 
DNA damage, dysplasia, and finally well differentiated to poorly differentiated HCC (figure 1.1). 
Telomere shortening is accompanied starting with chronic liver disease and cirrhosis, followed by 
genomic instability and telomerase reactivation and occasionally structural aberrations in genes 
and chromosomes. During this multistep process, a number of molecular alterations must occur, 
but only a limited number of is known currently. These aberrations can be listed as tumor 
suppressor genes and oncogenes including TP53, β-catenin, ErbB receptor family members, MET 
and its ligand hepatocyte growth factor (HGF), p16(INK4a), E-cadherin. Alterations in 
microRNA expression may also be implicated in hepatocellular carcinogenesis [30-32]. The table 
showing the mutation types and rates of tumor suppressors and oncogenes are listed in the table 
1.1.  
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Figure 1.1: Multistage processes of hepatocarcinogenesis [8, 13] (modified from ref.  8 and 13). 
 
Table 1.1:  Mutations in tumor suppressor genes and oncogenes in HCC 
Genes Mutation Rates References 
p53 28-50% [33-34] 
M6P/IGF2R 25-55% [35-36] 
β-catenin 18-41% [37-38] 
p16 10% [39] 
Axin1&Axin2 5-10% [40] 
Smad2&Smad4 3-6% [41] 
BRCA2 5% [42] 
Rb rare [43] 
Ras rare [44] 
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Recent advances showed that liver cancer cells harbor aberrant epigenetic abnormalities, 
suggesting that together with genetic events, epigenetics promote cancer progression. For 
instance, the CDKN2A gene encoding p16Ink4a and ARF proteins are not mutated whereas they 
are epigenetically silenced. More than 50% of HCCs display de novo methylation of the promoter 
of CDKN2A gene, resulting in loss of gene expression [13, 45]. Epigenetic mechanisms also 
contribute to strong expression of genes like TGF-α and IGF-2, promoting of growth of 
hepatocytes during hepatocarcinogenesis [46] . 
Characterization of events involved in HCC dedifferentiation and invasiveness are ill 
known. Hepatocyte nuclear factors and E-cadherin of epithelial markers were downregulated in 
HCC [3, 47] and this is associated with tumor invasion and metastasis. In contrast, HCC 
invasiveness and/or metastasis are positive for mesenchymal markers such as snail [48], twist 
[49] and vimentin [50]. These changes represent the epithelial-mesenchymal transition (EMT) in 
HCC, as shown by in vitro studies [51-56]. Terminally differentiated hepatocytes express 
hepatocyte nuclear factor-4α (Hnf-4α) [57-58], and its expression is downregulated during HCC 
progression in mice [59]. This process is characterized by accumulation of genetic events like  
chromosomal gains and losses, as well as p53 mutations [6] and identified as dedifferentiation. A 
rare exception to this picture is the CTNNB1 gene that encodes β-catenin, a key component of 
the Wnt/β-catenin (canonical Wnt) signaling pathway. 
 
1.4 Role of β-catenin In HCC 
In the presence of wnt/canonical signaling ligands, these ligands binds to Frizzled 
receptor, disheveled is recruited to membrane and inhibits the GSK3b kinase and β-catenin is no 
longer phosphorylated and accumulated inside the cytoplasm and is translocated to nucleus, 
further activating several targets including MYC, cyclin-D1 and MMP7 (figure 1.2) [60]. 
β-catenin mutations were found to be associated with a subset of low grade (well-
differentiated) HCCs with good prognosis and chromosome stability [40, 61-65]. Among 366 
HCCs studied by Hsu et al., β-catenin mutations were associated with grade I histology. Another 
 6 
 
 
Figure 1.2: Overview of the canonical Wnt signaling pathway, (Modified from ref. 60) A) In the absence of Wnt 
ligands, the cytoplasmic  β-catenin is degraded in the destruction complex, composed of APC, axin/conductin, and 
GSK-3β. First, β-catenin is phosphorylated on Ser 45 residue by CKIα (priming), primed  β-catenin is further 
phosphorylated at Thr 41, Ser 37, and Ser 33 residues by GSK-3β. Phosphorylation of these amino acids triggers 
ubiquitination of β-catenin by β-TrCP and degradation in proteasomes. Therefore, the cytoplasmic level of  β-catenin 
is kept low in  the absence of Wnt. The LEF/TCFs cannot activate the target genes without β-catenin. The WIF-1, 
sFRP, and/or Dkk can inhibit the Wnt signaling by binding to Wnt ligands or LRP5/6. B) In the presence of Wnt, a) 
Wnt signaling triggers CKIε-dependent phosphorylation of Dvl (Dsh) and enhances the binding of Dvl (Dsh) to Frat-
1. Frat-1 binds to GSK-3β in the Axin complex, resulting in a reduction of the phosphorylation of β-catenin by GSK-
3β; or b) Wnt triggers the phosphorylation of LRP6 by CK1γ and GSK3β, which provides a docking site for Axin 
and recruits it to the plasma membrane. Wnt also enhances the binding of Dvl (Dsh) to Frizzled, and Dvl (Dsh) 
bound to Frizzled is necessary for the formation of a complex between Axin and LRP6, resulting in reduced 
phosphorylation of β-catenin and Axin by GSK3β. Therefore, β-catenin escapes from phosphorylation and 
subsequent ubiquitination, and accumulates in the cytoplasm. The accumulated cytoplasmic β-catenin goes into the 
nucleus, where it binds to LEF/TCFs and activates the transcription of target genes 
 
study with similarly high number of tumors (n = 372) also showed that mutant nuclear β-catenin 
is associated with non-invasive tumor and but not with portal vein tumor thrombi [63]. In 
addition, β-catenin mutations were associated with good survival rates. Study of canonical Wnt 
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signaling activity in primary tumors is possible indirectly by using target genes [62]. For 
instance, using glutamine synthetase (encoded by canonical Wnt signaling target GLUL gene) as 
a marker for canonical Wnt signal activity, Audard et al. showed that 36% HCCs displayed 
canonical Wnt activation. These tumors are compatible with well-differentiated morphology. The 
association of β-catenin mutation and nuclear translocation with well-differentiated tumor grade 
was also reported using several transgenic mouse models of HCC [62, 66]. Liver tumors from c-
myc and c-myc/TGF-β1 transgenic mice showed activated beta-catenin. However, it was very 
rare with faster growing and histologically more aggressive HCCs in the same model. Thus 
nuclear translocation of β-catenin and activation of canonical Wnt signaling are early events 
mostly affecting well-differentiated HCCs. 
Mutations of β-catenin gene were initially identified in colorectal cancers, leading to 
aberrant β-catenin protein accumulation and constitutive activation of canonical Wnt signaling. 
APC gene mutations in colorectal cancer and AXIN1 in HCC also activate canonical Wnt 
signaling by β-catenin protein accumulation. Therefore, both β-catenin, APC or AXIN1 
mutations are considered to display active or constitutive canonical Wnt signalling [67]. Only a 
subset of HCC is associated with activated of canonical Wnt signaling as opposed to colorectal 
cancers. Interestingly, oncogenic β-catenin expressing transgenic mice develop only 
hepatomegaly [68-69], in contrast to intestinal polyposis and microadenoma in intestinal cells 
[70]. 
Taken together, Wnt pathway and β-catenin mutations may play a dual role in HCC, both 
in the initiation of HCC by close association of β-catenin mutation with well differentiated HCC 
and later stages as well [5].  
 
1.4.1 Structure of beta-catenin protein and interaction partners 
The protein β-catenin has a dual role; one in the establishment and maintenance of cell–
cell adhesion at adherens junctions, and the other in the regulation of gene expression through 
Wnt signaling [71-72]. Both of these roles are conserved throughout evolution [73]. The protein 
is composed of short N-terminal, C-terminal domains interrupted with central core domain 
consisting of 12 armadillo repeats (Figure 1.3). Both structural and signal regulatory roles are 
associated with all three domains [74]. β-catenin need partners to perform its function. α-catenin 
[75-76] and βTrCP [77] are the main partners binding at N-terminal domain. The α-catenin 
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binding, together with E-cadherin binding to the central core domain is required for adhesion role 
of β-catenin [78]. The BTrCP binding is necessary for its subsequent degradation of β-catenin 
after phosphorylation of specific sites at the same N-terminal domain by glycogen synthase 
kinase 3 beta (GSK-3β). This phosphorylation event is facilitated by a multiprotein complex 
including Axin which bind to β-catenin through armadillo repeat domain [74, 79], and (APC). 
The presence of Wnt ligands or active Wnt signalling efficiently decreases the destruction of β-
catenin via inhibition of GSK-3β. LEF/TCF factors (TCF) bind to the armadillo repeat domain 
for its function in transcriptional activation of Wnt target genes. ICAT and Chibby proteins for 
inhibitory roles compete with TCF for binding to the same core domain [80-81]. 
 
Figure 1.3 Schematic view of β-catenin protein domains, principal interacting proteins and monoclonal 
antibody epitopes [Yuzugullu et al, unpublished data]. 
 
The C-terminal domain of β-catenin has not been of great interest until recently. This 
acidic tail is the primary transactivation domain and TBP, CBP and p300 [82], as well as Teashirt 
[83], Chibby [80] are all associated through this domain. The C-terminal domain, together with 
the last three armadillo repeats of the core domain has been recently involved in nuclear import-
export of the β-catenin protein [84]. Indeed the last 70 amino acids of β-catenin appear to play a 
crucial role in cytonuclear shuttling of β-catenin [85]. A relatively new and interesting aspect of 
the C-terminal domain of β-catenin is its interaction with a growing list of PSD95/DlgA/ZO-1 
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homology (PDZ)-interaction domain proteins. The PDZ domain is a specific protein-interaction 
module with an interaction ‘pocket’ that can be filled by a PDZ motif ‘ligand’. The PDZ motifs 
are consensus sequences that usually located at the extreme intracellular carboxyl terminus. The 
last 4 amino acids of β-catenin (DTDL) which is highly conserved among all metezoans 
excluding C. elagans [73] is a consensus PDZ motif D(S/T)XL (X denotes any residue) [86]. 
Proteins bind to these PDZ motifs and thus can target directly or indirectly, cluster and cycle the 
receptors, ion channels as well as transporters. PDZ proteins can link the signaling pathways and 
different components. Such roles implicate their role in many diseases. They control the pre- and 
post synaptic proteins in neurotransmission and plasticity. At the synapse, PDZ proteins have a 
role in neurotransmitter vesicle docking and receptor cycling. Cell movements, migration, 
polarity, and neighbouring cell interactions, as well as cell phenotypes including morphology are 
controlled with PDZ machinery. Beta-catenin interacts with several PDZ proteins including 
synaptic scaffolding molecule (S-SCAM; [87-90], its non-neuronal isoform called membrane-
associated guanylate kinase with inverted domain organization-1 (MAGI-1; [91], Na+/H+ 
exchanger regulatory factor-1/EBP50  (NHERF-1; [92-93] and NHERF-2; [94], Tax-1 interacting 
protein (TIP-1; [95-96], LIN-7 [97]. 
Cadherins and catenins play important roles in synapse assembly. The PDZ domain of β-
catenin is involved in the localization of a reserved pool of synaptic vesicles [98]. If beta-catenin 
is lost in hippocampal pyramidal neurons, this leads to misregulation of response in response to 
prolonged repetitive stimulation and a corresponding decrease of vesicles. Beta-catenin 
modulation of vesicle localization is mediated by its PDZ binding domain [99]. Epithelial and 
neuronal beta-catenin interacts with LIN-7 PDZ proteins. This event is Ca2+ dependent and is 
mediated direct linking of LIN-7 to the C-terminal beta-catenin PDZ target sequence. Therefore it 
is ensured that LIN-7 is relocated to the junctions via beta-catenin and is a specific event. 
Moreover, when LIN-7 is present at the beta-catenin-containing junctions, it determines the 
accumulation of binding partners, thus suggesting the mechanism by which beta-catenin mediates 
the organization of the junctional domain [97]. Functional studies showed that in mouse 
embryonic fibroblasts, NHERF1 associates directly via PDZ2 domain with beta-catenin and is 
required for beta-catenin localization at the cell-cell junctions. NHERF1 inhibits cell motility and 
is required to suppress anchorage-independent growth. Thus, NHERF1 appears to be a cofactor 
with an essential role in the integrity of epithelial tissues by maintaining the proper localization 
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and complex assembly of β-catenin [93]. NHERF-2 links the N cadherin/catenin complex to the 
platelet-derived growth factor receptor to modulate the actin cytoskeleton and regulate cell 
motility [94].  In brain, being a multi-PDZ domain scaffolding protein, S-SCAM, binds and 
interacts with several different ligands including PTEN (phosphatase and tensin homolog), 
dendrin, axin, beta- and delta-catenin, dasm1 (dendrite arborization and synapse maturation 1), 
neuroligin, hyperpolarization-activated cation channels, beta1-adrenergic receptors, and NMDA 
receptors [100]. MAGI-1, presumably through its association with β-catenin, is required for Rap1 
activation upon cell-cell contact and for enhancement of vascular endothelial cadherin-mediated 
cell adhesion [101]. TIP-1 binding to β-catenin inhibits its transcriptional activity and the 
overexpression of TIP-1 results in reduced proliferative capacity of colorectal cancer cells [95], 
suggesting an important role for TIP-1 interaction with the PDZ motif of β-catenin in the control 
of Wnt/β-catenin signaling. Interaction of the C-terminal domain of beta-catenin with PDZ 
domain-containing proteins is required to shape axon arbors of retinal ganglion cells [102].  
 
1.5  Protein Kinase and Phosphatase Genes 
In eukaryotic cells, signal transduction is mediated by protein kinases and phosphatases; 
by remodifying substrate activity. Protein kinases are among the largest families of genes in 
eukaryotes constituting about 2-2,5 % of the genome [103-104] and have been intensively 
studied. Cell metabolism, transcription, cell cycle progression, apoptosis, differentiation, 
cytoskeletal rearrangement, invasion and cell movement are controlled by protein kinases. 
Protein kinases are also implicated in critical regulation of cellular communication during 
development.  
A total of 518 kinase genes are indentified so far [105] classified into 8 distinct classes, Table 
1.2.  
 
Table 1.2 Kinase distribution by major groups in human and model systems (modified from [105]) 
Group Families Subfamilies Yeast 
kinases 
Worm 
kinases 
Fly 
kinases 
Human 
kinases 
Human 
pseudogenes 
Novel 
human 
kinases 
AGC 14 21 17 30 30 63 6 7 
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CAMK 17 33 21 46 32 74 39 10 
CK1 3 5 4 85 10 12 5 2 
CMGC 8 24 21 49 33 61 12 3 
Other 37 39 38 67 45 83 21 23 
STE 3 13 14 25 18 47 6 4 
Tyrosine 
kinase 
30 30 0 90 32 90 5 5 
Tyrosine 
kinase-like 
7 13 0 15 17 43 6 5 
RGC 1 1 0 27 6 5 3 0 
Atypical-
PDHK 
1 1 2 1 1 5 0 0 
Atypical-
Alpha 
1 2 0 4 1 6 0 0 
Atypical-
RIO 
1 3 2 3 3 3 1 2 
Atypical-
A6 
1 1 1 2 1 2 2 0 
Atypical-
Other 
7 7 2 1 2 9 0 4 
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Atypical-
ABC1 
1 1 3 3 3 5 0 5 
Atypical-
BRD 
1 1 0 1 1 4 0 1 
Atypical-
PIKK 
1 6 5 5 5 6 0 0 
Total 134 201 130 454 240 518 106 71 
 
 
Phosphatases act in reverse functions with kinases, remove the phosphate groups from 
phosphorylated proteins and thus phosphorylation and dephosphorylation depend on the highly 
regulated and opposing actions of kinases and phosphatases acting on the same substrate. 
Phosphatases are also classified into distinct classes depending on the substrate specificity (table 
1.3).  
 
Table 1.3.  Phosphatase distribution by major groups in human and model systems(modified from [106-110]) 
Class Substrate Reference 
Tyrosine-specific phosphatases Phospho-Tyrosine [106] 
Serine/Threonine specific phosphatases Phospho-Serine/Threonine [107] 
Dual Specificity Phosphatases Phospho-Tyrosine/Serine/Threonine [108] 
Histidine Phosphatase Phospho-Histidine [109] 
Lipid Phosphatase Phosphatidyl-Inositol-3,4,5-Triphosphate [110] 
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1.5.1 Role of Kinases and Phosphatases in cancer 
Certain classes of signalling proteins and pathways are targeted much more frequently by 
oncogenic mutations than other genes [111]. Thus, as being enzymes governing extracellular 
growth, differentiation and developmental signals, mutations and dysregulation of protein kinases 
and phosphatases play causal roles in several human disease including cancer as well [112-113].  
 
1.5.2 Role of Kinases and Phosphatases in liver cancer 
Activation of phosphoinositide 3-kinases (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) signaling pathway in HCC occurs between 30–50% of all cases and related to poor 
prognosis [114]. Active signalling is due to aberrant activation of tyrosine kinase receptor EGFR, 
IGF1R, MET, VEGFR, PDGFR or through constitutive activation of PI3K due to loss of function 
of PTEN. Loss of heterozygosity in PTEN locus (i.e. 10q) is frequent in HCC and mutation rates 
are fairly low in HCC, ranging from 0 to 11% [115]. Raf/Ras/Erk pathway is generally activated 
in advanced stages of liver cancer, due to upstream signalling from EGF, HGF or IGF signals 
[116]. These informations are incomplete and fragmentary. Indeed, a systematic analysis of 
protein kinases and phosphatases in HCC is lacking. There has also been no report of systematic 
analysis of the effects of systematic inactivation of kinases and phosphatases in these cancers.  
 
1.6 Role of H19/IGF2 locus in HCC 
The non-coding gene H19 and IGF2 genes are co-located in the same locus and are under 
the control of genomic imprinting, which leads to reciprocal monoallelic expression of H19 from 
the maternal allele and IGF2 from the paternal allele [117]. Loss of imprinting is observed for 
both H19 and IGF2. Moreover, H19 is highly expressed in liver cancer and has been shown to 
behave like an oncogene for liver cancer and it is essential for tumor cell growth [118]. Several 
studies showed that IGF-II is overexpressed in human HCCs and in some premalignant lesions 
[119-121] and this is correlated with loss of imprinting [122]. 
 
1.7 Senescence of hepatocytes and chronic liver disease 
Liver cirrhosis, the irreversible terminal stage of chronic liver disease characterized by 
fibrous scarring, is a major cause of morbidity and mortality worldwide, with no effective 
therapy. Complications such as accumulation of ascites, bleeding, and portal hypertension are 
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frequent in patients with cirrhosis. The only effective therapy for cirrhosis is organ 
transplantation. 
Normal hepatocytes in the adult liver are quiescent, they are renewed slowly, 
approximately once a year, as estimated by telomere loss which is 50–120 bp per year in healthy 
individuals [123-124]. However, as well as animal models chronic liver diseases showed that, 
liver has enormous regenerative capacity [125]. Exposure to viral and non viral damaging agents 
or as shown in partial hepatectomy, mature hepatocytes proliferates enormously and this process 
is so called regenerative capacity of liver. In addition, hepatocyte-progenitor cells are induced to 
restore liver hepatocyte populations [126]. However, hepatocytes, since they do not have 
telomerase activity, like other somatic cells, they cannot avoid telomere shortening during rounds 
of cell divisions. For this reason, liver cirrhosis is associated with decreased hepatoycte 
proliferation [127], is now considered to be a result of senescence arrest [13].  
Cellular senescence is a permanent arrest of the cell cycle in response to diverse stress 
conditions such as dysfunctional telomeres, DNA damage, strong mitotic signals and disrupted 
chromatin (figure 1.4). Senescence, a strong anti-cancer mechanism is regulated by p53-
retinoblastoma pathway and involves the activation of p21Cip1, p16Ink4a and p15Ink4b cyclin-
dependent kinase (CDK) inhibitors [128]. Frequent inactivation of TP53 and CDKN2A genes, 
together with frequent upregulation of telomerase reverse transcriptase (TERT) strongly suggest 
that HCC tumor cells may bypass senescence to become immortalized [13].  Nevertheless, the 
detection of senescent cells in nearly 50% of HCC tumors provides evidence for the capacity of 
HCC cells to undergo senescence arrest under appropriate conditions [129]. Immortal HCC cell 
lines can spontaneously generate progeny that undergo replicative senescence [130]. Murine 
HCC tumors generated by the expression of a mutant Ras gene in p53-deficient hepatoblasts can 
be cleared by a massive senescence response upon reactivation of p53 expression [131-132]; and 
c-myc oncogene inactivation in murine HCCs results in senescence-mediated tumor regression  
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Fig. 1.4  DNA damage and p53 activation play a central role in different senescence pathways DNA damage 
(often in the form of double-strand breaks) activate upstream kinases (ATM and ATR) leading to p53 
phosphorylation by CHK1 and CHK2 kinases. Phosphorylated p53 is released from MDM, and stabilized in order to 
induce senescence arrest or apoptosis (not shown here). (Modified from [13]). 
 
1.8 Histone modifications 
Major histone modifications include DNA methylation, covalent modifications of histones 
and repositioning of histones. Among these three, we started to understand the role of post-
translational modifications of histones recently compared to DNA methylation. 
Chromatin consists of repeating units of nucleosomes and the nucleosome consists of 146bp 
DNA wrapped to an octamer of four histone proteins (H3, H4, H2A and H2B). Basically, the 
protruding N-terminal ends of histone proteins are covalently modified by eight distinct types of 
mechanisms. Acetylations, methylation of lysines and arginines, phosphorylation, ubiquitylation, 
sumoylation, ADP ribosylation and proline isomeration are the eight major histone modifications 
and dictate the complexicity of regulation and biological roles. These covalent modifications 
work together to dictate and regulate the functioning of genome and change the local structure of 
the chromatin and in chromatin compaction, transcription regulation, DNA repair and replication, 
thus eventually contributes to genome to manifest itself as different phenotypes in differantiation 
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as well as diseases like cancer. To sum up, we can call these modifications as ‘histone codes’, a 
complicated code written by histone modifying enzymes and read by histone binding proteins. 
The complexity of code comes not only from different numbers of histone modifications reaching 
as high as 70 but also degree of modification (methylation at lysines or arginines may be one of 
three different forms: mono-, di-, or trimethyl for lysines and mono- or di- (asymmetric or 
symmetric) for arginines [133]  and cross-talk between these codes [134]. The function of each 
code is difficult to understand and only recently we started to understand the biological functions. 
Modifications like lysine acetylation may affect the chromatin structure by neutralizing the basic 
negative charge of lysines and causing a permissive chromatin conformation for transcription to 
start. Phosphorylation is another way of changing the charge of chromatin thus leading to 
important consequences like mitosis and apoptosis [135-136]. Lysine methylation, in contrast to 
lysine acetylation has a different meaning depending on which lysine residues being methylated. 
This is because of the fact that histone methyl transferases have substrate specificity compared to 
histone acetyltransferases. The complexes in which enzymes are found [137], proteins associating 
with the enzymes of residue to modify [138], and the degree of methylation (mono-, di-, or tri-) 
[139] are the factors for residue specificity and thus biological roles. For instance, trimethylation 
of Histone 3 lysine 4 (H3K4Me3) on gene promoters means transcriptional activation, 
trimethylation of H3 lysine 36 (H3K36Me3) on gene coding region and histone 3 lysine 79 
trimethylation (H3K79Me3) means transcriptional activation [140-141],  whereas trimethylation 
of histone 3 lysine 9 (H3K9Me3) and lysine27 (H3K27Me3) on gene promoters means 
transcriptional repression [134]. After these codes are written by histone modifying enzymes, 
these codes are read by proteins that are recruited to these specific modifications and that have 
binding domains suitable for these histone marks. For example, methylation is recognized by 
chromo-like domains of the Royal family (chromo, tudor, MBT) and nonrelated PHD domains, 
acetylation is recognized by bromodomains, and phosphorylation is recognized by a domain 
within 14-3-3 proteins (figure 1.5). 
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Figure 1.5 Recruitment of proteins to histones (modified from [134])  
 
The dynamic and reversible modifications of each histone residue are regulated by 
specific enzymes. Histone acetyltransferases (HATs) add acetyl groups and histone deacetylases 
(HDACs) removes these and histone methyltransferases (HMTs) transfers methyl groups and 
histone demethylases (HDMs) reverses this [142-143]. The list of each type of enzymes is listed 
in table 1.4. 
 
Table 1.4 Histone modifying enzymes and residues (modified from [134]) 
Enzymes that Modify 
Histones Residues Modified  
Acetyltransferase Lysine Methyltransferase 
HAT1 H4 (K5, K12) SUV39H1 H3K9 
CBP/P300 H3 (K14, K18) H4 (K5, K8) H2A (K5) H2B (K12, K15) SUV39H2 H3K9 
PCAF/GCN5 H3 (K9, K14, K18) G9a H3K9 
TIP60 H4 (K5, K8, K12, K16) H3 K14 ESET/SETDB1 H3K9 
HB01 (ScESA1, SpMST1) H4 (K5, K8, K12) EuHMTase/GLP H3K9 
ScSAS3 H3 (K14, K23) CLL8 H3K9 
ScSAS2 (SpMST2) H4 K16 SpClr4 H3K9 
ScRTT109 H3 K56 MLL1 H3K4 
Deacetylases MLL2 H3K4 
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SirT2 (ScSir2) H4 K16 MLL3 H3K4 
Lysine Demethylases 
MLL4 H3K4 
LSD1/BHC110 H3K4 MLL5 H3K4 
JHDM1a H3K36 SET1A H3K4 
JHDM1b H3K36 SET1B H3K4 
JHDM2a H3K9 ASH1 H3K4 
JHDM2b H3K9 Sc/Sp SET1 H3K4 
JMJD2A/JHDM3A H3K9, H3K36 
SET2  
(Sc/Sp SET2) H3K36 
JMJD2B H3K9 NSD1 H3K36 
JMJD2C/GASC1 H3K9, H3K36 SYMD2 H3K36 
JMJD2D H3K9 DOT1 H3K79 
JMJD6 H3R2, H4R3 H3K9 H3K79 
Arginine Methlytransferases Residues Modified Pr-SET 7/8 H4K20 
CARM1 H3(R2,R17,R26) SUV4 20H1 H4K20 
PRMT4 H4R3 SUV420H2 H4K20 
PRMT5 H3R8,H4R3 PRMT5 H4K20 
Serine/Threonine Kinases Residues Modified EZH2 H3K27 
Haspin H3T3 RIZ1 H3K9 
MSK1 H3S28 Ubiquitilases 
MSK2 H3S28 Bmi/Ring1A H2AK119 
CKII H4S1 RNF20/RNF40 H2BK120 
Mst1 H2BS14 
 
1.8.1 Histone modifications in HCC and other cancers 
High-throughput sequencing technologies (Chip-seq) have enabled to elucidate the roles 
and characterization of histone modifications and aberrations in enzymes in diseases and 
tumorigenesis as well. Fraga et al, showed that global loss of acetylated H4-lysine 16 (H4K16Ac) 
and trimethylated H4-lysine 20 is a hallmark of human cancer including breast and liver cancer 
(H4K20Me3) [133]. HDACs are often overexpressed in various types of cancers including 
prostate and gastric tumors including liver cancer and there are drugs targeting HDACs under 
clinical trials   [144-146]. Abnormal HAT activities are also observed in cancers, viral oncogene 
proteins such as E1A target CBP/P300 and disrupt their interaction with PCAF [147]. In 
leukemia, HAT and HAT related enzymes are reported to make fusion proteins [148]. Aberrant 
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alterations in methylation of H3K9 and H3K7 in cancer are also reported [149-150]. EZH2 is a 
histone methyl transferase acting on H3K27 residue is overexpressed in breast, prostate and liver 
cancers [149, 151]. Another histone methyltransferase acting on H3K9, G9a is associated with 
liver cancer [152]. MLL gene, acting on H3K4 is frequently makes fusion proteins with Hox 
genes and involves in leukemia [153]. Histone demethylases are also upregulated in prostate 
cancer and involved in tumorigenesis [142]. 
 
1.8.2 H3K4 methylation  
Trithroax (Trx-G) group proteins are involved in H3K4 methylation and evolutionary 
conserved from flies to mammals. They are involved in epigenetic activation of homeodomain 
genes, whereas Polycomb repressor group (PcG) proteins mediate their silencing. These two 
antagonistic groups of proteins control important aspects of differentiation and proliferation 
[154].   
 
1.8.2.1 MLL and SMYD3 – H3K4 methyltransferases 
The mixed lineage leukemia (MLL) protein, SET domain containing H3K4 
methyltransferase and activates of Hox gene expression during development. MLL and Hox 
genes frequently make fusion proteins, and involves in Leukemia [153]. SET- and MYND-
domain-containing protein 3 (SMYD3), methyltransferase of H3K4, is found to be upregulated in 
colorectal and hepatocellular carcinoma cell lines and enhances cell growth and promotes 
transformation, whereas its inhibition represses cell growth in cancer cell lines [155]. 
 
1.8.3  H3K9 Methylation 
Histone H3 lysine 9 (H3K9) methylation is recognized by HP1 and involves in 
heterochromatin formation and correlates with gene silencing in a variety of organisms. 
SUV39H1 and SUV39H2, mammalian homologues of Drosophila SU (VAR)3–9, are SET 
domain containing Histone methyltransferases acting on H3K9 residues. 
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1.8.3.1    SUV39H H3K9 methyltransferases 
Single knockouts of SUV39H1-/- and SUV39H2 -/- mice are viable with no clear 
phenotype, however double knockout of both enzymes exhibit phenotypes. They show marked 
chromosomal instability, contributing to B-cell lymphoma, compromised viability. Correlating 
with their methyltransferase roles, reduction of H3K9Me2 and H3K9Me3 is observed with 
tumorigenic events that are: chromosomal abnormalities mainly mis-segregation, abnormally 
long telomeres and perturbration of Heterochromatin Protein 1 (HP1) binding at pericentric 
heterochromatin and telomeres [156]. SUV39H1 and HP1 interact with pRb to mediate gene 
silencing of Rb targets [157]. SUV39H1 also prevents Ras-induced tumorigenesis by promoting 
senescence [158]. No SUV39H1 mutations have been reported in human cancers yet.  
 
1.8.4 H3K27 methylation  
Polycomb group (PcG) proteins that are initially genetically defined in Drosophila 
melanogaster are the main complex acting on H3K27 methylation. There are two polycomb 
repressor complexes (PRC1 and PRC2). Consisting of BMI-1, Ring-1, HPH and HPC, PRC1 
recognizes trimethylates H3K27 and mediates the maintenance of the silent state. PRC2, consists 
of enhancer of zeste homologue 2 (EZH2), suppressor of zeste 12 (SUV12) and embryonic 
ectoderm development (EED), instantiates gene repression with interacting partners like HDACs 
and DNA methyltransferases (DNMTs) [159].  
 
1.8.4.1   EZH2 and JMJD3 enzymes 
EZH2 is a histone methyl transferase acting on H3K27 residue is overexpressed in breast, 
prostate, colorectal carcinoma, bladder cancer, multiple myeloma and liver cancers [149, 151]. It 
plays essential roles in embryonic development and stem cell renewal  [159]. EZH2 protein 
interacting with DNMTs to EZH2 target gene promoters suggests that EZH2 involves in silencing 
of tumor-suppressor genes during cancer cell evolution [160]. A Jumonji C family histone 3 
lysine-27 (H3K27) demethylase, Jmjd3, plays a crucial role in development and macrophage 
plasticity and inflammation [161] The role of JMJD3 in human cancer is not clear yet. 
 21 
 
1.8.5 H3K36 methylation  
H3K36Me3 is found on the 3` end of elongated transcripts and implicated in transcription 
elongation. In budding yeast, it is found in at the 3` end of active genes and associated with RNA 
pol II, and found to have a role suppression of internal erroneous transcripts by recruiting 
complexes involving histone deactylase [162-163].    
 
1.8.5.1 SETD2 methyltransferases 
SETD2, histone methyltransferase gene acting on H3K36, is nonredundantly responsible 
for trimethylation of the histone mark H3K36. loss of H3K36me3 is found in 7 out of the 10 
cleared renal cell carcinoma cell lines and missense mutations of SETD2 is found in 2 out of 10 
primary cRCC [164]. SETD2 also associates with TP53 protein and Overexpression of SETD2 
upregulated the expression levels of a subset of p53 targets including puma, noxa, p53AIP1, fas, 
p21, tsp1, huntingtin, but downregulated that of hdm2 [165]. 
 
1.8.5.2 FBXL11 Histone demethylases 
The FBXL11, also named JHDM1A (CWYD domain-containing histone demethylase 1A) 
or KDM2A was discovered in 2006 as an enzyme catalyzing preferably in the demethylation of 
histone H3 lysine-dimethyl-36 in monomethyl-lysine [166]. In contrast to its orthologue 
(FBXL10/JHDM1B/KDM2B), the FBXL11 is apparently specific to the residue histone 3 lysine-
36 (H3K36) [167]. Knockdown of its orthologue, FBXL10, in primary mouse embryonic 
fibroblasts inhibits cell proliferation and induces cellular senescence in a pRb- and p53 pathway-
dependent manner [166]. 
 
1.8.6 H4K20 Methylation 
Recent articles using mass spectrometry in human and in Drosophila melanogaster cells 
showed that the dimethylation of H4K20 is abundant, and H4K20me1 and H4K20me3 are 
relatively few in abundance. H4K20 methylation status also changes dynamically during the cell 
cycle and, notably, 98% of newly synthesized histone H4 becomes dimethylated within a few cell 
cycles [168]. Each methylation state for this residue has distinct functions. H4K20me2 involves 
in DNA repair and serves as a binding site for 53BP1 [169-170]. H4K20me1 has a role in 
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transcription and located on active genes [171-172]. H4K20Me3 is involved in pericentromeric 
heterochromatin formation and loss of trimethylation together with H4K16 acetylation is 
implicated in human cancer [133, 173]. Thus, there is a dynamic change in H4K20 methylation 
status. There has been no histone demethylation enzyme found acting on this residue. 
 
1.8.6.1    Suv420H1 methyltransferase 
Together with SUV39H1/2 and SUV420H1/2 enzymes have emerged as a hallmark of 
pericentric heterochromatin [174]. The loss of trimethylation of H4K20 in human cancer would 
suggest that the role of SUV420H1/H2 enzyme as a tumor suppressor role because controlled 
chromatin organization is crucial for gene expression regulation and genome stability.  
 
1.9 DNA Methylation 
 DNMT3a and DNMT3b are de novo DNA methyltransferases responsible for methylation 
of 5` cytosine of CpG dinucleotides within the genome. DNMT1a is the other enzyme 
responsible for maintaining DNA methylation using the hemimethylated DNA as the substrate. 
These methylated DNAs are generally associated with silenced genes and condensed chromatin 
[175]. These methylation sites serve as docking site for silencing proteins.  
  One of the best examples of these silencing proteins is the DNA methyl binding protein, 
the MeCP2 (methyl-CpG binding protein) specifically recognize methylated cytosine residues. 
They recruit histone deacetylases (HDACS) to silence these genes. MeCP2 gene mutations are 
responsible for 95% of Rett syndrome [176]. 
 
1.9.1 DNA Methylation and cancer 
CpG dinucleotides are generally methylated in a normal cell, except in front of many 
active genes. Cancer cells display global hypomethylation and a hypermethylation of CpG islands 
[177]. Loss of DNA methylation is associated with activation of proto-oncogenes like c-jun, c-
MYC as well as H-Ras and also responsible for genomic instability. On the other hand, 
methylation of CpG dinucleotides is associated with silencing of tumor suppressor genes. APC, 
E-cadherin, p16Ink4a, SOCS-1, GSTP1, RASSF1A, Cox-2, CFTR, CCND2, and RIZ1 genes are 
found to be frequently methylated and thus silenced in HCC [178]. hTERT expression is also 
regulated by DNA methylation [179].  Some microRNAs including miRNA-1 is shown to be 
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silenced by DNA methylation and associated with liver cancer [180].  Reduced expression of T-
cadherin via DNA methylation is also found to be associated with development of liver cancer 
[181].  
 The level of global DNA methylation and CpG hypermethylations are found to be 
associated with clinical outcome of several cancers including liver cancer [182].   
 
1.10 Role of ATAD2 gene in cancer 
ATAD2 is a gene of unknown function encoding a protein with a bromodomain and an 
ATPase domain of the AAA family suggesting functions related to genome regulation [183]. 
Reports from several independent groups established ATAD2 overexpression in a large set of 
tumors including breast, prostate, lung, and liver cancers [183,184,186]. The ATAD2 gene maps 
to 8q24.3 4.3 Mb distal to MYC, a well known oncogene. This chromosomal region is amplified 
frequently in different cancers, including HCC. Ciro et al. [184] have recently shown that 
ATAD2 gene is amplified in 17% of breast cancers and its overexpression correlates with tumor 
aggressivity in breast and lung cancers [183-184]. The exact mechanisms of ATAD2 
overexpression in tumor cells and its cellular functions are presently unknown. However, recent 
studies indicate that ATAD2 is a direct target of E2F genes of the retinoblastoma pathway that is 
frequently deregulated in cancer cells [184]. Interestingly, ATAD2 was also identified as a 
critical co-activator of both E2Fs and c-MYC [184-185]. Downregulation of ATAD2 by siRNA 
or shRNA inhibits the entry of quiescent cells into S phase resulting in decreased colony-forming 
ability as well as inhibition of cell proliferation [184]. ATAD2 downregulation has also been 
associated with increased apoptotic response in some cell lines [183, 186]. Interestingly, some 
cell lines may not be responsive to ATAD2 inhibition [186]. Thus, ATAD2 overexpression in 
cancer cells could be due to either gene amplification or retinoblastoma pathway deregulation and 
that it may display oncogenic activity by its contribution to E2F- and c-MYC-mediated 
transcriptional activation.  
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CHAPTER 2. OBJECTIVES AND RATIONALE 
 
As indicated previously, HCC kills nearly 600.000 people each year and the only effective 
therapy for this cancer is liver transplantation or tumor ablation when the tumor is small enough. 
These tumors are surprisingly resistant to conventional therapies such as chemotherapy and 
radiotherapy. Moreover, as HCC is almost always associated with cirrhosis, the treatment with 
cytotoxic agents is dangerous as they will also affect hepatic functions of the diseased liver. 
Therefore, there is urgent need to find novel therapeutic approaches against HCC in order to 
diminish death toll. One potentially useful approach is so called “targeted therapy”, chemical or 
biological therapy based on targeting cancer-specific events (such oncogene activation, 
neoangiogenesis, and epigenetic alterations). However, this is a very difficult task for HCC, as 
only a few genetic and epigenetic targets are known, as reviewed in chapter 1.  
Our overall goal is to discover “druggable target genes” in HCC. In other words, we wish 
to identify novel genes and novel mechanisms involved in these cancers in order to use them as 
potential therapeutic targets.  
During my thesis work, I developed different approaches to find new mechanisms and 
novel targets:   
1-Deciphering the role of canonical Wnt signaling in HCC:  We hypothesized that canonical Wnt 
signaling is not only selectively activated in well-differentiated, but also repressed in poorly 
differentiated HCCs. To test this, we characterized and classified HCC cell lines according to 
their differentiation status and compared their expression of Wnt pathway genes, and activity of 
canonical Wnt signalling. In some cancers, due to mutations affecting APC, Axin and beta-
catenin, wnt-beta-catenin pathway is abnormally activated in the absence of a Wnt ligand, and 
beta-catenin accumulating in cytoplasm and nucleus, activates Wnt target genes. For this aim, we 
identified monoclonal antibodies (Mabs) that selectively recognize membrane-bound, 
cytoplasmic and nuclear beta-catenin forms and test the clinical value of such Mabs in several 
human cancer types. 
2. Systematic screening of protein kinases and phosphatases as potential therapeutic targets: 
There is evidence of aberrant activation of several signaling cascades in HCC, and a multikinase 
inhibitor, sorafenib, has shown survival benefits in patients with advanced HCC. We used siRNA 
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to screen a large number of kinases and phosphatases to identify related genes involved in HCC 
cell survival. 
3-Screening of a set of selected epigenetic regulators as potential therapeutic targets: Genetic 
mutations are irreversible and some mutated genes such as TP53 can not be targeted for therapy. 
In contrast, epigenetic alterations in cancer cells are reversible in principle. Therefore, they may 
be ideal candidates for targeted therapy. Accordingly, histone acetylation and DNA methylation 
have been used as potential targets in the past. Among others, histone deacetylase inhibitors that 
stimulate histone acetylation and chemical analogs of methylated cytosine that induce DNA 
hypomethylation have been effectively used to inhibit the growth of tumor cells or to eliminate 
them by an apoptotic response [187]. Recent studies have indicated that senescence arrest or 
senescence escape could be regulated by epigenetic changes on chromatin. We wanted to identify 
key histone methylation and acetylation changes associated with senescence or senescence 
escape, and select key histone modifying enzymes, as potential targets for “pro-senescence” 
interventions (therapeutic interventions that allow senescence induction in cancer cells).  
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Reagents 
All laboratory chemicals were purchased from either Sigma (St. Louis, MO, U.S.A), 
Farmitalia Carlo Erba (Milano, Italy), Merck (Schucdarf, Germany), VWR company, 
(International S.A.S. Le Périgares, France). 
Methanol: Sigma (St. Louis, MO, U.S.A) 
Toluene: Sigma (St. Louis, MO, U.S.A) 
Hydrochloric Acid 0,37 %: from Farmitalia Carlo Erba (Milano, Italy) 
Formaldehyde 4 % : from VWR company, (International S.A.S..  Le Périgares, France) 
DNA isolation kit: Flexigene DNA Kit with catalog number 51204 from Qiagen 
(Courtaboeuf –France) 
Quick PCR purification kit with catalog number 28104 from Qiagen (Courtaboeuf –
France) 
Hispeed Plasmid Maxi kit with catalog number 12663 from Qiagen (Courtaboeuf –
France) 
QI Prep Spin Mini kit with catalog number 27106 from Qiagen (Courtaboeuf –France). 
Sigma senescence cells kit: with catalog number CS0030 from Sigma (St. Louis, MO, 
U.S.A). 
MN RNA isolation kit with catalog number 740955250 from MACHEREY-NAGEL 
GmbH & Co. KG ( Düren · Germany) 
Saponin from Quillaja bark : catalog number, S4521-25G from Sigma (St. Louis, MO, 
U.S.A) 
Nuclear fast Red : catalog number N3020 form Sigma (St. Louis, MO, U.S.A) 
Mayer’s Haematoxylin: MHS16 from Sigma (St. Louis, MO, U.S.A) 
Crystal Violet: catalog number C0775 from Sigma (St. Louis, MO, U.S.A) 
Coomassie Brilliant Blue R: catalog number B8647-1EA from Sigma (St. Louis, MO, 
U.S.A) 
Ponceau Stain Solution: catalog number PH70-1L from Sigma (St. Louis, MO, U.S.A) 
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Hexadimethrine Bromide: catalog number H9268-10G from Sigma (St. Louis, MO, 
U.S.A) 
 
3.1.2 Bacterial Strains 
 The bacterial strain used in this work was: E. coli: DH5α and M15. Competent cells for 
Lentivirus studies Stbl3 Competent cells from Invitrogen Company and TAM1 ready competent 
cells from Active Motif (Rixensart, Belgium). 
 
3.1.3 Enzymes 
 Restriction endonucleases used for gene cloning were purchased from either MBI 
Fermentas GmbH (Germany) or from Gibco Invitrogen SARL –France .  
 
3.1.4 Nucleic Acids 
 DNA molecular weight standard and ultrapure deoxyribonucleotides were purchased from 
MBI Fermentas GmbH (Germany). pEGFP-N1 (Clontech, Palo Alto, CA), pcDNA3 (Invitrogen), 
pCI-Neo (Promega), pSuper, pSuperior.puro, pSuper.retro.gfp.neo (Oligoengine), and pGEX-4T1 
(Amersham/Pharmacia, NJ, USA) were commercially obtained. pCDNA3-S33Y were prepared 
by inserting of  S33Y cDNA from pCI-Neo-S33Y into pcDNA3. pAUCT-∆N-β-catenin were 
prepared by inserting  Xho I/Not I fragment of pCI-Neo-S33Y into pAUCT/CCW vector.  
pAUCT-C/EBPα was prepared by inserting BamHI-XhoI from pCDNA3.C/EBPα into 
pAUCT/CCW. The pShuttle-IRES-Wnt5a expression plasmid was constructed by subcloning of 
an EcoRI-cut Wnt5a cDNA fragment from plasmid pGEMTz-Wnt5a vector (a gift from R. 
Kemler) into BglII site of the pShuttle-IRES-hrGFP-1 vector (Stratagene, USA). pCI-Neo-mutant 
β-catenin (S33Y) expression plasmid, and pGL3-OT and pGL3-OF reporter plasmids were kindly 
provided by B. Vogelstein. The pAUCT-delta N-β-catenin plasmid expressing N-terminally 
truncated β-catenin (aa 98-781) under the control of Tet repressor was constructed using pAUCT-
CCW vector (gift from Ali Fattaey, USA). A cDNA fragment of XhoI-NotI digestion from pCI-
Neo-mutant β-catenin (S33Y) plasmid was inserted into XhoI-NotI site of pAUCT-CCW vector. 
PEGFP-Survivin vector is gift from Stephan Dimitrov team at Institute Albert Bonniot. 
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 PEGFP-GW-Suv420H1 was a gift from Gunnar Schotta from Research Institute of Molecular 
Pathology(IMP), Vienna. PEGFP-BRDT plasmid was a gift from Saadi Kochbin team at Institue 
Albert Bonniot. 
PGipz shRNAmir against gapdh with catalog numbers RHS4371, Scrambled with catalog 
number RHS4346, non-eukaryatic target RHS4480, FBXL11 with catalog numbers 
V2LHS_51035, V2LHS_51037, V2LHS_245727, JMJD2B with catalog numbers RHS4430-
98713709, RHS4430-98714014, JMJD3 gene with catalog number  RHS4430-98705669, SETD2 
with RHS4430-99293307, RHS4430-98841349, RMM4431-99214758, SMYD2 with RHS4430-
99149990, RHS4430-98896463 and Suv420H1 with  RHS4430-99138317,  RHS4430-99138820 
were purchased from Openbiosystems (USA). 
pTRIPz shRNAmir lentiviral vector targeting ATAD2 and shCTRL were purchased from 
open Biosystems company with catalog number RHS4696-99634057. 
 
3.1.5 Oligonucleotides 
 The sequencing-primer used for cycle sequencing reactions  oligonucleotides used in 
polymerase chain reactions (PCR), and 60 bp. HPLC grade oligos used for gene knock-down 
experiments were synthesized by either İONTEK (Istanbul, Turkey) or Eurofins MWG Operon 
(Roissy CDG, France).  
 
3.1.6 Electrophoresis and gel imaging, luciferase assay, ELISA readings and 
spectrophotometer 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical Company 
Ltd. (St. Louis, MO, USA) and from Agarose D5 DNA grade from Euromedex 
(Souffelweyersheim-France). Horizontal electrophoresis apparatuses were from Stratagene 
(Heidelberg, Germany) and Mupid –ex company E-C Apparatus Corporation (Florida, USA). 
The power supply Power-PAC300 and Power-PAC200 was from Bio Rad Laboratories (CA, 
USA). GeneFlash SYNGENE Bioimaging is used to visualize DNA. The Molecular Analyst 
software used in agarose gel profile visualizing was from BioRad Laboratories (CA, USA). The 
Reporter Microplate Luminometer Reader was from Turner BioSystems Inc (Sunnyvale, CA, 
USA). ELISA reader and Spectrophotometer were from Beckman. 
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3.1.7 Tissue culture reagents  
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum was obtained from 
GIBCO Invitrogen company (Invitrogen SARL –France).  L-glutamine, calcium and magnesium-
free phosphate buffered saline (PBS), Penicillin/Streptomycin mixture was from Biological 
Industries, MEM Non essential aminoacids 10X and HBBS Hanks balanced salt sln and 0,5% 
trypsin-EDTA 10X were purchased from GIBCO Invitrogen company (Invitrogen SARL –
France). Tissue culture flasks, petri dishes, 15 ml polycarbonate centrifuge tubes with lids and 
cryotubes were purchased from Costar Corp. VWR Company, (International S.A.S. Le Périgares, 
France). Geneticin-G418 sulfate was purchased GIBCO Invitrogen Company (Invitrogen SARL 
–France).  Puromycin and Doxorubucin hydrochloride was purchased from Sigma (St. Louis, 
MO, USA).  
 
3.1.8 Antibodies and chemiluminescence  
 The antibodies used in immunoblotting (western blotting) were obtained from different 
sources, and their working dilutions are given in Table 3.2. 
ECL and ECL plus Western Blotting detection kit was purchased from Amersham 
Pharmacia Biotech Ltd. (Buckinghamshire, UK). 
 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General Solutions 
50X Tris-acetic acid-EDTA (TAE):  2 M Tris-acetate, 50 mM EDTA pH 8.5 
 Diluted to 1X for working solution purchased from 
Euromedex. 
 
Ethidium bromide:    Uptime Interchim company 
10 mg/ml in water (stock solution), 
       30 ng/ml (working solution) 
 
4X Gel loading buffer:   Purchased from Invitrogen (SARL –France).   
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Bradford Stock Solution  purchased as ready sln from Sigma company with 
catalog number B6916 
 
3.2.2 Microbiological media, reagents and antibiotics 
Luria-Bertani medium (LB)   LB Medium : LB Broth 20g/L ROTH 
LB Agar: Lenox Agar from Invitrogen SARL –
France 
Glycerol stock solution 65% glycerol, 0.1 M MgSO4, 0.025 M Tris.Cl, pH 
8.0 
 
Ampicillin 100 mg/ml solution in double-distilled water, 
sterilized by filtration and stored at -20°C (stock 
solution).100 µg/ml (working solution) 
Kanamycin 300 mg/ml solution in double-distilled water 
sterilized by filtration and stored at -20°C (stock 
solution). Working solution was 30 µg/ml. 
0.1 M IPTG                                 1.41 g IPTG in 50 ml double-distilled water,            
sterilized by filtration and stored at -20oC. 
SOB medium:   Per liter: 20 g tryptone (2%), 5 g yeast extract 
(0.5%), 0.584 gr NaCl (10 mM), 0.1864 g KCl (2.5 
mM) autotclaved to sterilize. Then, 2.46 g MgSO4 
and 2.03 g MgCl2 (10 mM) are added. 
SOC medium:  was purchased from P/N 46/0700 Invitrogen 
company  
Transformation Buffer (TB):    NuPage 20X Transfer buffer from Invitrogen 
company  
Glycerol stock solution 65% glycerol, 0.1 M MgSO4, 0.025 M Tris.Cl, pH 
8.0. were mixed with 50% bacteria culture. 
Alternatively, 25% glycerol were added into bacteria 
culture.  
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3.2.3 Tissue culture solutions 
DMEM/RPMI working medium 10% FBS, 1% penicillin/streptomycin, 1% Non-
Essential Amino Acid were added and stored at 4oC.  
 
 
10X Phosphate-buffered saline (PBS) Purchased from Invitrogen Company Invitrogen 
SARL –France 
 
 
3.2.4 BES Transfection solutions 
2.5 M CaCl2 3.675 g CaCl2 in 10 ml double-distilled water. 
Sterilized by filtration through 0,2µm filter. Stored at 
-20°C 
100 mM BES, pH 6.95 0.2132 g BES (N,N-bis(2-hydroxyethly) in double-
distilled water. pH was adjusted to 6.95 with NaOH 
at room temperature. Stored at -20°C 
2X BBS (BES buffer saline) 50 mM BES, pH 6.95, 280 mM NaCl, 1.5 mM 
Na2HPO4 in double-distilled water. Sterilized by 
filtration through 0,2µm filter. Stored at -20°C. 
 
3.2.5    Antibiotics 
Geneticin-G418 Sulfate) 500 mg/ml solution in double-distilled water. 
Sterilized by filtration and stored at -20°C (stock 
solution). 500 µg/ml (working solution for stable cell 
line selection), and 250 µg/ml (working solution for 
maintenance of stable cell lines). 
Puromycin 2 mg/ml solution in double-distilled water, sterilized 
by filtration (0.2 um pores) and stored at -20°C 
(stock solution). 2 µg/ml (working solution for stable 
cell line selection), and 1 µg/ml (working solution for 
maintenance of stable cell lines). 
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Tetracycline 1 mg/ml solution in 70% Ethanol, sterilized by 
filtration (0.2 um pores) and stored at -20°C (stock 
solution). 5 µg/ml (working solution). 
3.2.6 Immunoblotting solutions 
 
10X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M NaCl, pH 7.6 in 
double distilled water.  
TBS-Tween (TBS-T) 0.1-0.5% Tween-20 solution in TBS. (Prepared 
freshly) 
Blocking solution 3-5% (w/v) non-fat milk, 0.1-0.5% Tween-20 in 
TBS. 5 % BSA for histone antibodies (Prepared 
freshly). 
 
3.2.7 RNA Study Solutions 
 
DEPC-treated water 0.1% Diethylpyrocarbonate (DEPC) (v/v) in double-
distilled water was stirred in loosely plugged bottle. 
Then autoclaved and stored at room temperature.    
 
3.2.8    Immunofluorescence solutions 
H33258 fluorochrome dye 1 mg/ml solution in double-distilled water and stored 
at -20 °C. Working solution was 1 µg/ml. 
DAPI (4', 6-diamidino-2-phenylindole)        0.1-1 µg/ml (working solution in PBS). 
4% paraformaldehyde 4 g paraformaldehyde, 5 mM NaOH in 100 ml. PBS, 
pH 7.4. Stable at 4°C for a week. 
 PBS-TritonX-100 (PBS-T) 0.1 TritonX-100 in PBS. 
 
3.3 METHODS 
3.3.1 General Methods 
3.3.1.1    Long term storage of bacterial strains  
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To keep bacterial cells including plasmid in it or as empty for future experiments and to 
have a stock of strain in a laboratory is necessary. The most frequently used method is “Glycerol-
Stock” method.  A single colony picked from either an agar plate or a loop-full of bacterial stock 
was inoculated into 5 ml LB (with a selective agent if necessary) in 15 ml screw capped tubes. 
Tubes were incubated overnight at 37oC and at 200 rpm. For glycerol stock, 700 µl of saturated 
culture was added into 700 ml of 65% glycerol v/v (32.5 ml glycerol, 5 ml MgSO4, 1.25 ml Tris-
Cl pH 8.0 completed to 50 ml with sterile water).  This mix was frozen/stored at –70 or -80oC 
 
3.3.1.2   Purification of plasmid DNA using Qiagen miniprep kit 
This method was preferred for isolation of plasmids in order to use in sequencing or 
cloning procedures. 5 ml of saturated culture was used for isolation of plasmid DNA by using 
“QI Prep spin miniprep plasmid DNA purification kit” (Qiagen- Courtaboeuf –France)) following 
manufacture’s instructions. 
 
3.3.1.3   Large-scale plasmid DNA purification 
This method was used for isolation of plasmids in order to use in sequencing or 
mammalian cell transfection procedures by using “Hispeed Qiagen large-scale plasmid DNA 
purification kit” following manufacture’s instructions. 
 
3.3.1.4   Quantification and qualification of nucleic acids 
Concentration and purity of the double stranded nucleic acids (plasmid and genomic 
DNAs), oligonucleotides and total RNAs were determined by using the Nanodrop from 
Thermoscientific Company. 
 
3.3.1.5    Restriction enzyme digestion of DNA 
 Restriction enzyme digestions were routinely performed in 20 µl reaction volumes and 
typically 0.5-5 µg DNA was used. Reactions were carried out with the appropriate reaction buffer 
and conditions according to the manufacturer’s recommendations. 
 Digestion of DNA with two different restriction enzymes was performed in the same 
reaction buffer to provide the optimal condition for both restriction enzymes. If no single reaction 
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buffer could be found to satisfy the buffer requirements of both enzymes, the reactions were 
carried out sequentially.  
 
3.3.1.6   Gel electrophoresis of nucleic acids 
3.3.1.6.1   Horizontal agarose gels of DNA samples 
DNA fragments were fractionated by horizontal electrophoresis by using standard buffers 
and solutions. DNA fragments less than 1 kb were generally separated on 1.0% or 20 % agarose 
gel, those  greater than 1 kb (up to 11 kb) were separated on 0.8 % agarose gels. 
 Agarose gels were completely dissolved in 1x TAE electrophoresis buffer to required 
percentage in microwave and ethidium bromide was added to final concentration of 30 µg/ml. 
The DNA samples were mixed with one volume loading buffer and loaded onto gels. The gel was 
run in 1x TAE at different voltage and time depending on the size of the fragments at room 
temperature. 
 
3.3.2 Computer analyses 
 Restriction endonuclease maps of the plasmid DNAs were analyzed by using the 
WebCutter program (Max Heiman, 1995, maxwell@minerva.cis.yale.edu) available for free and 
public use at http://rna.lundberg.gu.se/cutter2/. Primers were designed by using web software 
provided by Steve Rozen and Whitehead Institute for Biomedical Research at 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Alignments of nucleic acids or protein 
sequence were performed by using web page at http://www.ncbi.nlm.nih.gov/BLAST/. 
 
3.3.3    Characterization of Ig subtype of the anti-β-catenin antibodies 
Subtypes of anti-β-catenin antibodies were identified by using “ImmmunoPure 
Monoclonal Antibody Isotyping Kit II” (Pierce) following kit instructions. 
 
3.3.4 Tissue culture techniques 
3.3.4.1 Cell Lines and stable clones 
 15 HCC derived cell lines (FLC4, Huh7, FOCUS, Mahlavu, Hep40, Hep3B, HepG2, 
PLC/PRF/5, SK-Hep1, Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) were used in this 
study, and cultured as described in previously [188]. Human colorectal carcinoma cell lines 
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SW480 (APC nonsense mutation at aa 446) and SW837 (APC nonsense mutation at aa 483) were 
grown in high glucose DMEM. Wnt3a expressing-mouse fibroblast NIH3T3-wnt3a cell line was 
obtained from R. Kemler. 
Normal Lung Fibroblast cell line was MRC5 and MRC5-hTERT and hela (ATCC) cell 
lines were cultivated in DMEM. Huh7-, HepG2 and Hep3B-derived isogenic clones were 
obtained by either puromycin (1,5 µg/ml) selection after infection with pGIPz or pTRIPz 
(Invitrogen) or Geneticin (1500 µg/ml) for cells transfected with PEGFP-N1 and Suv420H1 
enzyme expressing plasmid, and surviving expressing plasmid. Maintanance of stable cells were 
performed either using puromycin (0,25 µg/ml) or in the presence of 200 µg/ml geneticin G-418 
sulfate depending on the plasmid selection markers. 
 
3.3.4.2 Cryopreservation of cell lines 
 Exponentially growing cells (70% confluency) were harvested by trypsinization and 
neutralized with growth medium. The cells were counted and precipitated at 1500 rpm for 5 min. 
The pellet was suspended in a freezing solution (10% DMSO, 20% FCS and 70% DMEM for 
adherent cells; 10% DMSO, 90% FCS for special cells) at a concentration of 4x106cells/ml.  1 ml 
of this solution was placed into 1 ml screw capped-cryotubes.  The tubes were left at -70°C 
overnight in a shuttle containing isopropanol. The next day, the tubes were transferred into the 
liquid nitrogen storage tank. 
 
3.3.4.3 Thawing cell lines 
One vial of the frozen cell line from the liquid nitrogen tank was taken and 
immediately put into ice. The vial was left 1 minute on the bench to allow excess nitrogen to 
evaporate and then placed into 37oC water bath until the external part of the cell solution was 
thawed (takes approximately 1-2 minutes). The cells were resuspended gently using a pipette 
and transferred immediately into a 15 ml. sterile tube containing 10 ml cold fresh medium. 
The cells were centrifuged at 1500 rpm at 4oC for 5 minutes. Supernatant was discarded and 
the pellet was resuspended in 10 ml 37oC culture medium to be plated into 100 mm dish. 
After overnight incubation in a humidified incubator at 37°supplied with 5% CO2, culture 
mediums were replenished. 
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3.4 Growth conditions of cells 
 Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 supplemented with 10% 
FCS, 1 mM glutamine and penicillin and streptomycin (50 mg/ml), and 1% NEAA was used to 
culture the HCC cell lines. The cells were incubated in at 37°C in an incubator with an 
atmosphere of 5% CO2 in air. Empty vector transfected stable clones were cultured in parental 
cell line’s culture medium + 200 µg/ml geneticin G-418 sulfate, or 1 µg/ml puromycin. 
Doxycycline inducible cells were cultured in parental cell line’s culture medium + 200 µg/ml 
geneticin G-418 sulfate + 3 - 5 µg/ml doxycycline.  
 The cells were passaged before reaching confluence. The growth medium was aspirated 
and the cells were washed once with calcium and phosphate-free PBS. Trypsin was added to the 
flask to remove the monolayer cells from the surface.  The fresh medium was added and the 
suspension was pipetted gently to disperse the cells. The cells were transferred to either fresh 
petri dishes or fresh flasks using different dilutions (from 1:2 to 1:10) depending on requirements. 
 All media and solutions used for culture were kept at 4°C (except stock solutions) and 
warmed to 37°C before use. 
 
3.5     Transfection and Virus Production 
pGIPz and/or pTRIPz shRNAmir lentiviral and shCTRL were purchased from open 
Biosystems company. After transformation into STBL3 replication incompetent cells according 
to manufacturer`s recommendation, maxi prep isolation was performed. For transfection Trans-
Lentiviral GIPz Packaging Mix with Hek-293TA cells and Arrest-in transfection reagents from 
Open-biosystems Company (Huntsville, USA) were used. All lentiviral studies were performed at 
Security level 2. 5.5 x 10 6 rapidly growing (split two days before) Hek293TA cells were plated 
into 10cm plates one day before. At the day of transfection, cell media were changed to serum 
free and antibiotic free media. 28,5 ug (26 ul) Trans-lentiviral packaging mix and 9ug of pGIPz 
or pTRIPz transfer vector was mixed into 1ml serum free media. Arrest-in transfection reagent 
(187,5 ul) was mixed into 1ml serum free media in a separate tube. The diluted DNA mix and 
transfection reagent is combined and mixed rapidly and incubated 20 minutes at room 
temperature. After this incubation 3ml of serum free media was added to transfection-DNA 
complexes and mixed gently and overlaid onto Hek293-TA cells containing plate and incubated 6 
hours. Transfection mixture is replaced with 12 ml standard media, and 48-72 hours later media 
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containing virus particles were collected and filtered 0,45 uM PVDF filters and either directly 
used or kept at 4 C for up to 1 week.  
 
3.6     Transduction of cells with viruses 
The day before transduction cells were seeded into 24 well plates so that next day the 
confluency is about 30%-50%. The day of infection, media is aspirated and virus containing 
media is overlaid either using 6-8 µg/ml of Hexadimethrine Bromide in virus containing media 
1mL for 6 well plates or 250 uL for 24 well plates. Cells were incubated with virus containing 
media for 4-6 hours and after incubation the media is removed and cells were cultured for 24 
hours and selection with 1 µg/ml puromycin (Sigma) was started or continued for further 
experiments.  
 
3.7  Transfection and Colony-forming ability assay 
Cell survival was determined by assessing cell growth in 100 mm dishes after exposure to 
Trichostatin-A TSA(sigma). 100,000 HepG2, Hep3b, Hela and MRC5 (PDL 32) cells were 
seeded in 6-well plates and 24 hours later cells were transfected with ATAD2 siRNAs ordered 
from Eurogentec (France) (ATAD2 siRNA sequences:  Atad2 siRNA1  
ACUAACACUGCUGAAGCUG;Atad2 siRNA2  GGUUGUAGCUCCUCCAAAU, Atad2 
siRNA3  GCUAAGGAUUUCGAGGUAG,Atad2 siRNA4  
UCUUCUGCUGUCAGUGAUC,siCTRL  GGCCUUUCACUACUCCUAC) using 
Oligofectamine transfection reagent using the protocol that Invitrogen recommends. 200 µM of 
siRNA and 4 µl of oligofectamine transfection reagent is used to transfect cells for 6 hours 
without serum and antibiotics. 3X serum containing media is added at the end of 6 hours and 3 
days later cells are either treated with tricostatin-A  (0,1 µM, 0,5 µM or 1 µM) for 24 hours or 
directly plated into 10 cm plates in triplicates. Equal volume of cells was plated into each plate. 
After 10 days of cell culture, colonies were fixed in cold methanol, stained with Crystal Violet 
(Sigma), and counted in triplicate experiments. Cell survival was calculated as the % ratio of cell 
numbers in treated versus untreated cells. Survival parameters were determined by plotting in 
excel. 
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3.8  Western immunoblotting  
RIPA extracted or nuclear extracted proteins were subjected to electrophoresis using 10% 
or 4-12% Bis-Tris NuPAGE Novex or 3-8% Tris-Acetate Nupage mini gel systems (Invitrogen), 
according to the manufacturer’s instructions. For detection whole cell lysates using RIPA 
extraction is used. For the detection of phosphorylated proteins, cell lysates were prepared 
according to the protocol provided by the supplier using the following lysis buffer: 20 mmol/L 
Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 1 
mmol/L Na3VO4, 1 µg/ml leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride.  Following 
electrophoresis, proteins were transferred on to Immobilon-P PVDF membrane (Millipore, USA), 
and analyzed, using antibodies against target proteins.  
 
3.9  Senescence-associated beta-galactosidase (SABG) assay 
SABG activity was detected as described previously by dimri et al 1995, using senescent 
cell staining kit (Sigma). 
 
3.10    Indirect immunofluorescence and confocal microscopy 
Cells were fixed with 4% formaldehyde, and permeabilized with PBS supplemented with 
0.5% saponine (Sigma) and 0.3% Triton X-100 (Sigma). After blocking for one hour, cells were 
incubated overnight at 4°C, with 1` antibodies, after washing with PBS-(0,03%) Triton-X, 
secondary antibodies conjugated to Alexa 568 or Alexa 488 (Invitrogen), counterstained with 
DAPI, and observed using Apotome (Zeiss) microscope. Images were captured with an Axiocam 
HRc color CCD camera (Zeiss) and digitally saved using Axio Imager software (Zeiss). Confocal 
microscopy analysis were examined under Zeiss LSM 510 Meta laser scanning confocal 
microscope (MPI Freibourg, Germany) using 488 nm and 543 nm laser excitation lines, and 
photographed. 
 
3.11 Cell cycle analysis and bromodeoxyuridine (BrdU) incorporation assay 
Cells were washed twice in PBS and fixed in ice-cold ethanol for 10 min. After two PBS 
washes, cells were incubated with 20 µg/ml of RNase A (Fermentas) at 37°C for 10 minutes and 
stained with propidium iodide (10 µg/ml in PBS; Sigma). Cell cycle distribution was determined 
by flow cytometry using FacScan and the CellQuest software (Becton Dickinson). Cell cycle 
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analysis combined with BrdU incorporation assay was done as described, except that cells were 
first labeled with 10 µmol/L BrdU (Sigma) for 2 hours prior to each testing time, and cells 
subjected to anti-BrdU staining after DNA denaturation with 4N HCl for 30 minutes using FITC-
conjugated anti-BrdU antibody (BD Bioscience) at room temperature for 30 minutes in the dark.  
 
3.12 Detection of Apoptosis using Annexin V staining 
Cells were collected by centrifugation and resuspended by Annexin V binding buffer and 
stained with annexin V-cy3 dye and incubated 5 minutes at dark and further analyzed with FACS 
scan (Beckton Dickonson) with FL2 channel. 
 
3.13 Detection of Histone acetylation levels using FACS  
For detection of acetylation using FACS, we followed the protocol previously published 
by [189]. At day 3 of transfection, cells were collected and fixed for 15 minutes in 1% 
formaldehyde in PBS on ice and refixed using 70% EtOH. Cells were washed with 1XPBS 
containing 1% BSA and permeabilized with 0,1% Triton-X 100 for 10 minutes at room 
temperature and fixed with 10% normal goat serum and incubated with either H3PanAc (abcam 
ab47915) and H4PanAc (Upstate 06598) antibodies in 1%BSA-PBS solution and followed by 
Alexa488-conjugated secondary antibody (Invitrogen). After washes, cells were resuspended in 
PI (10 µg/ml in PBS; Sigma) and quantified by FACS scan (Beckton Dickonson) with FL1 and 
FL2 channel and imaged by FCS express V3 program. 
 
3.14 Treatment of cell lines with TGF-beta and Doxorubucin  
Purified recombinant human TGF-β1 (R&D Systems, Minneapolis, USA) was 
reconstituted in sterile 4 mM HCl containing 1 mg/ml bovine serum albumin (BSA, Sigma, St. 
Louis, MO, USA).Doxorubicine hydrochloride from Sigma, (St. Louis, MO, USA) were obtained 
commercially and solubilized as suggested by the manufacturers. 
 
3.15 RNAi screening protocol 
3.15.1 Optimization Protocol for RNAi 
We ordered siRNAs targeting 126 kinase and 28 phosphatase genes form TRANSAT 
company in France. As a negative control against non eukaryotic sequences (scrambled) were 
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used. For positive control, we used a general positive control Polo like kinase (PLK) siRNA. This 
gene is implicated and essential for in cell division. We decided to look for inhibition of growth 
after knockdown of each gene. Inhibition of growth may be due to apoptosis, senescence and 
growth arrest so we used a sensitive method to quantify the viable cells after transfection.  This 
method is originally developed in USA by NCI to screen for inhibitors against 60 cancer cell 
lines[190]. For the optimization studies, we used 96 well plates and plated 2000 and 5000 Huh7 
cells in 0,2 mL media. 24 hours after plating, we transfected cells using 200nM PLK siRNA 
positive control using three different transfection reagents Oligofectamine (Invitrogen), 
Lipofectamine 2000 (Invitrogen, ref 11668), Fugene 6 (Roche). 
Among these Fugene was eliminated because of toxicity and oligofectamine is chosen 
because of transfection efficiency. We optimized best amounts of reagent per amount of siRNAs. 
We used 200nM siRNA and 5000 cells per well of 96 well plate. After 6 hours of transfection, 
we added 50 µl of three times more serum containing media over the cells and after 72 hours, we 
performed Sulforhodamine B Staining protocol. We also included SCR siRNA and for each 
target we used 3 different siRNAs to eliminate off-target problem. 
  
3.16 Sulforhodamine B staining protocol 
Sulforhodamine B (C27H30N2O7S2) is a fluorescent dye to quantify cellular proteins of 
cultured cells. The dye has absorbance at 585 nm light and fluorescence emission at 607 nm light. 
We fixed our cells using % 50 trichloroacetic acid for 1 hour at 4° C and stained with % 0.4% 
Sulforhodamine B solution for 30 minutes. After staining cells were washed four times with % 1 
acetic acid solution and air dried. The dye is then dissolved in 10 µM TRIS base solution, and 
absorbance is read at 540 nm wavelength.  
The results were obtained in triplicates and normalized to the negative SCR siRNA and 
Standard errors are also included. 
 
3.17    In vivo Targeting and Screening 
To optimize in vivo targeting and imaging, we obtained xenograft models of Huh7 cells 
and Alexa labelled RAFT-RGD and again Alexa dye labelled Transferrin were used. 
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3.18 Xenograft models  
We injected 10 x 107 Huh7 cells in 100 µl PBS on the back of 10 NMRI-neo (Naval 
Medical Research Institute) immunodeficient mice. We observed the tumor of 8-10 mm diameter 
in size of all treated mice. Cells were injected s.c. into NMRI nude mice. Tumors and 
nontumorigenic cells at the injection sites were collected at day 37 and analyzed. These 
experiments have been approved by the Bilkent University Animal Ethics Committee. 
 
 3.19 Optical imaging of mice bearing tumors 
After injection of day 25, we imaged mice using two different dyes. We used 200 µl of 
Alexa labelled RAFT-RGD and 100 µl of Alexa dye labelled Transferrin to image the mice. We 
anesthetized the mice and injected the dye, and start imaging process after 30 minutes, 1 hour, 2 
hours, 3 hours and 24 hours later. Excitation wavelength was 630 nm and filtered emission 
wavelength was 665nm, and images were obtained either 100 ms or 200 ms using Hamamatsu 
digital camera (C4742-98-26LWGS, Hamamatsu Photonics K.K., Japan). Wasabi software was 
used to process images. 
 
3.20 Transient transfection of eukaryotic cells using “Lipofectamine Reagent” 
Transfection was performed with Lipofectamine 2000 reagent (Invitrogen) following 
manufacturer’s instructions. 
 
3.21 Extraction of total RNA from tissue culture cells and tissue samples 
Total RNAs were isolated from cultured cells using the NucleoSpin RNA II Kit (MN 
Machete-Nagel, Duren, Germany) according to the manufacturer’s protocol. 
 
3.22 First strand cDNA synthesis 
First strand cDNA synthesis from total RNA was performed using RevertAid First Strand 
cDNA synthesis kit (MBI Fermantas, Germany). The first strand reactions were primed with 
oligo(dT) primer to specifically amplified mRNA population with 3’-poly(A) tails.  
 1 to 5 µg total RNA was used to synthesize the first stand cDNA following the 
manufacturer’s instruction.  After 1:1 dilution of total reaction products in DNAse free water, 2 
µl of diluted first strand cDNA was used for PCR.  
 42 
 
3.23     Primer design for expression analysis by semi-quantitative PCR 
 The primer pairs that have been used in expression profile analyses were designed 
carefully. Forward and reverse primer were positioned on different exons of the gene of 
interest, so that the primer pair was either be able to produce a longer amplicon from genomic 
DNA or  not be able to amplify from the covered genomic DNA region in a given PCR 
condition (critical parameter was extension time). Therefore the amplicon, which was 
amplified from cDNA, was not be longer than 1500 bp. Primers used for expression analysis 
have been designed strictly considering these criteria, and listed in Table 3.1. 
 
3.24 Fidelity and DNA contamination control in first strand cDNAs 
The fidelity and genomic DNA contamination of first strand cDNAs were checked 
before performing expression analyses. 2 µl of diluted first strand cDNA was used for cold-
PCR amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript. 
GAPDH primer pair was designed to skip introns so that the products coming form gDNA 
have higher products. 
 
3.25 Expression analysis of a gene by semi-quantitative PCR 
10 x Invitrogen PCR supermixes were used to perform PCR according to manufacturer’s 
recommendation. 
 
3.26 Protocol for quantitative PCR 
Quantitative PCR was performed using power Syber green (2X) PCR master mix 
(Stratagene company Massy- France) and (100 ng) cDNA as a template and 1 µl of 10 pmol 
forward and reverse primers. Stratagene Mx-3005 QPCR apparatus was used. The number of 
optimal PCR cycle was determined by an initial study for each gene by performing 45-cycle 
PCR. Agarose gels were analyzed by Densitometric Fluorescence-Chemiluminescence image 
analyzer and The Molecular Analyst software (BioRad).  
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Table 3.1: PCR primer list 
Primer name Sequence 5`-3` 
hAES-Rev CATCACATAGTGACGCTGCAT 
hAES-For ACCTACCCCAGCAACTCAAA 
CtBP1-Rev CCATCCGACAAGTAAGGG 
CtBP1-For CATCATCGTCCGGATTG 
Chibby-Rev AGCAGTGGACTCTGAAAGCA 
Chibby-For GGATCCCCGACTATGAACCT 
AXIN2-Rev TTTTTTGTGCTTTGGGCACTATG 
AXIN2-For CAGCGAGTATTACTGCTACTCGAAA 
ICAT-Rev TCTTCCGTCTCCGACCTGGA 
ICAT-For AAGAGTCCGGAGGAGATGTAC 
Axin2-Rev ATCTCCTCAAACACCGCTCCA 
Axin2-For CTGGCTCCAGAAGATCACAAAG 
hTLE1-Rev AGGCTTGCCGAGACCTGGACG 
hTLE1-For GGCAGTGCCGGCCTTCTTGCG 
hTLE2-Rev CGTTGAGAGTGCTGTGGGAGC 
hTLE2-For AGTGCTACGGGGCTGCTTGCT 
hTLE3-Rev TTTGGTCTTGGAGGAAGGTG 
hTLE3-For AAGGACAGCTTGAGCCGATA 
hTLE4-Rev CAGGTCCCAAATGGACAAAG 
hTLE4-For TCAAGGTCTGGGACATCAGC 
SETD2_201_Rev TAGGGAACACACATGCCAAG 
SETD2_201_For GGACAGTTTAAGTTCTCCTGCAA 
 44 
SETD2_001_Rev GTCGTCCCTGTTCTTCCAAA 
SETD2_001_For CGACCCCTGAAGAAGAAGAA 
FBXL11_203_For CGTGTTGCAATCTGGTTCCT 
FBXL11_201_For TGAGAATATCAGCTATCTTGAGAGAAA 
FBXL11_201_203_Rev CACCCCGCTGAATATACTCTACA 
FBXL11_202_For ATTGCTGGGAATGTCCAAAG 
FBXL11_202_Rev CAAAGTCTCTTGTCGCAGCA 
Suv420h1F1 TGGAGATGGGTTCTTTGGAG 
Rat-ATAD2-2-for TTC ATG AGG AAA GGT GCT GA 
Rat-ATAD2-2-rev GAG ATC CGA TGC CCT CTT CT 
ATAD2-rat-For CCT CCC AGG TCA CAG ACA TT 
ATAD2-rat-Rev CAG CTG CTG CTG CTC TAC CT 
H19-RsaI-for CCA CCA CAT CAT CCC AGA GC 
H19-RsaI-rev GAA TGC TTG AAG GCT GCT CC 
GapDH-For GGC TGA GAA CGG GAA GCT TGT CAT 
GapDH-Rev CAG CCT TCT CCA TGG TGG TGA AGA 
JMJD2B-201-202-For ATC TCC ATG GAC GTG TTC GT  
JMJD2B-201-Rev GTA CCC TCC CCA GGG AAC T  
JMJD2B-202-Rev AGA TGC TTT GGC CTC TCC TC  
Human ATAD2For AGGCTCATTGGAAAAACCT 
Human ATAD2Rev CCTGCGGAAGATAATCGGTA 
 
3.27 Crude total protein extraction 
           Adherent monolayer cells (both stable and parental cells) were grown to 70% confluency 
in growth medium without selective antibiotic. After removal of growth medium, cells were 
washed twice with ice-cold PBS to remove any serum residue. 400 µl of RIPA lysis-buffer (150 
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mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% sodium deoxycholate, 1 % NP-40, 0.1% SDS and 1X 
Complete Protein Inhibitor mix (Roche)) was added into 10 cm tissue culture petri dish, and cells 
were scraped with rubber scrapper. Complete lysis was achieved by pipetting of crude cell lysates 
several times and by incubating the lysates on ice for 30 min, and then centrifuged at 13.000 g for 
30 minutes. Total cell protein was collected as supernatant. 
3.28 Nuclear extract isolation protocol 
Cells were lysed using a buffer containing 0,5 M KCL, 0,1% NP40, 0,5 mM DTT, 0,5 
mM PMSF and TSA (50 ng/ml), 1x Protease inhibitor cocktail and 0,5 mL of pre-made buffer 
with 40% Glycerol and 6mM MgCl2 and 100 mM Hepes pH 7,9 and incubated on ice for 10 
minutes. Cell were pelleted and resuspended equal amount of the same buffer and sonicated 5 
minutes at high level with Bioraptor and further incubated on ice for 10 minutes and pelleted. 
Supernatant is containing chromatin proteins.  
 
3.29 Quantification of proteins using Bradford Assay 
The conventional Bradford protein assay was employed to quantity the protein in the 
lysates obtained from either crude total. After protein quantification, protein lysates were 
aliquoted into fresh tubes and, stored at –70°C.  
 
Table 3.2 Antibodies used in this study and their dilution in various protocols 
Antibody Working Dilution 
(WB) 
Working Dilution 
(IF) 
Source/Clone/Cat # 
β-catenin (MAb) 1:5000  Transduction Labs 
 β-catenin (MAb) 4C9 1:1  Home made 4C9 
β-catenin (MAb) 
9E10 
1:1  Home made 9E10 
vimentin  1:250 Becton Dickinson 
clone3B4 
P15 1:2000  SantaCruz Sc612 
Active Caspase 3 1:1000  Epitomics 1476-1 
Cyclin D1 1:500  SantaCruz 
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p16 1:500  SantaCruz Sc468 
Rb 1:1000  Becton Dickinson 
BD554136 
Calnexin(Rabbit PAb) 1:10000  Sigma 
Cyclin E 1:500  Transduction Labs 
Cyclin A 1:500  Abcam 
p21Cip1 1:500  Santa Cruz 
E-cadherin  1:2000  Santa Cruz 7870 
PTEN 1:500  Cascade biosciences 
 
P-ERK1/2  1:1500  Cell Signaling 
ERK1/2  1:1500  Cell Signaling 
phopho-AKT  1:750  Cell Signaling 9275 
P44/p42  1:1500  Cell Signaling 9107 
Pp44/pp42  1:1500  Cell Signaling 9106 
NFKB  1:200  SantaCruz sc8414 
HNF4  1:200  SantaCruz sc8987 
HNF1a  1:200  SantaCruz sc8986 
Z01    Transduction labs 
Connexin43    SantaCruz sc9059 
Total AKT 1:1000  Rabbit cell signaling 
Bax rabbit  1:500  Upstate 06-499  
Bak rabbit  1:500  Pharmingen 556396 
Bad  1:1000  SantaCruz sc9292  
P53-ser15    Cell signaling 9284 
BCL-XL  1:500  SantaCruz sc7195 
P21  1:500  Calbiochem OP24 
tubulin   Calbiochem cp06 
cyclinA  1:200  SantaCruz sc596  
C-myc 1:200  SantaCruz sc42  
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E2F1  1:200  SantaCruz sc193  
Albumin  1:1000  Abcam Ab10241 
AFP1  1:500  Abcam Ab3980 
Anti trypsin  1:1000  Abcam Ab9399 
Bax rabbit  1:500  Upstate 06-499  
H3K56Ac  
 
1 :500  Gift from Arnauld (eq 2) 
H3K23Ac 1:500  US biologicals  
H3K18Ac  
 
1:1000  Home made antibody 
H4K5Ac 1:500 1:50 Home made antibody 
ATAD2 antibody 1:500 1:200 Sigma (HPA019860) 
H3PanAcetyl 1:500  Abcam 47915 
H4PanAcetyl 1:500 1:250 Upstate 06598 
HDAC1 1:200  SantaCruz Sc7872 
HDAC2 1:200  SantaCruz Sc7899 
HDAC4 1:200  SantaCruz Sc5245 
HDAC5 1:500  Home made 605(U309) 
P300 1:1000  SantaCruz Sc584 
PCAF 1:200  SantaCruz Sc8999 
HAT1 1:500  Sigma H7161 
H3K4Me3 1:5000 1:1200 Abcam ab8580   
H3K9Me1 1:2000 1:600 Abcam ab9045 
H3 K9 Me3 1:5000 1:1200 Upstate 07-523   
H3 K27 Me1 1:5000 1:1200 Upstate 07-448   
H3 K27 Me3 1:5000 1:1200 Upstate 07-449    
H3 K36 Me3   1:2000 1:600 Abcam ab 9050 
H3 K79 Me3 1:2000 1:300 Abcam ab2621 
H4K20Me3 1:2000 1:600 Upstate 07-463   
H3 Pab 1:500  Abcam 1791 
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H4 Pab   1:500  Abcam10158 
Phopho P38 1:1000  Cell Signaling 9211 
P38 kinase  1:1000  Cell Signaling 9212 
Akt   Cell Signaling 9272 
Phospho SAPK/JNK 1:1000  Cell Signaling 9251 
SAPK/JNK 1:1000  Cell Signaling 9252 
H3K4Me1 1:2000 1:800 Upstate 07-436 
H3K27Me2 0,5 µg/ml 1:600 Abcam Ab24684 
H3K36Me1  1:600 Abcam Ab9048 
H3K36Me2  1:500 Upstate 07-274 
H4K20Me1 1:1000 1:600 Abcam Ab9051 
H4K20Me2 1:2000 1:250 Abcam Ab9052 
Setd2  1:100 Abcam Ab31358 
EZH2 0,4 µg/ml 1:100 Abcam Ab3748 
WHSC1  1:200 Abcam Abcam75359 
H3R2Me2  1:600 Upstate Ups07585 
H3R17Me2  1:900 Abcam Abcam 8284 
H4R3Me2  1:600 Upstate Ups 07-213 
Survivin 1 µg/ml 1:200 Abcam Ab469 
Suv420H1(0032) 1:2000 (pure)  COVALABs 
Connexin32   SantaCruz Sc7258 
twist 1:1000 1:500 SantaCruz Sc81417 
Bim 1:1000  Cell Signaling 2819 
E6 1:500  SantaCruz Sc166689 
E7 1:500  SantaCruz Sc6981 
 (WB: western blotting, IF: Immunofluorescence) 
 
3.30 Luciferase assay 
Endogenous TCF/LEF-dependent transcriptional activity was tested by using pGL3-OT 
and pGL3-OF reporter plasmids, as described previously [41], except that cells were transfected 
using Lipofectamine 2000 reagent (Invitrogen), following instructions provide by the supplier. 
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Mutant β-catenin-induced TCF/LEF-dependent transcriptional activity was tested after co-
transfection of cells with pCI-Neo-mutant β-catenin (S33Y) expression plasmid (1.75 µg/well) 
together with the reporter plasmids. pCI-Neo (1.75 µg/well) was used as negative control. The 
effect of Wnt5a expression on TCF/LEF-dependent transcriptional activity was tested using Huh7 
and HepG2 cell lines. Huh7 cell line was co-transfected with pCI-Neo-mutant β-catenin (S33Y) 
expression plasmid (1 µg/well) together with either pShuttle-IRES-Wnt5a (0.75 µg/well) or the 
empty vector pShuttle-IRES-hrGFP-1 (0.75 µg/well) and pGL3-OT/pGL3-OF reporter plasmids 
(0.75 µg/well for each). At 48 hour following transfection, luciferase assay was performed by 
using Luciferase Reporter Gene Assay, constant light signal kit (Roche Diagnostics GmbH., 
Mannheim, Germany). Luciferase activity was read with The Reporter® Microplate 
Luminometer (Turner BioSystems Inc., Sunnyvale, CA) and data was normalized according to 
transfection efficiency obtained with each transfection, as described previously [41]. HepG2 cell 
line was co-transfected with either pShuttle-IRES-Wnt5a (0.5 µg/well) or the empty vector 
pShuttle-IRES-hrGFP-1 (0.5 µg/well) and pGL3-OT/pGL3-OF reporter plasmids (0.5 µg/well for 
each), with an internal control (0.05 µg/well pRL-TK Renilla luciferase vector) in a 12-well plate, 
using Lipofectamine 2000 Transfection Reagent. Forty-eight hours post-transfection, the cells 
were washed with PBS, and lysed in passive lysis buffer (Dual Luciferase kit; Promega). The cell 
lysates were transferred into an OptiPlate 96-well plate (Perkin-Elmer) and assayed in a 1420-
Multilabel counter luminometer, VICTOR3 (Perkin-Elmer) using the Dual-Luciferase kit 
(Promega). Relative TOP-FLASH luciferase units were measured and normalized against Renilla 
luciferase activity and further normalized luciferase activity against FOP-FLASH activity. All 
transfection experiments were performed in triplicate and data were expressed as mean of 
triplicate values (±S. D.) and p values were calculated. TCF/LEF activity was reported as the 
ratio of normalized luciferase activities obtained with pGL-OT and pGL-OF plasmids, 
respectively (mean ± S. D.). 
 
3.31  Immunohistochemical studies for β-catenin Mabs 
A total of 176 tumor samples including 54 colorectal cancer (48 adenocarcinoma, 2 signet 
ring cell carcinoma, 3 mucinous carcinoma, 1 villous adenocarcinoma), 32 hepatocellular 
carcinoma, 54 breast cancer (28 in situ ductal carcinoma and 26 invasive ductal carcinoma), and 
42 endometrial cancer were tested for β-catenin immunoreactivity using 4C9 monoclonal 
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antibody. Three-micrometer-thick sections from the paraffin-embedded formalin-fixed blocks 
were used for hematoxylin-eosin staining and immunohistochemical studies. All sections for 
immunostaining were deparaffinized with xylene and alcohol and subject to antigen retrieval with 
microwave in Tris-EDTA buffer (pH 8.0) for 20 minutes. The endogenous peroxidase activity 
was blocked with 3 % hydrogen peroxide for 15 minutes at room temperature, and the sections 
were incubated with 1:5000 diluted anti-ß catenin antibody (4C9) for 1 hour at room temperature. 
After 3 washes in phosphate-buffered saline, the signals were detected by the Dako EnVision + 
Dual method, according to the manufacturer's instructions. After the third washing in phosphate-
buffered saline, the specimens were incubated with diamino-benzidine at the appropriate 
concentration for development. The specimens were counterstained with hematoxylin. The 
intensity of β-catenin staining was graded as negative (0-4% positive cells), weakly positive (5-
25% positive cells), moderately positive (26-75% positive cells), or strongly positive (76-100% 
positive cells). 
 
3.32 Immunohistochemistry analysis of ATAD2 using tissue microarray 
Tissue microarray containing 38 HCC with different TNM classification and 8 normal 
liver samples with catalog number LV-482 were purchased from Tebu-bio company (France). 
Tissues were deparrafinized using toluene and alcohol and subjected to antigen retrieval using 
citrate buffer pH 6.0 from Dia-Path (Italy) using water bath for 25 minutes. peroxidase activity 
was blocked with 3 % hydrogen peroxide for 15 minutes at room temperature, and the sections 
were incubated with 1:5000 diluted polyclonal Rabbit anti-ATAD2 antibody (Sigma ) for 1 hour 
at room temperature. After 3 washes in phosphate-buffered saline, the signals were detected by 
the Dako EnVision + Dual method, according to the manufacturer's instructions. The specimens 
were counterstained with hematoxylin and eosin. 
 
3.33 Statistical analysis 
The statistical significance using was tested by using either Fisher Exact Probability Test 
ot paired t-test using an on-line tool http://faculty.vassar.edu/lowry/Vas sarStats.html. 
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CHAPTER 4. RESULTS 
 
4.1 Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular 
carcinoma cells 
This work was done in collaboration with other graduate students of Ozturk Lab. 
Therefore, some date reported here has been produced by other students. We present here all key 
experiments used for a recent publication (Yuzugullu et al., 2010) in order to keep the unity of 
the whole study.  
We used a panel of HCC cell lines to characterize differentiation-dependent functions of 
Wnt pathway and canonical Wnt signaling in HCC. 
 
4.1.1 Classification of hepatocellular carcinoma cell lines into "well-differentiated" and 
"poorly differentiated" subtypes 
HCC cell lines were recently classified into "epithelial" and "mesenchymal" types based 
on E-cadherin and vimentin expression, sequentially [54]. Using 15 cell lines we checked the α-
fetoprotein (AFP) expression (Figure 4.1.1). Positive expression were shown in six cell lines 
Huh7, Hep40, HepG2, Hep3B, Hep3B-TR, PLC/PRF/5; negative cell lines were SNU182, 
SNU387, SNU398, SNU423, SNU449, SK-Hep1, Mahlavu, FOCUS or weakly expressing cell 
lines were (SNU475). All AFP-positive (AFP+) cell lines also expressed E-cadherin, whereas 
only 3/9 (33%) of AFP- cell lines expressed this epithelial marker. AFP negative cell lines were 
also positive for mesenchymal cell markers including vimentin, slug, snail, twist-1 and twist-2. 
These markers also displayed weakly positive expression in some AFP positive cell lines. 
Immunocytochemical analysis of vimentin protein was performed in five AFP+ and five AFP- 
cell lines to confirm the results (Figure 4.1.2). Strong and homogenous immunostaining were 
detected with all five AFP- cell lines. In contrast, either negative or heterogeneous positivity were 
seen for AFP+ cells lines. These results showed that AFP+ HCC cell lines were epithelial-like, 
but they also expressed some of the mesenchymal cell markers at different degrees. In contrast, 
AFP- cell lines were strongly positive for mesenchymal markers but not with epithelial marker E-
cadherin. Marked heterogeneity was obtained for mesenchymal markers. For example, SNU182 
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was positive for all five markers tested, whereas FOCUS was positive only for vimentin. 
 
Figure 4.1.1 Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in 
HCC cell lines. Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. 
GAPDH was used as a control for expression analyses. 
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Figure 4.1.2 Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC 
cell lines Cells grown on coverslips were subjected to immunoperoxidase assay using anti-vimentin antibody 
(brown), and counterstained with hematoxylin (blue). 
 
HNF-4α and its downstream target HNF-1α are well characterized hepatocyte-associated 
epithelial cell markers [3]. Involved in liver development and hepatocyte specification, both are 
specific markers for well-differentiated function and morphology [191]. RT-PCR analysis in four 
AFP+, and seven AFP- cell lines showed that the expression of these HNFs displayed perfect 
correlation with the expression of AFP (Figure 4.1.3.a): four AFP+ cell lines Huh7, Hep3B, 
HepG2, Hep40 were also highly positive for both HNF-4α and HNF-1α. On the other hand, seven 
AFP- cell lines SNU398, SNU475, SNU449, SNU387, FOCUS, Mahlavu, SNU182 did not 
express these factors. Only weak HNF-4α expression was observed for SNU449, another AFP- 
cell line. Epithelial cells show low motility, whereas mesenchymal cells display high motility and 
invasive phenotypes. To test the epithelial and mesenchymal gene expression patterns of HCC 
cells correlated with their in vitro motility, we used wound-healing assay. After wounding, AFP- 
HCC cells (Mahlavu, SNU449, SNU475, SNU182) moved through the wound, whereas AFP+ 
HCC cells (Huh7, Hep3B, HepG2, Hep40) cells did not (Figure 4.1.3.b; Hep40 and SNU182 data 
not shown). These data showed that poorly differentiated cell lines display higher motility 
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(Figure 4.1.3.c). These data have been produced in the laboratory of N. Atabey (Dokuz Eylul 
University). 
 
 
Figure 4.1.3 Expression of hepatocyte lineage markers HNF-4α and HNF-1α in HCC cell lines correlate with 
low motility. (a) Selective expression of HNF-4α and HNF-1α in AFP+ HCC cell lines. (b. c) Differential motility of 
AFP+ and AFP- HCC cell lines. Cells were cultured in six-well culture plates, and a single linear wound was made 
with a pipette tip in confluent monolayer cells. The distances between wound edges were measured at fixed points in 
each dish according to standardized template. After 24 hours migration, cell migration into the wound was visualized 
using phase contrast microscopy at ×20 magnification (b). The number of cells migrating beyond the wound edge 
was counted (c). Assays in six replicates, error bars; SD. SNU475 cells are larger cells giving rise to visual 
overestimation of migrating cell number in the picture shown in b. 
 
Taken together, we classified our panel of HCC cell lines into two subtypes (Table 4.1.1). 
HepG2, Huh7, Hep3B and Hep40 cell lines were grouped into "well-differentiated" phenotype, 
because they express AFP, E-cadherin, HNF-4α and HNF-1α, and they display low motility 
and/or low invasiveness. Most of these features are confined to "well-differentiated" HCC tumors 
[2, 59, 192-193]. The remaining seven cell lines (SNU398, SNU475, SNU449, SNU387, 
FOCUS, Mahlavu, SNU182) were classified as "poorly-differentiated" HCC cell lines, because 
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of lack of expression of both hepatocyte lineage and epithelial cell markers. In addition, they 
shared many features with mesenchymal cells including the expression of mesenchymal markers 
(vimentin, slug, snail, twist-1, and twist-2), high motility and invasiveness. These expression and 
migratory features are associated with tumor dedifferentiation and confined to poorly 
differentiated HCCs [48-49, 55, 194].   
 
Table 4.1.1: Well-differentiated and poorly differentiated HCC cell lines according to 
hepatocyte lineage, epithelial and mesenchymal markers, and in vitro motility and 
invasiveness assays  
 
 
Cell Lines 
Fetal 
Hepatocyte 
Marker 
 
Epithelial & Hepatocyte 
Markers 
 
Mesenchymal markers 
 
Motility 
 
Invasiveness 
 AFP HNF4a HNF1a E-
cadherin 
Vimentin Slug Snail Twist-
1 
Twist-
2 
  
Well-
differentiated 
           
HepG2 High High High Low (-) Low Low Low High Low Low [55] 
Huh7 High High High High Low (±) Low Low (-) Low Low [55] 
Hep3B High High High High Low High Low (-) (-) Low Low ([195] 
Hep40 High High High Low High (-) High High Low Low n.t. 
Poorly 
differentiated 
           
SNU398 (-) (-) (-) Low High Low High High High Low n.t. 
SNU475 (±) (-) (-) (-) High High High High Low High n.t. 
SNU449 (-) Low (-) (±) High Low Low High High High n.t. 
SNU387 (-) (-) (-) (-) Low High High (-) (±) n.t. n.t. 
FOCUS (-) (-) (-) Low High Low (-) (-) Low n.t. n.t. 
Mahlavu (-) (-) (-) (±) High Low (-) High Low High High [195] 
SNU182 (-) (-) (±) High high High High High High High n.t. 
 
 (-); not detected; ±; traces; n.t.; not tested. 
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4.1.2 Expression TCF/LEF family of transcription factors 
Using the same panel of HCC cell lines, we analyzed the expression of 45 Wnt pathway 
genes by RT-PCR assay for TCF/LEF factors. The TCF-1 and TCF-4 were highly expressed in 
all HCC cell lines, while TCF-3 expression was limited to a subset of cell lines (Figure 4.1.4). 
LEF-1 expression was negative or weak, except for SNU398 cells. These findings indicated that 
all HCC cells were equipped with at least two nuclear factors mediating canonical Wnt signaling. 
These experiments have been performed by K.Benhaj [5]. 
 
 
Figure 4.1.4 Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell lines. 
Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay of four members of 
TCF/LEF family. See Figure 4.1.3 for GAPDH loading control. 
 
4.1.3 Expression of Frizzled receptors and LRP co-receptors 
Next, 10 Frizzled receptors and their two co-receptors were analyzed.  Two canonical 
(FZD1, FZD5) and three noncanonical (FZD3, FZD4, FZD6) Frizzled receptors were positive in 
all cell lines tested. Also, most of the cell lines expressed FZD2, FZD7 and FZD8 (Figure 4.1.5-
top). All cell lines also expressed LRP-5 and LRP-6 co-receptors (Figure 4.1.5-bottom). HCC cell 
lines were equipped with canonical and noncanonial Wnt signaling receptors, so that each HCC 
cell line was likely to respond to both canonical and noncanonical Wnt signals. These 
experiments have been performed by K.Benhaj. 
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Figure 4.1.5 Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma 
cell lines (Modified from [5]).  Frizzled receptors involved in canonical and noncanonical Wnt signaling were tested 
for expression by RT-PCR assay (Top). The expression of LRP co-receptors was analyzed similarly (bottom). Total 
RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. See Figure 4.1.3 for 
GAPDH loading control. 
 
4.1.4 Differential expression of canonical and noncanonical Wnt ligands 
In humans, 19 known genes encoding canonical and noncanonical Wnt ligands were 
identified [196]. Among eight known canonical Wnt ligands, only Wnt3 was strongly and 
uniformly expressed in all cell lines tested. Most of the cell lines also expressed Wnt10b strongly 
(Figure 4.1.6). Four out of seven noncanonical Wnt ligands, Wnt4, Wnt5a, Wnt5b and Wnt 7b 
were expressed in most of the poorly differentiated cell lines tested. Well differentiated cell lines 
did not express these ligands. Wnt4, Wnt5a and Wnt5b transcripts were not detectable in three 
cell lines, and Wnt7b in two of this group of cell lines (Figure 4.1.7-top). Other Wnt ligands were 
not characterized in terms of their specificity [196]. Among these ligands, Wnt9a expression was 
detectable in nearly all cell lines tested. In contrast, Wnt9b and Wnt2b expressions were 
associated to well differentiated and poorly differentiated cell lines, respectively (Figure 4.1.7-
bottom).  
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Figure 4.1.6 Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell lines (Modified 
from [5]). Canonical Wnt ligands were tested for expression by RT-PCR assay. Total RNAs were extracted from cell 
lines and used to detect gene expression by RT-PCR assay. See Figure 4.1.3 for GAPDH loading control. 
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Figure 4.1.7 Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in 
hepatocellular carcinoma cell lines (Modified from [5]). Noncanonical and unclassified Wnt ligands were tested 
for expression by RT-PCR assay. Total RNAs were extracted from cell lines and used to detect gene expression by 
RT-PCR assay. See Figure 4.1.3 for GAPDH loading control. 
 
HCC cell lines, independent of their differentiation status, were equipped with major components 
of Wnt signaling pathway with the exception of noncanonical Wnt ligands. In contrast, Wnt 
ligand expression displayed two types of selectivity. First, among known canonical ligands, only 
Wnt3 and Wnt10b displayed strong expression in most cell lines showing no specificity at all. 
Second, four noncanonical Wnt ligands were expressed in HCC cell lines with a high selectivity 
for poorly differentiated ones. These findings may have several implications. Most, most HCC 
cell lines were equipped with an canonical Wnt ligands, as reported previously for breast and 
ovarian cancer cell lines [197]. In contrast, selective expression of noncanonical Wnt ligands in 
only poorly differentiated cell lines could be due to autrocrine noncanonical Wnt signaling 
system in these cells. Paracrine mechanism is another possibility also. Noncanonical Wnt ligands 
including Wnt 5a might inhibit canonical Wnt signaling in HCC cells, as previously reported in 
other cell types [198-200]. These experiments have been performed by K.Benhaj [5]. 
 
4.1.5 Autocrine canonical Wnt signaling in well differentiated hepatocellular carcinoma 
cell lines 
Activated TCF/LEF-dependent transcription by canonical signalling activity can be 
quantified by reporters containing TCF/LEF-responsive elements [67, 201]. We surveyed 
canonical Wnt signaling in HCC cell lines using TCF/LEF reporter pGL3-OT plasmid, as 
described previously [202]. First, we compared TCF/LEF (TCF) activity in three cell lines with 
known mutations in canonical Wnt signaling pathway (Figure 4.1.8.a). Hepatoblastoma-derived 
well-differentiated HepG2 cell line displays β-catenin mutation. Poorly-differentiated SNU398 
and SNU475 cell lines display β-catenin and AXIN1 mutations, respectively [188, 203]. We 
obtained the highest normalized TCF activity with HepG2 cells. Compared to HepG2, SNU398 
cells displayed 50% less TCF activity. SNU475 cells despite having Axin1 deletion (data not 
shown; [188, 203], no TCF activity is detected in SNU475 cells. On the other hand, another 
AXIN1 mutant cell line PLC/PRF/5 also being a well differentiated cell line, showed high TCF 
activity [203].  
 60 
We also screened the TCF activity of other cell lines that displayed wild-type β-catenin 
and AXIN1 status [188, 202-203]. (3-4 fold) TCF activity was detected in well-differentiated 
Huh7 and Hep3B cell lines; this is low but found to be significant. Whereas, all five poorly 
differentiated cell lines SNU449, SNU387, FOCUS, Mahlavu and SNU182 and well 
differentiated Hep40 cell line showed no detectable TCF activity (Figure 4.1.8.b).  Hep40 cells, 
being a well differentiated cell line was included in this group although it shows a missense 
AXIN1 mutation/polymorphism (R454H). This is because functional significance of this 
mutation is not fully characterised [202]. 
 
Figure 4.1.8 Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in 
poorly differentiated hepatocellular carcinoma cell lines (modified from[5]). (a) Comparative analysis of the 
canonical Wnt signaling in hepatoma cell lines with known mutations of β-catenin or Axin-1 genes. TCF reporter 
assay shows that well-differentiated HepG2 cells display high signaling activity. In contrast, canonical Wnt signaling 
is attenuated in poorly differentiated SNU398, and undetectable in poorly differentiated SNU475 cell line. Assays in 
triplicate, error bars; SD. (b) Comparative analysis of the canonical Wnt signaling in HCC cell lines with wild-type 
β-catenin and Axin-1 genes. Huh7 and Hep3B cell lines (both well-differentiated) display weak but significantly 
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increased TCF reporter activity. Other cell lines (all poorly differentiated, except Hep40) display no detectable TCF 
reporter activity. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) 
plasmids, respectively. Assays in triplicate, error bars; S. D. Cells were transfected with the reporter gene pGL3-OT 
(OT) harboring LEF-1/TCF binding sites for β-catenin and the corresponding pGL3-OF (OF) without these sites. 
 
Taken together, 12 hepatoma cell lines were tested for TCF activity. Independent of β-
catenin or AXIN1 status, TCF activity was detected in four out of five (80%) well-differentiated 
cell lines, whereas only one out of seven (14%) poorly differentiated cell lines had constitutive 
TCF activity. First, this data correlated with the hypothesis that well-differentiated HCC cell lines 
display in general an autocrine/paracrine canonical Wnt signaling. Second, the great majority of 
poorly differentiated cell lines lack such autocrine/paracrine activity despite the expression of 
canonical Wnt3 ligand.  
 
4.1.6 Canonical Wnt signaling is repressed in poorly differentiated hepatocellular 
carcinoma cells 
The lack of canonical Wnt activity in poorly differentiated cells could be due to either 
lack of significant signaling activity, or alternatively to an active repression. Axin2, HTLE 
family, hAES, Chibby, CTBP and ICAT downstream to β-catenin display inhibitory activity on 
canonical Wnt signalling [204]. We checked the expression of these genes, but failed to detect 
any correlation with TCF activity or differentiation state (Figure 4.1.9).  
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Figure 4.1.9 Expression analysis of genes inhibiting canonical Wnt signaling downstream to β-catenin in HCC 
cells. Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH RT-
PCR was used as a loading control. 
Next, we compared TCF activity in Huh7, SNU449 and SNU182 cell lines ectopically 
expressing a mutant (S33Y)-β-catenin (Figure 4.1.10). Total β-catenin protein in Huh7 and 
SNU449 but not that strong with SNU182 cells was detected after transient transfection (Figure 
4.1.10a). Well-differentiated Huh7 cells responded to mutant β-catenin expression by a strong 
activation of TCF/LEF reporter (130 folds). Under the same experimental conditions, only 5 folds 
activity was detected in SNU449 cells. SNU182 cells were totally unresponsive (Figure 4.1.10b) 
[5]. These important differences between well-differentiated and two different poorly 
differentiated cell lines are apparently not due because of transient transfection efficiencies, the 
measured activities have been normalized by dual luciferase assay (see material and methods 
section). 
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Figure 4.1.10 Ectopic expression of mutant β-catenin induces high canonical Wnt activity in well-
differentiated, but not in poorly differentiated hepatocellular carcinoma cells (modified from [5]). (a) Well-
differentiated Huh7, and poorly differentiated SNU449 and SNU182 cell lines were co-transfected with either pCI-
neo-mutant β-catenin (S33Y) plasmid (S33Y-β-catenin +) or empty pCI-neo plasmid (S33Y-β-catenin -), and cellular 
β-catenin levels at post-transfection 48 h were tested by immunoblotting. Calnexin was used as a loading control. (b) 
Cell lines were treated as described, then pCI-neo-mutant β-catenin (S33Y)-transfected cells were subjected to TCF 
reporter assay. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, 
respectively. Assays in triplicate, error bars; SD. Co-transfections included pGL-OT or pGL-OF, in addition to pCI-
neo plasmids in both (a) and (b). 
 
Next, we generated a clone from SNU449 cells (SNU449-cl8) with Tet repressor 
controlled expression of N-terminally truncated β-catenin (aa 98-781) in order to confirm this 
data.  These forms of mutant β-catenin are frequently detected in cancer cells including HCC. 
The lack of Ser/Thr phosphorylation sites (aa Ser23, Ser29, Ser33, Ser37, Thr41, Ser45) that are 
critically involved in its ubiquitin-mediated degradation, leads to oncogenic activation canonical 
Wnt signaling [67]. As shown in figure 4.11a, SNU449-cl8 cells expressed only wild-type 
β−catenin in the presence of tetracycline (Tet-on conditions), while expressing both wild-type 
and truncated β-catenin at comparable levels in Tet-off conditions. Only a weak activation (3-4 
folds) of TCF reporter activity was obtained, similar to data obtained by transient transfection 
experiments (Figure 4.1.11b). This low level of activation was similar to that seen in well-
differentiated HCC cells in the absence of β-catenin or Axin-1 mutation (Fig. 4.1.8b), and 
confirmed that Wnt signaling is actively repressed in this poorly differentiated HCC cell line. For 
comparison, well-differentiated HepG2 cells expressing wild-type and a similar N-terminally 
truncated β-catenin (D25-140aa) activated TCF reporter gene by more than 60-fold (Figure 
4.1.8a). In other words, although both Tet-off SNU449-cl8 and HepG2 cells displayed a 
heterozygous truncating β-catenin mutation, TCF activation was 15-fold less in poorly 
differentiated SNU449 background.  We performed immunofluorescence detection to see 
accumulation of truncated β-catenin using confocal microscopy (Figure 4.1.11c). The induction 
of truncated β-catenin in Tet-off SNU449-cl8 cells did not change membrane form of β-catenin 
distribution significantly. Only a weak cytoplasmic accumulation with slight increases in both 
membrane and nuclear localization were observed. Whereas  in colorectal cancer cells (APC-
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mutated), used as a positive control [205], we detected strong nuclear accumulation of β-catenin 
by the same technique.   
 
Figure 4.1.11 Minimal TCF reporter activity and lack of nuclear accumulation of mutant β-catenin in poorly 
differentiated SNU449.cl8 cells (modified from [5]). SNU449 cells were stably transfected with Tet-responsive 
∆N-β-catenin expression vector to obtain SNU448.cl8 cells. (a) Induced expression of N-terminally truncated ∆N-β-
catenin protein in the Tet-Off conditions, as tested by western blot assay. Total cell lysates were extracted from cells 
and subjected to western blot assay using anti-β-catenin antibody. (b) TCF activity is only weakly induced in Tet-off 
conditions, as tested by duplicate experiments. (c) SNU449.cl8 cells at Tet-On state express wild-type endogenous β-
catenin protein principally located at cell membrane. Under Tet-Off conditions the staining pattern remains almost 
identical despite ∆N-β-catenin expression. Note lack of nuclear accumulation. SW480 cells used as positive control 
displayed strong nuclear β-catenin staining. Cells were grown on coverslips, subjected to indirect 
immunofluorescence assay using anti-β-catenin antibody (red), counterstained with DAPI (blue) and examined by 
confocal microscopy. 
 
4.1.7 WNT5A inhibits canonical Wnt signaling in HCC cells 
Wnt5a is best known for its antagonistic effect on canonical Wnt signaling  [206]. 
Therefore, we ectopically expressed Wnt5a and checked its effect on mutant-β-catenin-induced 
TCF activity in Huh7 cell line. In the absence of Wnt5a, TCF activity was measured more than 
160-fold by mutant β-catenin in this cell line. Co-expression of Wnt5a resulted in three-fold 
repression of TCF activity (Figure 4.1.12a).  To confirm our observations, we also tested the 
effects of Wnt5a on TCF activity induced by endogenous mutant β-catenin using HepG2 cell 
line. The expression of Wnt5a in this cell line caused a significant inhibition of TCF activation 
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mediated by endogenous β-catenin (P < 0.05; Figure 4.1.12b). We concluded that Wnt5a that is 
selectively expressed in poorly differentiated HCC cell lines, and probably similarly acting 
selectively in the repression of canonical Wnt signaling in these cells.    
 
Figure 4.1.12 Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cells. (a) Huh7 cells were co-
transfected with either pCI-neo-mutant β-catenin (S33Y) plasmid (S33Y-β-catenin +) along with pShuttle-IRES-
WNT5a or empty pShuttle-IRES vector. 48 hours post transfection; cells were subjected to TCF reporter assay. TCF 
activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays 
in triplicate, error bars; SD. Co-transfections included pGL-OT or pGL-OF, in addition to pCI-neo-S33Y-β-catenin 
and pIRES plasmids. (b) HepG2 experiments were performed under similar conditions, except that pCI-neo-mutant 
β-catenin (S33Y) plasmid was omitted. 
 
4.2 Selective monoclonal antibodies directed against C-terminal domain of β−Catenin 
We aimed to develop monoclonal antibodies (Mabs) that selectively recognize membrane-
bound, cytoplasmic and nuclear beta-catenin forms and to test their clinical value using 
immunohistochemical staining of several tumor samples. For this purpose a former PhD student 
Nuri Ozturk obtained several home–made monoclonal antibodies and characterized the epitopes 
of each antibody. The details of immunization and hybridoma procedure and epitope mapping 
can be found at thesis of Dr. Nuri Ozturk (Ozturk, 2006). Here we will discuss further 
characterization of these monoclonal antibodies (Mabs). The two Mabs (9E10 and 4C9) with 
selective recognition ability were identified. These Mabs recognized partially overlapping 
epitopes located at the last 10 amino acid residues of β-catenin. 9E10 was directed against a 
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seven amino acid epitope (771-SNQLAWF-777), the 4C9 was directed against the last four 
amino acids (DTDL) that is a binding site for PDZ-domain proteins (Ozturk N. unpublished 
data). 
4.2.1 Antibody Isotyping  
4C9 and 9E10 was classified as IgG1( ) by a mouse monoclonal antibody isotyping kit 
(Pierce ELISA Mouse Antibody Isotyping Kit, US).  
 
4.2.2 Selective immunoreactivity of 4C9 and 9E10 antibodies against cellular β-Catenin  
Among all known anti-β-catenin antibodies, our 4C9 and 9E10 antibodies occupy a 
particular position because together they are directed against the last 10 carboxy-terminal amino 
acids. This end of β-catenin is implicated in interactions with a handful of different proteins 
displaying PDZ domains, such β-catenin complexes are expected to be retained in specific 
locations where such PDZ domain proteins are located. For example, several of these proteins are 
known to anchor their binding partners in close proximity of plasma membrane. On the other 
hand, β-catenin has also known to be found in the cytoplasm as well as in the nucleus particularly 
when it is not involved in cadherin-mediated cellular adhesion and/or transducing wnt signaling 
into gene regulation at nuclear level. It is unknown whether such cytoplasmic and nuclear forms 
of β-catenin are also complexed with PDZ-domain proteins. We hypothesized that our antibodies 
could react selectively with different, presumably PDZ-bound and PDZ-free forms of β-catenin 
in different cellular locations; we tested in situ immunoreactivity of our antibodies with cellular 
β-catenin using immunoperoxidase, immunofluorescence and confocal microscopy techniques.  
To explore selective immunoreactivity of 4C9 and 9E10 antibodies, we performed detailed 
analyses on different cell lines using confocal microscopy techniques. It is known that activating 
mutations in the Wnt/β-Catenin pathway lead to accumulation of β-Catenin in the cytoplasm as 
well as in the nucleus where it interacts with TCF/LEF family of transcription factors and 
activates transcription of the Wnt responsive genes. Based on this model we have used 
immunofluorescence staining to study the effect of the mutations identified in the APC mutant 
colorectal carcinoma cell lines SW480, SW837 and β-Catenin mutant HCC cell line Snu398-i 
and ∆N-β-Catenin expressing inducible clone of another HCC cell line Snu449-c8. SW480 
colorectal carcinoma cells containing a truncated APC were intensely stained in the nucleus and 
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cytoplasm by both 4C9 and 9E10 whereas commercial anti-β-Catenin antibody (Transduction 
Labs) stained in the nucleus weakly. SW480 was not stained in the membrane with any of these 
antibodies (Figure 4.2.1.A).  Another APC mutant colorectal carcinoma cell line, SW837 was 
stained positively in the nucleus, with a very weak membrane staining by 4C9 and 9E10 whereas 
membrane was stained continuously by commercial anti-β-Catenin antibody and nucleus was 
negative (Figure 4.2.1.B). Snu398-i which has a missense β-Catenin mutation, showed that both 
antibodies showed a intense nuclear staining, while 4C9 and 9E10 have weak membrane staining 
when compared to commercial anti- β-Catenin antibody (Figure 4.2.1.C). These findings confirm 
that mutations in the Wnt/ β-Catenin pathway elements were activating and β-Catenin 
accumulates in the nucleus as mentioned above. Also extensive analysis of an inducible clone 
which stably expressed mutant β-Catenin (∆N-β-Catenin) and a mouse fibroblast cell line which 
expresses Wnt3a ligand stably confirmed this statement. Snu449.c8 with a tetracycline 
regulatable expression of mutant β-Catenin (∆N-β-Catenin) showed a 16 fold induction of Axin2 
which is a direct target of β-Catenin (Yuzugullu et al., unpublished data). This clone expresses 
∆N- β-Catenin in the absence of tetracycline. Snu449.c8 cells were stained intensely more in the 
nucleus and cytoplasm when compared to non-induced state. Commercial anti-β-Catenin 
antibody stained the membrane uniformly whereas 4C9 and 9E10 has an intense nuclear staining 
like APC mutant colorectal carcinoma cell lines (Figure 4.2.2.A and 4.2.2.B). Further 
experiments with Nih3T3 cells stably expressing wnt3a ligand also showed consistent data with 
the previous results. Cells cultured with the wnt3a conditioned media checked for the autocrine 
activity. Cells were stained in the nucleus intensely with 9E10 whereas membrane was not 
stained. Commercial anti-β-Catenin antibody had a uniform membrane staining (Figure 4.2.1.D). 
These results showed that as in colon cancer models, β-catenin and APC mutations led to 
accumulation of β-Catenin both in the cytoplasm and nucleus. Also our hybridomas successfully 
reacted against β-catenin in the nucleus and cytoplasm whereas membrane staining was more 
intense with commercial anti- β-Catenin antibody as shown with various cell types with different 
mutation status.    
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Figure 4.2.1 Confocal microscopy of 4C9, 9E10 and commercial β-catenin antibodies in β-catenin mutant cell 
lines.  Strong nuclear staining with 4C9 and 9E10 antibodies but not with commercial antibody in APC mutant 
colorectal carcinoma cell lines in (a) SW480 cell line, (b) in SW837, (c) in beta-catenin mutant HCC cell line 
Snu398-i and (d) wnt3a induced Nih3T3 cells. Note that commercial β-catenin antibody reacted to membrane beta-
catenin forms. Cells were grown on coverslips, subjected to indirect immunofluorescence assay using anti-β-catenin 
antibody (red), counterstained with DAPI (blue) and examined by confocal microscopy. 
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Figure 4.2.2 Confocal microscopy of 4C9, 9E10 and commercial β-catenin antibodies in poorly 
differentiated SNU449.cl8 cells.  (a) SNU449.cl8 cells at Tet-On state express wild-type endogenous β-catenin 
protein principally located at cell membrane. (b) Under Tet-Off conditions, ∆N-β-catenin accumulated in the nucleus 
detected by 4C9 and 9E10 Mabs but not with commercial antibody. Cells were grown on coverslips, subjected to 
indirect immunofluorescence assay using anti-β-catenin antibody (red), counterstained with DAPI (blue) and 
examined by confocal microscopy. 
 
4.2.3 9E10 Mab immunoreactivity with primary tissue and tumor samples: 
In order to show the selective immunoreactivity of these Mabs, we used 
immunohistochemistry staining of β-catenin in several types of paraffin embedded normal and 
carcinoma specimens. We first performed a comparative staining between the two antibodies 
using a total of 28 in situ ductal carcinoma and 26 invasive ductal carcinoma specimens. Staining 
in normal breast areas showed that both antibodies showed the same pattern of immunoreactivity 
specific to membrane with incomplete pattern with no nuclear staining (Figure 4.2.3.A and 
4.2.3.C). For the two different types of breast cancer tissues, both 4C9 and 9E10, showed 
heterogenous membrane staining, while nuclear and/or cytoplasmic stainings were not observed 
(Figure 4.2.3.B and 4.2.3.D). 
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Figure 4.2.3 Immunohistochemistry analysis of 4C9 and 9E10 in paraffin embedded normal and breast cancer 
samples. DAB Staining in normal breast areas showed that both antibodies showed the same pattern of 
immunoreactivity specific to membrane with incomplete pattern with no nuclear staining in (A) and (C), 
heterogenous membrane staining, while nuclear and/or cytoplasmic stainings were not observed in (B) and D). 
Based on these stainings, our antibodies showed specific immunoreactivity to membrane form of β−catenin in 35 of 
54 breast tumors (65 %) with 61% of in situ ductal carcinoma and 69% of invasive ductal carcinoma showing mostly 
weakly or moderately heterogeneous membrane staining (Table 4.2.1) 
 
Since both antibodies showed similar staining pattern in breast cancer samples, we 
continued analyzing a panel of carcinoma tissues with only clone 9E10. A total of 32 
hepatocellular carcinoma, 43 endometrial carcinomas and 62 colon carcinoma samples were 
stained with 9E10 Mab. 
Table 4.2.1 Distribution of membrane form of β-catenin expression in the tumor samples 
Tumor Type (n) Negative1 
(%) 
Weakly 
Positive2 
(%) 
Moderately 
Positive3 
(%) 
Highly Positive4 
(%) 
Total 
Positive 
(%) 
Colorectal carcinoma (54) 
        
2 
(3.5) 
 
2 
(3.5) 
 
9 
(17.0) 
 
41 
(76.0) 
 
51 
 (94.5) 
 
Hepatocellular carcinoma (32) 20 
(62.5) 
3 
(9.5) 
5 
(15.5) 
 
4 
(12.5) 
 
12 
(37.5) 
Endometrial carcinoma (42) 
      
 
30 
(71.5) 
2 
(5.0) 
4 
(9.5) 
 
6 
(14.0) 
 
12 
(28.5) 
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Breast carcinoma (54)  
     
    
  In situ ductal carcinoma (28) 
     
 
 Invasive ductal carcinoma (26) 
 
19 
(35.0) 
 
11 
(39.5) 
 
8 
(31.0) 
14 
(30.0) 
 
6 
(21.5) 
 
8 
(31.0) 
18 
(33.0) 
 
9 
(32.0) 
 
9 
(35.0) 
 
3 
(6.0) 
 
2 
(7.0) 
 
1 
(4.0) 
 
35 
(65.0) 
 
17 
(61.0) 
 
18 
(69.0) 
1=0-4%; 2=5-25%; 3=26-75%; 4=76-100% 
 
We performed immunohistochemistry staining in 33 hyperplastic and 42 endometrium 
tumor samples. In hyperplastic lesions of endometrium samples, heterogeneous β-catenin 
membrane staining was observed in 17 of (51,5%) 33 samples. Only one sample showed 
cytoplasmic staining, while nuclear staining was not observed in any elements of hyperplastic 
lesions. Membrane β-catenin staining patterns were observed in 12 of (28,5%) 42 of endometrial 
carcinomas, ranging from strong membrane (14%) staining to weak (5%) staining (Figure 4.2.4). 
Cytoplasmic immunostaining was observed only in 3 samples (< 1%). In one case with 
coexistence of carcinoma and atypical hyperplasia lesions, membrane immunoreactivity was 
found to be decreased in the former as compared to the latter, while nuclear immunoreactivity 
was not found in both lesions in all samples. 
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Figure 4.2.4 Immunohistochemistry analysis of 9E10 in paraffin embedded carcinoma samples. DAB Staining 
in nuclear positive mucinous colon carcinoma, nucleus negative, cytoplasm and membrane positive colon 
adenocarcinoma, only membrane positive colon adenocarcinoma and membrane and cytoplasm positive invasive 
breast cancer and only membrane positive endometrial cancer samples. 
 
We also stained 32 Hepatocellular carcinoma samples using the same technique. 12 of 
(37,5%) 35 samples exhibited membrane staining with different levels of staining. Nuclear and/or 
cytoplasmic staining was not observed in these samples.   
Previous reports showed that nuclear β catenin expression was highly associated with 
progression of colorectal tissue from normal epithelial tissue, polyps, adenomas, to carcinomas. 
Therefore we analyzed immunoreactivity of our antibody using a total of 54 patients with 
colorectal carcinoma samples, namely: 48 colorectal adenocarcinoma, 2 colorectal signet ring cell 
carcinomas, 3 mucinous carcinomas and 1 villous adenocarcinoma. Among these, two of the 
colorectal signet ring cell carcinoma samples were found to be negative. For the remaining colon 
carcinoma samples, 50 of (96,2%) 54 showed moderately or strong membrane staining with a 
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percentage of 17% versus % 76 respectively . Weakly and moderately nuclear, with or without 
cytoplasmic, immunostaining was apparent in 11 (20.5%) of 54 carcinomas. Weakly stained 
cytoplasmic β-catenin was found in 15 of (28%) of all samples (Figure 4.2.4). Table 4.2.2. 
 
Table 4.2.2 Distribution of different forms of ß-catenin expression in 54 colorectal cancer samples using 9E10 
antibody. 
Cellular  
localization 
Negative1 
(%) 
Weakly 
Positive2 
(%) 
Moderately 
Positive3 
(%) 
Highly 
Positive4 
(%) 
Total 
Positive 
(%) 
Nucleus 
 
 
Cytoplasm 
 
 
Membrane 
 
 
43 
(79.5) 
 
39 
(72.0) 
 
2 
(3.5) 
 
9 
(16.5) 
 
15 
(28.0) 
 
2 
(3.5) 
 
2 
(4.0) 
 
0 
(0.0) 
 
9 
(17.0) 
 
0 
(0.0) 
 
0 
(0.0) 
 
41 
(76.0) 
 
11 
(20.5) 
 
15 
(28.0) 
 
51 
 (94.5) 
 
 
 
4.3    Targeting human kinome and phosphatome in hepatocellular carcinoma cells using 
RNAi  
Our aim was to identify and inhibit human kinase and phosphatase genes that are 
contributing to escape from senescence. We started this project using our unique in vitro model 
of immortality/senescence. This model is composed of isogenic clones of liver cancer cell line 
Huh7. One isogenic clone was immortal and the other is senescence programmed. In 2006, our 
laboratory showed that this immortal clone of huh7 cell line is immortal and have the capacity to 
form tumor in nude mice whereas the other have reverted from immortality, and have a limited 
lifespan just like hepatocytes, and do not have the capacity to form tumors in vivo [130]. Using 
these two isogenic clones, we performed microarray analysis and more than 54000 probes were 
analyzed. We mapped 518 kinase and 223 phosphatases in this array and searched for kinases and 
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phosphatases that are upregulated more than 1 fold in immortal isogenic clones with respect to 
either early passages of senescent clones or in senescencent clone. We obtained 126 kinase genes 
and 28 phosphatase genes that are upregulated more than 1 fold in immortal clone. We further 
qualified and listed these genes using Pubmed and online databases like Oncomine and publicly 
annotated cancer genes lists and finally ordered these genes and called this list as “the priority 
list”. 
We further validated these genes using microarray expression results of cirrhotic and 
HCC samples performed in our laboratory. After siRNA screening of these target genes, we used 
automated system to check the efficiency of knockdown using the method that National Cancer 
Institute (NCI) is using.  
 
4.3.1 Validation of kinase and phosphatase target genes  
We validated our priority ordered genes using differentially expressed gene lists of in vivo 
microarray results performed in our group using HCC and cirrhotic samples. As a total 22 
cirrhotic and 17 HCC samples were used in this experiment and 6017 differentially expressed 
genes with p value ≤ 0,05 (Bagislar et al., unpublished data). We searched for the genes that are 
listed in 6017 differentially expressed genes. The values are listed in table 4.3.1 for kinases and 
Table 4.3.2. for phosphatases. 
 
Table 4.3.1 Validation of kinases obtained in vitro and in vivo 
Gene 
Symbol 
Probe 
Number 
Average 
Normal 
Log. 
Average 
tumor 
Log. 
Tumor- 
normal Log 
Tumor-normal 
fold change 
CDC2 203213_at 5.63 7.13 1.5 2.8 
CDC2 210559_s_at 4.88 6.27 1.4 2.6 
PBK 219148_at 4.22 5.52 1.3 2.5 
BUB1 209642_at 3.89 5.14 1.25 2.4 
CDC2 203214_x_at 5.21 6.2 0.99 2.0 
NEK3 239539_at 4.78 5.46 0.68 1.6 
CDK6 224851_at 8.25 8.93 0.68 1.6 
CASK 211208_s_at 8 8.63 0.63 1.5 
IRAK1 201587_s_at 8.32 8.94 0.62 1.5 
CASK 207620_s_at 6.18 6.76 0.59 1.5 
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PLK4 204887_s_at 5.21 5.79 0.58 1.5 
PAK1 230100_x_at 6.04 6.51 0.47 1.4 
PAK2 208877_at 8.19 8.65 0.47 1.4 
PLK1 202240_at 5.26 5.71 0.45 1.4 
PLK4 204886_at 2.83 3.28 0.45 1.4 
MASTL 228468_at 5.39 5.84 0.45 1.4 
HIPK2 225116_at 8.73 9.14 0.41 1.3 
BUB1 215509_s_at 4.05 4.46 0.4 1.3 
TRRAP 202642_s_at 7.73 8.1 0.37 1.3 
MAP3K7 206854_s_at 7.97 8.33 0.36 1.3 
MAP2K2 202424_at 8.62 8.98 0.36 1.3 
NEK3 213116_at 7.08 7.41 0.33 1.3 
HIPK2 225097_at 9.01 9.34 0.33 1.3 
TLK1 210379_s_at 4.68 5 0.32 1.2 
PAK2 236283_x_at 6.88 7.18 0.3 1.2 
MAP3K7 206853_s_at 6.82 7.1 0.28 1.2 
MAPKAPK2 201460_at 8.3 8.57 0.27 1.2 
PLK4 211088_s_at 2.95 3.14 0.18 1.1 
BUB1 216277_at 3.32 3.46 0.14 1.1 
 
Table 4.3.2 Validation of phosphatase genes obtained in vitro and in vivo  
Gene 
Symbol 
Probe 
Number 
Average 
Normal 
Log. 
Average 
tumor 
Log. 
Tumor- 
normal Log 
Tumor-normal 
fold change 
CDKN3 1555758_a_at 5.04 6.49 1.45 2.73 
CDKN3 209714_s_at 5.33 6.51 1.18 2.27 
PSPH 205194_at 5.57 6.29 0.72 1.65 
PPP3CB 209817_at 7.18 7.66 0.48 1.39 
PTPN11 212610_at 10.23 10.67 0.44 1.36 
PTPRM 1555579_s_at 8.51 8.93 0.42 1.34 
CDC25C 217010_s_at 3.66 4.03 0.37 1.29 
PTPRM 203329_at 8.04 8.38 0.34 1.27 
PTPN18 1569552_at 3.21 3.54 0.33 1.26 
PPP4R1 201594_s_at 8.8 9.09 0.29 1.22 
PNKP 218961_s_at 6.76 7.01 0.25 1.19 
PTPN18 203555_at 7.5 7.7 0.2 1.15 
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4.3.2 In vitro screening 
We screened a total of 378 siRNAs targeting 126 kinase genes and 84 siRNAs targeting 
28 phosphatases in vitro using Huh7 cells. We obtained and quantified the viable cells left in the 
plates after 72 hours of transfection. We calculated normalized values and inhibition rates of each 
transfection and listed them as in table 4.3.3. In table 4.3.3 and figure 4.3.1, we showed the 
kinase genes showing 70% or more inhibition. In table 4.3.4. and figure 4.3.2 we showed the  
phosphatases whose knock down induced growth inhibition of 50% or more. As a total of all 
siRNAs, 6% of kinases and 17% of phosphatase genes were found to be effective.  
 
Table 4.3.3 in vitro screening results of kinases 
Group name Gene Name Repeat 1 Repeat 2 Repeat 3 Mean STDV Normalized survival % 
OTH22_1071 PLK1_1071 0.296 0.383 0.525 0.401 0.116 55.7 
OTH22_1316 PLK1_1316 0.142 0.244 0.521 0.302 0.196 41.9 
OTH22_881 PLK1_881 0.128 0.180 0.299 0.202 0.088 28.1 
CAM13_287 CHK1_287 0.276 0.258 0.193 0.242 0.044 33.6 
CAM13_758 CHK1_758 0.241 0.203 0.221 0.222 0.019 30.7 
CAM13_908 CHK1_908 0.228 0.395 0.356 0.326 0.087 45.3 
CAM2_182 CaMK1a_182 0.112 0.148 0.151 0.137 0.022 19.0 
CAM2_192 CaMK1a_192 0.134 0.147 0.144 0.142 0.007 19.6 
CAM2_426 CaMK1a_426 0.136 0.127 0.112 0.125 0.012 17.3 
CAM47_000 smMLCK_000 0.130 0.127 0.229 0.162 0.058 22.5 
CAM47_001 smMLCK_001 0.186 0.118 0.200 0.168 0.044 23.3 
CAM47_002 smMLCK_002 0.128 0.175 0.374 0.226 0.131 31.3 
CAM59_1664 PKD3_1664 0.472 0.393 0.444 0.436 0.040 60.5 
CAM59_550 PKD3_550 0.287 0.169 0.201 0.219 0.061 30.4 
CAM59_603 PKD3_603 0.216 0.259 0.180 0.218 0.040 30.3 
CAM9_1002 CaMK2d_1002 0.356 0.392 0.217 0.322 0.092 44.6 
CAM9_1063 CaMK2d_1063 0.302 0.125 0.178 0.202 0.091 28.0 
CAM9_981 CaMK2d_981 0.367 0.214 0.181 0.254 0.099 35.2 
CMG11_1253 PCTAIRE2_1253 0.133 0.198 0.564 0.298 0.232 41.4 
CMG11_1333 PCTAIRE2_1333 0.233 0.441 0.287 0.320 0.108 44.4 
CMG11_943 PCTAIRE2_943 0.223 0.187 0.237 0.216 0.026 29.9 
CMG2_213 CDC2_213 0.144 0.241 0.275 0.220 0.068 30.5 
CMG2_322 CDC2_322 0.203 0.211 0.271 0.228 0.037 31.7 
CMG2_69 CDC2_69 0.180 0.241 0.219 0.213 0.031 29.6 
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Figure 4.3.1. Normalized survival percentage of kinase genes 
 
Table 4.3.4 in vitro screening results of phosphatases 
Group name Gene Name Repeat 1 Repeat 2 Repeat 3 Mean STDV Normalized survival % 
PTP030-1824 PTPN11-1824 0.952 0.853 1.106 0.970 0.127 134.6 
PTP030-5015 PTPN11-5015 0.217 0.218 0.302 0.246 0.049 34.1 
PTP030-5849 PTPN11-5849 0.479 0.567 0.615 0.554 0.069 76.8 
OTHER2-014-241 INPP4A-241 1.251 1.285 1.341 1.292 0.045 179.2 
OTHER2-014-2463 INPP4A-2463 0.274 0.299 0.404 0.326 0.069 45.2 
OTHER2-014-550 INPP4A-550 0.212 0.359 0.879 0.483 0.350 67.0 
PTP001-2273 PTPRA-2273 0.743 1.063 1.069 0.958 0.187 132.9 
PTP001-2836 PTPRA-2836 0.390 0.402 0.411 0.401 0.011 55.6 
PTP001-333 PTPRA-333 0.297 0.365 0.391 0.351 0.049 48.7 
OTHER3-10-513 PNKP-513 0.525 0.482 0.723 0.577 0.129 80.0 
OTHER3-10-514 PNKP-514 0.327 0.330 0.434 0.364 0.061 50.4 
OTHER3-10-550 PNKP-550 1.329 1.201 1.287 1.272 0.065 176.5 
PTP001-2273 PTPRA-2273 0.743 1.063 1.069 0.958 0.187 132.9 
PTP001-2836 PTPRA-2836 0.390 0.402 0.411 0.401 0.011 55.6 
PTP001-333 PTPRA-333 0.297 0.365 0.391 0.351 0.049 48.7 
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Figure 4.3.2 Normalized survival percentage of phosphatase genes 
 
We also showed the map of effective kinases on the human kinome tree as in figure 4.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3    Map showing the effective kinases in the kinome tree 
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4.3.3 Development of in vivo screening method 
In order to validate the effect of knockdowns of kinases and phosphatases we developed 
xenograft models using Huh7 cell line. 10x10 7 cells were injected on the back of the nude mice 
and after xenograft models are obtained, using Alexa-RAFT-RGD and Alexa Transferrin dyes 
targeting only tumor cells, we tried to image implanted tumor cells using fluorescent imagers. 
Although we obtained images of xenograft tumors under white light both imaging and targeting 
methods were negative (figure 4.3.4.A) Since Alexa labelled RAFT-RGD molecules are targeting 
αV-β3 integrin molecules on the membrane surface of Huh7 cells, it seems that these cells are 
negative for this type of receptor. These results also showed that Huh7 cells are transferrin 
receptor negative as well (figure 4.3.4.B). All the Alexa RAFT-RGD dyes are observed in 
kidneys if the animal rather than the tumor as observed in the pictures. Positive control cells of 
TSA cell line were imaged nicely (figure 4.3.4.C) 
 
Figure 4.3.4 in vivo imaging of Alexa-RAFT RGD targeted Huh7 xenograft tumors in A. in vivo 
imaging of Alexa-transferrin targeted Huh7 xenograft tumors in B. Positive control cells (TSA cells) imaged 
with RAFT molecule in C. 
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4.4 Epigenetic targets in liver cancer  
In order to identify novel epigenetic marks associated with immortality and senescence, 
we have characterized the histone methylation patterns in vitro and in vivo. We analyzed isogenic 
senescent and immortal HCC cells, as well as cirrhosis and HCC tissues. (Bagislar S. & 
Yuzugullu H. unpublished data). To test this hypothesis, we performed immunoblotting and 
immunostaining of each histone methylation pattern. Immunoblotting results in vitro and in vivo 
are already discussed in the PhD dissertation of Sevgi Bagislar (Bagislar, 2010). To confirm the 
results using a second in vitro method, we have stained isolated normal hepatocytes, immortal 
Huh7 cells and as a senescence model, we have treated Huh7 cells 3 days with low dose 
Doxorubucin (50 ng/mL). We showed that senescence is induced more than 90% for both Huh7 
cells and HepG2 with 3 days and persisted up to 6 days (figure 4.4.1)(Gursoy-Yuzugullu et al 
unpublished data ).  
 
Figure 4.4.1 SABG staining of HepG2 and Huh-7 cells and the rate of SABG-positive cells reached as 
high as %90 percent after LD DOX treatment for 3 days and persisted up to day 6 as well. 
 
Immunoblotting with H3K4Me1 showed that both normal hepatocytes and Huh7 cells and 
senescent cells were homogenously weak positive, and for H3K4Me3 remained strong positive 
for all cell types (figure 4.4.2.A top). For H3K9me1 and H3K9me3, cells were stained strongly 
positive. These residues were also found to be all same for all the conditions tested. For H3K27 
residues, normal hepatocytes were stained strong positive for mono and tri methyl antibodies and 
a weak staining of dimethyl K27. Doxorubucin treated Huh7 cells and immortal cells for all 
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methylation status of H3K27 were same. Dimethylation of H3K27 is found to be increased in 
Huh7 with respect to normal hepatocytes (figure 4.4.2.A bottom). Mono and trimethylation of 
H3K36 was strong for normal hepatocytes and remained the same for Huh7 immortal and 
senescence conditions, with a low staining pattern for monomethyl H3K36 in normal hepatocytes 
and a strong positivity for immortal huh7 cells (figure 4.4.2.B top). 
Only H4K20me3 is strong positive for normal hepatocytes, with monomethylation 
negative and dimethylation heterogenous positive. Monomethylation of H4K20 in Huh7 cells and 
senescence condition was scattered but strong positive. As confirmed here, H4K20me3 is 
decreased in Huh7 cells and became strong positive in Huh7 senescence conditions (figure 
4.4.2.B bottom).  
 
 
Figure 4.4.2 Immunostaining of Normal hepatocytes, Huh7 and LD-Doxorubucin treated Huh7 cells with 
methylation specific histone lysine antibodies. 
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For arginine residues of three conditions, H3R2Me2, H3R17Me2 and H4R3Me2 
remained unchanged with a strong nuclear positivity.  
Lastly we also checked Pan Acetyl staining of H4 and H4K5Acetylation in the three cell 
types. We found that all three conditions H4Pan Acetyl levels and H4K5Acetylation were strong 
positive and remained unchanged.  
 
Figure 4.4.2.C Immunostaining of Normal hepatocytes, Huh7 and LD-Doxorubucin treated Huh7 cells with 
arginine methylation and acetylation specific histone antibodies. 
 
4.4.1 Immunostaining of Histone modifying Enzymes in normal hepatocytes and immortal 
Huh7 cells and DNA damage induced senescence model 
After we have the levels of methylation of each histone mark in vitro, using the same 
conditions and models we also stained the histone modifying enzymes that we previously 
identified from differentially expressed gene list (unpublished data). These enzymes might be 
responsible for the decrease of global histone methylation in HCC. We stained EZH2 HMT 
enzyme acting on H3K27Me residue and it is clear from the staining that this enzyme is weakly 
expressed in normal hepatocytes and became strong positive in Huh7 cells and remained same in 
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our DNA damage senescence model (figure 4.4.3 top). We stained three enzymes acting on 
H3K36 residue, one demetylase FBXL11 and two histone methyltransferase SetD2 and WHSC1. 
Among these FBXL11 is studied extensively in this thesis. FBXL11 remained strong positive for 
the three  
 
Figure 4.4.3 Immunostaining of normal hepatocytes, Huh7 and LD-Doxorubucin treated Huh7 cells with 
EZH2, SETD8 and Suv420H1 enzyme antibodies. 
 
Conditions (figure 4.4.4 bottom). SetD2 a histone methyltransferase is stained weakly nuclear 
and some cytoplasmic staining in normal hepatocytes and correlating with H3K36me3 staining it 
is strongly positive in nucleus of huh7 cells and remained the same in senescence model as well 
(figure 4.4.4.top). Very interestingly WHSC1 gene a methyl transferase is negatively stained in 
normal hepatocytes and became very strongly nuclear positive for huh7 cells and remained strong 
in its senescence model (figure 4.4.4 middle).  
For the H4K20 methylation, we checked the status of two histone methyltransferase one 
SETD8 and the other our home made antibody Suv420H1 (0032). For SetD8, we obtained weak 
positivity in normal hepatocytes and a strong staining in Huh7 cells and senescence model, 
confirmed the increase in positivity of H4K20Me2 in huh7 and senescence cells. Lastly 
Suv420H1 enzyme is found negative for all the conditions tested. 
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Figure 4.4.4 Immunostaining of normal hepatocytes, Huh7 and LD-Doxorubucin treated Huh7 cells with 
SETD2, WHSC1 and FBXL11 enzyme antibodies. 
 
4.4.2 Histones are hypomethylated in HCC compared to cirrhosis and normal hepatocytes 
in vivo 
To check the in vivo relevance of these in vitro findings, we performed 
immunohistochemistry analysis with the antibodies of residues which were validated to be altered 
in-vitro using immunostaining and western blotting. We have collaborated with Dr. Funda 
Yılmaz in Ege University Department of Pathology for the staining of selected histone residues. 
She performed staining of formalin fixed paraffin-embedded normal liver, cirrhosis, and HCC 
tissue samples with H3K27me3, H4K20me3, H3K36me3, H3R17me2a, H4R3me2a residues. 
(Bağışlar and Yuzugullu et al., unpublished data). 
These data were also stated in the PhD dissertation of Dr. Sevgi Bagislar (Bagislar, 2010). 
During this part of my thesis, we performed many experiments together with her and in order to 
keep the unity, harmony and to keep the integrity of this part, I included the in vivo data as 
follows:
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Figure 4.4.5 Histone methylation in in-vivo Images of Pattern 1 and 2 staining. Homogenously and strongly 
stained areas were named as “Pattern 1”, on the other hand heterogeneous and weak staining, partial or local loss of 
nuclear positivity was called “Pattern 2”. Top, and middle panel images were examples of H3K36me3 staining, 
bottom panel from H3R17me2a straining.  
 
All normal livers stained showed a homogenous and ubiquitous nuclear positivity pattern 
in 10 samples. This kind of staining pattern will be named as pattern 1 (Figure 4.4.5). Local or 
dispersed loss of nuclear positivity in a heterogeneous fashion (pattern 2) is obtained for all 
(n=10) HCCs for all residues, and in cirrhosis for H4K20me3 and H3R17me2 (Figure 4.4.5). A 
significant decrease in macro regenerative nodules but not with micro-regenerative nodules was 
obtained for H3K36me3 and H3R17me2 residues. Loss of trimethylation of H3K27 residue was 
10% for cirrhotic samples (n=13) with a corresponding significantly higher decrease reaching to 
33% of HCC (n=10) was observed (Figure 4.4.6). Ubiquitous and homogeneous H4K20me3 
nuclear staining in normal livers decreased 33% for cirrhotic samples, and decreased more 
prominently, 75%, for HCC. The same decrease was observed with trimethylation of H3K36me3. 
H3K36Me3 staining decreased 33% for HCC samples. Partial loss was observed in 25% and 66% 
of cirrhosis and HCC samples, respectively. For H4R3me2a, staining decreased 12% for cirrhotic 
samples and 66% for HCC samples. These global hypomethylation of H3K27me3, H4K20me3, 
H3K36me3 and H4R3me2a in HCC positively correlated with in-vitro stainings performed with 
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immortal and senescent Huh7 clones. These residues may be involved in aberrant misregulation 
of oncogenes and tumor suppressors in HCC.   
 
Figure 4.4.6 Bar-chart representations of the results of immunohistochemistry counts of indicated histone 
residues. Y-axis values were calculated by dividing the number of pattern 1tissue samples to number of all tissue 
samples for a given histone residue and tissue type. A partial loss of the 5 residues tested in HCC samples was 
observed. Bottom chart represents the same counts comparing macro- and micro-regenerative nodules. H3K36me3 
and H3R17me2a residues were observed to loss ubiquitous staining pattern in macro-regenerative nodules compared 
to micro-regenerative nodules.   
 
4.4.3 Validation and targeting of histone modifying enzymes responsible for aberrant 
histone codes  
To search for these aberrant histone modifying enzymes playing a role during 
hepatocarcinogenesis, we have selected 5 enzymes acting on these validated methylated residues 
and further characterized their role in HCC. 
 87 
 
 
Figure 4.4.7 RT-PCR analysis of histone modifying enzymes in HCC cell lines. A) FBXL11 isoforms B.) 
SMYD2 gene C.) SETD2 gene isoforms and D.) JMJD2b isoforms. 
 
We selected enzymes acting on H3K9, H3K27, H3K36 and H4K20 residues. 
JHDM1a/FBXL11 and JMJD2b demetylase enzymes works on H3K36 residues, JMJD3 
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demetylase work on H3K27 residue and SETD2 and SMYD2 histone methyltransferases work on 
H3K36 residues and Suv420H1 histone methyl transferase enzyme works on H4K20 residue. We 
first checked the isoforms of each enzyme using databases and their expression levels in HCC 
cell lines using semi quantitative RT-PCR. We ordered specific primers to each isoforms of 
enzymes using different sequences and skipping introns as well. As shown in figure 4.4.7.A, we 
showed that FBXL11 demetylase enzyme isoform 203 is ubiquitiously expressed in all HCC cell 
lines tested, whereas isoform 201 and 202 do not exist. Another histone methyltransferase 
SMYD2 gene acting on the same residue with a single isoform is also ubiquitously expressed in 
HCC cell lines (figure 4.4.7.B). SetD2 histone methyltransferase also acting on H3K36Me 
residue have also two isoforms and isoform number 2-001 is also highly expressed in these cell 
lines tested (figure 4.4.7. C). JMJD2b enzyme acting on H3K9 and H3K27 with an isoform 
number 201 is highly expressed in 6 of 8 HCC cell lines tested (figure 4.4.7.D). Lastly, H4K20 
methyltransferase Suv420H1 has two isoforms and both isoforms are homogenously expressed in 
13 out of 14 HCC cell lines (figure 4.4.7.E). 
  
Figure 4.4.8 RT-PCR analysis of histone modifying enzymes in tumor and non-tumor pairs. FBXL11 isoforms  
SMYD2 gene and JMJD2 is shown. (NT: normal tissue, T: tumor sample) 
 
Further characterization of these selected enzymes, have a role in tumorigenesis process, 
we also checked their expression status in tumor and non tumor samples using semi quantitative 
RT-PCR method (figure 4.4.8). We selected FBXL11, JMJD2b and SMYD2 enzymes in the first 
place. Among these three residues FBXL11 enzyme is shown to be upregulated in 4 out 5 tumor 
samples with respect to non-tumor pairs. SMYD2 enzyme is found to be slightly increased in two 
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tumor samples with a homogenous expression in all the samples. JMJD2b is also positive in 3 
samples with no change between tumor and non tumor pairs. After confirmation to further 
characterize their roles in HCC, we selected minimum 2 shRNA lentiviral vectors to perform 
knockdown studies of these enzymes in HCC and screened all the enzymes listed above. 
Using two different shRNAmir expressing lentiviral vectors to knockdown the target enzymes; 
we covered nearly all the residues we validated. We also used one lentiviral vector targeting 
GapDH, two control lentiviral vectors targeting non-eukaryotic sequences and scrambled 
sequences. Bicistronic expression of GFP protein together with shRNA targeting each ezyme 
allowed us to follow the efficiency and effect of knockdown. We infected HepG2 cell line 
because of the fact that this cell line has a functional p53 and RB signaling pathway and Huh7 
cell line because we have the preliminary results of aberrant activation of these enzymes in this 
cell line (Bagislar et al, unpublished data). We infected the cells in 24 well plates in duplicates so 
that with one copy of each infection we screened phenotypic changes like apoptosis, growth 
arrest and senescence. The other copy of the infected cells were subjected to puromycin selection 
for 5 days till all the cells died in the control non-infected wells and we obtained stable clones of 
each infection. We ensured that infection was not toxic to cells using light microscopy.  
 
4.4.4 Validation of Knock-down of enzymes in HCC cells 
To ensure that we have successfully targeted HCC cells with shRNA constructs, we 
selected FBXL11 enzyme and further characterized because of easy access of Antibodies against 
FBXL11 and its aberrant upregulation in tumor cells. First we showed that our antibody is 
working, using immunoblotting of RIPA extracted total lysates of HCC cell lines, we confirmed 
the expression of FBXL11 enzyme in cell lines tested (figure 4.4.9.A). We showed that all cell 
lines expressed FBXL11 and there is not much difference between immortal Huh7 cell line and 
its isogenic early senescent and senescent clones. 
Using two cell lines, Huh7 and HepG2 cell line, we took the infected cells and took 
pictures of shRNAs targeting all the cells using DAPI staining and GFP color (figure 4.4.10.B). 
We isolated nuclear extracts and confirmed that FBXL11 is knocked down. We showed that 
FBXL11 is decreased significantly but not completely in huh7 and hepG2 cells (figure 4.4.10.C). 
Among the three shRNAs targeting FBXL11-sh35 was the most efficiently working lentivirus. 
We also find its role in liver cancer cells using H3K36 mono, di and tri methyl specific 
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antibodies. We showed that H3K36 trimethyl is slightly increased in all shRNAs targeting 
FBXL11 but not with shRNA control. We did not observe change in the corresponding dimethyl 
and monomethyl residues. 
 
Figure 4.4.9 FBXL11 knockdown in HepG2 and Huh7 cell lines. A. expression status of FBXL11 enzyme in cell 
lines B. GFP expressing shRNAmir targeting FBZL11 in infected Huh7 cells, C. Knockdown of FBXL11 as shown 
by FBXL11 antibody (sh-SCR stands for scrambled shRNA).  
 
 91 
 
Figure 4.4.10 Knockdown of enzymes failed to induce apoptosis and induce tumor suppressors, A. Knockdown 
of SetD2 enzyme in Huh7 cells and HepG2 cells (B) failed to induce senescence and failed to induce tumor 
suppressors (C) 
 
4.4.5  Knockdown of enzymes failed to induce apoptosis, senescence and inhibition of 
growth of cells 
Short term (3 days) and long term (7 days) light microscopy observations, together with 
SA-beta galactosidase staining showed that neither of the cell lines showed significant change in 
growth characteristics and cell phenotypes of cells with respect to control cells infected with 
either shRNA targeting GapDH or scrambled vectors. We asked the response of these cells to 
DNA damage induced and TGF-beta induced senescence responses. We treated cells with Low 
dose Doxorubucin and TGF-beta treatment for 3 days and checked their senescence responses. 
Results showed that knock-down of enzymes did not make significant change in their response to 
DNA damage induced senescence (figure 4.4.10 A and B). 
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4.4.6 Knockdown of enzymes failed to affect main p53 and Rb pathways 
Form all the infections of HepG2 cells, we extracted total protein lysates and checked 
whether the knockdown of these enzymes caused any change on major tumor suppressors like 
p21(Cip1), p16(Ink4a) and p15(Ink4b) were up-regulated (figure 4.4.10.C). We failed to observe 
any significant upregulation of all proteins confirming the result of the phenotypic observations 
and SA-beta-galactosidase results. This may be explained by the redundancy of histone 
methyltransferase and demethylase enzymes working in the same residue. For instance FBXL11, 
FBXL10 and JMJD2a and JMJD2c enzymes are demethylases working on H3K36 residue and 
methyltransferases NSD1, SETD2 and SMYD2 are also acting on the same residue.  
 
4.4.7 Role of Histone 4 K20 methylation and Suv420H1 enzyme in liver cancer 
We and others showed that there is a global loss of histone4K20 methylation in liver 
cancer [207] . We also isolated cells from 12 tumor and 12 cirrhotic livers and performed H4K20 
trimethyl western. Results showed that generally non tumor samples have high levels of trimethyl 
H4K20 with respect to HCC cells (figure 4.4.11.A). 
To understand the hypomethylation of histone 4 Lysine 20 residue in HCC cells, we 
checked the mono, di and tri methylation of HCC cell lines using immunoblotting (figure4.4.11 
B). To search for the enzyme responsible for this, we also checked the mRNA levels of 
Suv420H1 enzyme in these cell lines using quantitative RT-PCR (figure 4.4.11.C). We found a 
positive correlation of mRNA levels of the suv420H1 enzyme and H4K20 trimethyl levels. For 
instance Huh7 and Snu475 cell lines expressed the high levels of Suv40H1 enzymes on the other 
hand Snu398 and Snu423 cell lines showed the lowest levels of H4K20Me3 and Suv40H1 
transcripts. We saw that H4K20Me2 is ubiquitously expressed and monomethyl K20 is almost 
negative except Snu398 cells (figure4.4.11 B).  
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Figure 4.4.11 H4K20 methylation in HCC cells and tumor and non-tumor pairs, A. H4K20Me3 status in tumor 
and non-tumor samples (B) H4K20 mono, di and trimethylation status in HCC cell lines (C) Suv420H1 enzyme 
responsible for trimethylation of H4K20Me3. 
 
4.4.8    H4K20 trimethylation is upregulated in replicative senescence and DNA Damage 
induced senescence models 
To further understand the role of loss of trimethylation of Histone 4 K20, we checked the 
levels of H4K20Me3 in isogenic immortal and senescent clones of Huh7 and MRC5 cell lines.  
Both early senescencent and senescent clones of Huh7 and MRC5 increased the levels of 
H4K20Me3 as shown by immunostaining (figure 4.4.12 A and B). We also took HepG2 cells and 
Huh7 cells, used DNA damage induced senescence assay to check the levels of 
H4K20Methylation. Immunofluorescence, western blotting, immunostaining and SA-beta gal 
results were used to check the levels of methylation. After LD doxorubucin treatment for 3 days, 
we induced senescence using LD-DOX in HepG2 and Huh7 cells and costaining showed that 
4K20Me3 levels increased after treatment with a corresponding decrease in H4K20Me1 but not 
with H4K20Me2 residues. Immunoflurescence data confirmed these results as well. 
 (figure 4.4.13 A and C).  
 94 
 
Figure 4.4.12 H4K20Me3 levels in Huh7 cells and MRC5 cell lines A. immortal, early senescencent and senescent 
clones of Huh7 cells B. In immortal, early senescencent and senescent clones of MRC5 cells. 
 
To find the enzyme responsible for the increase of H4K20Me3 upregulation in normal cells 
and after Doxorubucin induced DNA damage models we checked the expression status of 
Suv420H1 using quantitative Real-time PCR. We took 8 cell lines and Low dose Doxorubucin is 
used to treat these cells for 3 days. And figure 4.4.13.D showed that 6 out of 8 cell lines tested 
Suv420H1 enzyme transcripts are increased. We confirmed this using immunostaining of 
Suv420H1 using a home made antibody, as shown in figure 4.4.3 bottom panel there is a slight 
increase in Suv420H1 levels in Huh7 cells treated with LD-Doxorubucin. 
 
4.4.9    Suv420H1 enzyme is the responsible enzyme for trimethylation of H4K20 
At that time, there were no working suv420H1 antibody (till we ordered an antibody from a 
company) so we continued characterizing the role of Suv420H1 in HCC using Mouse GFP 
tagged Suv420H1 expressing vector. We used Huh7 cell line to transiently overexpress mouse 
form of Suv420H1 enzyme, since this enzyme is fused to GFP tag, we could follow the 
transfected cells as well. As a control we used one GFP expressing vector, and a GFP fused 
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Figure 4.4.13 H4K20 methylation status in Huh7 cells after LD-Dox treatment A. H4K20 methylation is 
increased after DNA Damage senescence models (A) and (C), or using immunoblotting results in (B) and Suv420H1 
is responsible for this increase in liver cancer cells (D). 
 
BRDT, is a non functional enyzme expressing vector. BRDT is an acetyl binding protein and this 
vector codes for a non-functional form of BRDT protein. After 48 hours of transient transfection, 
we used immunofluorescence to check the levels of H4K20Me1, H420Me3, and H3K4Me3 is 
also used as a control (Figure 4.4.14). Results showed that mouse Suv420H1 is capable of 
increasing H4K20Me3 and since basal levels of H4K20me1 is already low; it was difficult to see 
the compensating decrease. GFP and BRDT-GFP expressing cells did not show these 
phenotypes. H3K4Me3 levels remained unchanged (Figure 4.4.14).   
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Figure 4.4.14 Effect of Suv420H1 overexpression in HCC cells  
 
Phenotypic observations showed us that transfected cells became multinucleated and 
looked like mitotic catastrophe (Figure 4.4.14).  These phenotypic changes were not observed 
with control vector transfected cells. Mitotic catastrophic cells occur due of the abnormal mitosis 
events. Cells cannot divide, generally look like multinucleated with abnormal shape of nuclei. So 
to test our hypothesis, we tried to make stable clones of Suv420H1. But unfortunately, we could 
not succeed this using HCC cell lines. We tried Huh7, HepG2 and Hep40 cell lines but we failed 
to get stable clones, although we could get colonies with GFP and BRDT-GFP vectors.  
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Figure 4.4.15 Suv420H1 did not induce apoptosis in HCC cells, A. Ectopic Suv420H1 overexpression did not 
induce apoptosis in Huh7 cells B. Histone methylation pattern after Suv420H1 overexpression. 
  
We tested if these cells are apoptotic or senescent using Annexin-V staining and SA-Beta-
gal subsequently (figure 4.4.15.A). We could not find a correlation of GFP positive and Annexin-
V stained apoptotic cells. We also could not observe senescent cells in Suv420H1-GFP 
transfected cells (data not shown). Using the immunofluorescence, we also checked Damage 
markers like p-p53 Ser20, phospho-ATM and H2AX. Neither of these markers showed 
significantly positive results with neither Suv420H1-GFP or BRDT-GFP or only GFP transfected 
cells (Figure 4.4.14).  We confirmed these finding using another technique. After 48 hours of 
transfection in Huh7 cells, we isolated histones and we checked H4K20Me3 and H4K20Me2 and 
H3K9Me3 and H3K4Me3 residues and also H2AX as a damage marker. Upon transfection we 
observed a strong increase in H4K20Me3 and H4K20Me2 residues. H3K4Me3 remained 
unchanged and we could not detect H2AX and H4K20Me1 (figure 4.4.15.B). To test mitotic 
catastrophe, we also checked H3S10-p, and we could not detect this protein either.  
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Thus we decided to change our model to non HCC cell line; we used hek293T cells for 
easy transfection. We obtained 4 stable clones for Suv420H1-GFP and 3 clones for GFP vector 
and 4 clones for BRDT-GFP vector. We did not observe unusual phenotype with any of these 
clones. We confirmed the function of ectopically expressed Suv420H1 enzyme as an increase in 
H4K20Me3 and a compensating decrease in H4K20Me1 and no change of H4K20Me2, and 
H3K9Me3 residues (figure 4.4.15.A).    
 
 
Figure 4.4.16 Effect of Suv420H1 ectopic expression in Hek293T cells and DNA damage response of cells did 
not change. A. Histone methylation status of suv420H1 overexpressing Hek293T stable clones and B. cell cycle 
response of these stable clones 
 
4.4.10 Suv420H1 failed to change the DNA Damage response of cells to Doxorubucin 
treatment 
We wanted to check whether Suv420H1 enyzme is involved in DNA damage response of 
cells. We already used Doxorubucin treatment to induce DNA damage, apoptosis and/or 
senescence. We treated Hek293T stable clones with doxorubucin for 3 days and using PI stain we 
checked cell cycle distribution in the presence or absence of Doxorubucin. As shown in figure 
4.4.16.B as a representative cell cycle pattern in the absence or presence of Doxorubucin, the 
response of Suv420H1-GFP clones, GFP clones and BRDT-GFP clones did not change. 
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In order to study the endogenous and human Suv420H1, we ordered Rabbit polyclonal 
antibody to COVALAB Company in France. They made one polyclonal antibody and using the 
small isoform of human Suv420H1 enzyme expressing vector, we transiently transfected small 
isoform of Suv420H1 enzyme in hek293T cells. Immunoblotting both affinity purified and non 
purified westerns showed that we could detect the by using this antibody. Before and after 
immunopurification we performed western blotting and optimized the dilution of the human 
Suv420H1 antibody. As can be observed at figure 4.4.17 we can detect small isoform of human 
Suv420H1 protein.  
 
 
Figure 4.4.17 new polyclonal Suv420H1 antibody (suv0032) recognized ectopically expressed small isoform of 
human Suv420H1 protein. 
 
4.4.11   Suv420H1 failed to regulate the imprinting of H19 gene inHCC cells 
H19 is normally a maternally imprinted non-coding gene and expressed only during 
embryonal development. Although its expression is shut off in most tissues postnatally, it is 
reactivated during adult tissue regeneration and also observed in Wilms tumor, lung cancer as 
well. Moreover, H19 is highly expressed in liver and has been shown to behave like an oncogene 
for liver cancer and it is essential for tumor cell growth[118]. Imprinting is regulated by DNA 
methylation on Imprinting Control Regions (ICR). Recently it is found that DNA methylation at 
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these ICR are associated with of Histone methylation especially with H3K9 and H4K20 [208] It 
is found that liver cells at the imprinted allele highly associated with H4K20me3 for H19 gene. 
So we hypothesized that overexpression of H4K20Me3 via Suv420H1 enzyme could change 
biallelic expression of H19 to monoallelic expression and inhibit HCC cells growth.  
 
Figure 4.4.18 The polymorphism analysis in H19 gene exon 5 (RsaI at bp 12511); H19 bases are numbered as 
found in GenBank Accession No. AF125183 (gi: 4731323). IGF2-758, IGF2-993, H19-12283, and H19-12679 
represent PCR primers for amplification of IGF2 and H19. (A)Predicted products for the A and B alleles of each 
polymorphism are drawn below the schematic. (C) Actual products of genotype analysis of HCC cell lines top. 
Actual products of cDNA RFLP in HCC cell lines showed monoallelic or biallelic expression of H19 gene. B. 
transient Suv420H1 overexpression did not change biallelic expression of H19 gene polymorphism. 
 
To assess our hypothesis we characterized HCC cell lines for loss of imprinting for H19 
gene using genomic and cDNA RFLP. The polymorphism was analyzed in H19 exon5 (RsaI at 
bp 12511). Non-imprinted allele (397 bp) is cut into 229 bp and 168 bp (figure 4.4.18.A). The 
 101 
PCR was performed both from genomic DNA of cell lines and cDNAs. After RsaI digestion and 
RFLP is load to gels. Among the tested 14 HCC cell lines, only FLC4 and Hep40 cell lines 
showed loss of imprinting. (figure 4.4.18. C). Therefore to test our hypothesis we tried to get 
stable clones of FLC4 and Hep40 cell line using Suv420H1-GFP plasmid. We could not obtain 
stable clones due to the problems mentioned above. We tried multiple (3X times) transient 
transfection of FLC4 cell lines with GFP expressing control vector and Suv420H1-GFP 
expression vector. We ensured that cells are all GFP positive under fluorescence microscope and 
isolated cDNA from these clones. We performed RFLP analysis using the same enzyme. We 
failed to change the allelic pattern of FLC4 cell line (figure 4.4.18.B). 
 
4.5 Role of ATAD2 gene in Liver Cancer 
4.5.1 Identification of ATAD2 
By combining gene expression profiles performed in our lab using isogenic senescent and 
immortal HCC cells, as well as cirrhosis and HCC tissues, we identified ATAD2 gene, predicted 
to be overexpressed in liver cancer and associated with immortality related genes network (figure 
4.5.1.A). Recently two groups showed that ATAD2 is highly expressed in several human solid 
tumors including lung, breast, and prostate and is a strong predictor of mortality in lung and 
breast cancers [184, 186]. ATAD2 is significantly amplified 2.4 fold in immortal huh7 cell line 
with respect to its senescent isogenic clone and also 4.2 fold in liver cancer with respect to 
cirrhotic samples (figure 4.5.1.B). ATAD2 gene is found in 8q24 chromosome region, a region 
frequently amplified and found near to MYC oncogene and is of 1,391 aminoacids long. In this 
locus ATAD2 is overexpressed together with other genes (figure 4.5.1.C). It has a conserved 
region of two AAA (ATPases Associated with diverse cellular Activities) domains [209] and a 
bromodomain for binding acetylated histones [210].  
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Figure 4.5.1 Identification of ATAD2, A. IPA analysis network showing ATAD2 in immortality related genes 
network, B. ATAD2 Fold change of differentially expressed genes including other histone related genes C. ATAD2 
gene and overexpression status of ATAD2 in 8q24 gene locus near Myc oncogene. 
 
4.5.2 ATAD2 is highly expressed in immortal HCC cells 
Further searches in databases showed that ATAD2 gene is overexpressed at least two fold 
in 76%  of paired HCC arrays [211] (Figure 4.5.1.C). We checked the levels of ATAD2 
transcripts in liver cancer cell lines using quantitative RT-PCR. Normal liver was used to 
normalize the expression of ATAD2 gene; we also included human normal lung fibroblast cell 
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line to compare to see if ATAD2 is up in immortal cells. We showed that 9 out of 14 liver cancer 
cell lines showed more than 5 fold expression of ATAD2 whereas both normal human liver and 
lung cell line showed the least expression (figure 4.5.2.A). We performed immunoblot analysis of 
ATAD2 to determine the protein expression in HCC cells and normal human liver tissue. We 
showed that the ATAD2 protein was readily detectable in all HCC cells, with Huh7, Hep40, 
HepG2, Hep3B and FLC4 cells displaying the highest protein levels (Fig.4.5.2. B), and that the 
ATAD2 protein is undetectable in normal human liver tissue. We used Hep3b cells transfected 
with siRNA1 to show the specificity of ATAD2 antibody. 
 
Figure 4.5.2 ATAD2 expression is up in  HCC cells, A. relative mRNA levels using Q-PCR B. Immunoblotting of 
ATAD2 in HCC cell lines and C. ATAD2 protein levels in senescence models of HCC D. ATAD2 is stained strongly 
in HCC cells. 
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Very recently, we showed that TGF-β is a potential senescence inducer in HCC cells and 
low-dose Doxorubucin treatment of HCC cells also induces senescence (Senturk, Mumcuoglu et 
al. 2010)(Gursoy-Yuzugullu, unpublished data). Using these two models, we checked the 
expression status of ATAD2 protein in HCC cells using immunoblotting. Hep3b, HepG2 and 
Huh7 cells showed a significant decrease of ATAD2 protein expression upon low-dose 
Doxorubucin treatment and a slight decrease of in Hep3b cells was observed in TGF-b treated 
Hep3b cells (Figure 4.5.2.C). Both assays showed that ATAD2 is up in immortal HCC cells but 
not in normal cells. To confirm this finding, we performed immunostaining of normal 
hepatocytes and compared the levels of protein expression with Huh7 cells either in the absence 
or presence of LD-Doxorubucin. Correlated with Q-PCR and western data, isolated normal 
human hepatocytes were ATAD2 negative and Huh7 cells were strongly stained, and LD-
Doxorubucin treatment decreased ATAD2 levels in Huh7 cells after 3 days (figure 4.5.2.D). 
 
4.5.3 ATAD2 expression is associated with high grade and increased risk of lymph node 
invasion of tumor cells 
To confirm the upregulation of ATAD2 in HCC in vivo, we checked ATAD2 expression 
in tumor and non-tumor pairs using both Quantitative RT-PCR and western blot techniques. 
Atad2 mRNA levels are higher in 5 out of 7 tumor tissues compared to non-tumor tissues (Figure 
4.5.C). Western blot analysis also showed that expression of ATAD2 in normal liver is down 
regulated. 4 normal liver samples were tested and 3 of them did not express ATAD2 protein 
(figure 4.5.3 A and B). Of 15 tumor non-tumor pairs were tested, 8 pairs have higher expression 
of ATAD2 in tumors and 5 in cirrhotic samples. And 3 of the cases showed unchanged (figure 
4.5.3. B). We also tested 24 separate cirrhotic samples and detected ATAD2 protein in 18 of the 
cases (figure 4.5.3.A). Thus, while we barely detected ATAD2 protein in normal livers, ATAD2 
expression was high in malignant livers. 
We performed immunohistochemical staining in HCC and normal liver tissue arrays to 
visualize the localization and expression status of ATAD2. 38 HCC samples with different grades 
and 8 normal liver samples were stained. ATAD2 staining was markedly nuclear positive in 16 
out of 38 HCC samples, with highly correlated with grades and TNM classification. 3 out of 18 
samples (16%) with T2N0 were positive and the positivity increased to 50% (9 out of 18) in 
T3NO samples. 2 of the T3N1 samples were positive. All of the normal livers (8/8) were ATAD2  
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Figure 4.5.3 ATAD2 expression status in malignant and normal cells A. in Cirrhotic tissues B. in tumor-non-
tumor pairs C. QPCR analysis in Tumor non-tumor pairs D. QPCR analysis of ATAD2 after rat liver regeneration 
models E. immunoblotting of QPCR of ATAD2 
 
Negative (Table 4.5.1).  Representative Stainings of positive tumor samples and negative normal 
livers were shown in figure 4.5.4. Taken together these results showed that ATAD2 expression is 
associated with high grade tumors and there is an increased risk of lymph node invasion of tumor 
cells. 
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(Table 4.5.1). Immunohistochemistry analysis of ATAD2 protein in HCC samples 
Pathologic Stage No of samples Positive Percentage% 
T2NO 18 3 17% 
T3NO 18 9 50% 
T3N1 2 2 100% 
Normal Liver 8 0 0% 
 
 
Figure 4.5.4 immunohistochemistry images of HCC samples (A and B) stained with ATAD2 whereas negative 
staining is observed in normal samples (C and D). 
To characterize the role of ATAD2 in hepatocyte growth, we checked the expression of 
ATAD2 after rat liver regeneration samples using both quantitative RT-PCR and western blot. 
ATAD2 mRNA levels reached to two fold after 18th hour peaking at 48th hour, and stayed more 
than 4 fold up to one week (figure 4.5.3.D). Immunoblotting data showed that the increase of 
ATAD2 peaked at 18th hour and also for day 3 and day 7 with different translation dynamics 
than the transcript expression (figure 4.5.3.E).    
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4.5.4 Inhibition of ATAD2 expression induces apoptosis in liver cancer cells and affects 
the growth of normal cells  
To investigate the role of ATAD2 in liver cancer, a panel of HCC cell lines was 
transfected with 4 different siRNAs targeting different sequences ATAD2 transcript and cell 
growth was checked compared to control siRNA using coomassie staining after 96 hours of 
transfection. 4 HCC cell lines, Hep3b, HepG2, FLC4 and Snu449 showed a higher growth 
inhibition at least two different siRNAs but not with control scrambled siRNA. ATAD2 
knockdown did not effect the growth of Huh7, PLC/PRF/5, Hep40 and Skhep1 cell lines (Figure 
4.5.5). We confirmed this data with colony formation experiment for Hep3b and HepG2 cells. 
We transfected these two cell lines with siRNA1, siRNA3 and control siRNA and after 72 hours 
of transfection, we plated equal volume of cells and checked colony formation capacities after 10 
days. Knockdown of ATAD2 significantly decreased the colony numbers in both HepG2 and 
Hep3b cells (figure 4.5.6.A and C). ATAD2 knockdown decreased the average colony numbers 
from 356 with control siRNA to 156 with siRNA1 and 192 with siRNA3. HepG2 cells formed 
771 colonies with control siRNA and 464 and 597 colonies in average with siRNA1 and siRNA3 
subsequentially. (Figure 4.5.6. B and D). 
 
Figure 4.5.5 ATAD2 knockdown inhibited cell growth of HCC cells as stained by coomassies staining after 
transfection with 4 different siRNA targeting ATAD2 and controlsiRNA at day 4. 
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Figure 4.5.6 Colony formation experiment of Hep3b and HepG2 cell lines after transfection of ATAD2 
siRNAs. A. Hep3b cells colony pictures in riplicates at day 13 and crystal violet stained and quantified colonies in B, 
C. HepG2 cells colony formation pictures in triplicates at day 13 and crystal violet stained and quantified colonies in 
D.  
To understand the mechanism of growth inhibition, we performed cell cycle analysis 
using FACS. Propidium Iodide (PI) staining of Hep3b and HepG2 cells after transfection with 
siRNA1 and siRNA3 at day 2 and day 3 showed that apoptosis is induced after ATAD2 
knockdown. G0 cells were quantified as 37% at day 2 and 61% at day 3 for Hep3b cells using 
siRNA1 and 7% and 13 % using siRNA3 for day 2 and day 3. The level of apoptosis in hepG2 
cells reached up to 40% with siRNA1 and 31% siRNA3 at day 3 (Figure 4.5.7 A and B). Huh7 
and Hep40 cells were found to be resistant to apoptosis after ATAD2 knockdown (Figure 
4.5.7.C). Apoptotic cells in Hep3b, HepG2, PLC/PRF/5 and FLC4 cell lines detached and 
rounded up, as shown in (figure 4.5.7.D). Further confirmation of apoptosis in these cells was 
made by Annexin-V FACS staining of cells at day 2. As expected, induction of apoptosis in 
Hep3b and HepG2 cells shifted Annexin-V positive cells to right as shown in the figure 4.5.7.E  
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Figure 4.5.7 Apoptosis was detected in Hep3b and HepG2 cells but not Huh7 and Hep40 cells. A. PI staining 
and further cell cycle analysis showed Go accumulation of A. Hep3b B. HepG2 but not D. Huh7 and Hep40 cells. D. 
Apoptotic cells detached and round up from all the cell lines except Huh7 E. Apoptosis was confirmed using 
Annexin-V FACS analysis F. Huh7 ATAD2 KD 
 
and quantified as in the graph (figure 4.5.7 Bottom). We did not observed the shift for Huh7 cells 
and to test the efficiency of knockdown in Huh7, we showed that knockdown of ATAD2 in Huh7 
was enough to induce apoptosis (figure 4.5.7.F). 
Knockdown of ATAD2 was quantified using quantitative RT-PCR in Hep3b and HepG2 
cells. Two different experiments using siRNA1 and control siRNA in triplicates showed that 
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ATAD2 transcripts were decreased significantly both in Hep3b and HepG2 cells (figure 4.5.8 
A.). Results were confirmed with western blotting as shown in figure 4.5.8.B.  
 
Figure 4.5.8 ATAD2 Knockdown is shown in Hep3b and HepG2 cells A. by QPCR B. western and pro and anti 
apoptotic genes were checked by western. 
 
4.5.5 Mechanism of Apoptosis in liver cancer cells 
We next investigated the molecular mechanism of apoptosis after ATAD2 knockdown in 
Hep3b and HepG2 cells. ATAD2 binds to acetylated histones with bromodomains and through its 
ATPase domain it may regulate DNA-Protein or other complexes on transcriptional regulation of 
apoptotic and non-apoptotic genes. To test this hypothesis we first determined the type of 
apoptosis and searched for molecular mechanism of apoptosis. 
Using activated caspase 3 antibody and western blotting, we confirmed that apoptosis is 
caspase 3 dependent (fig 4.5.8.B). To search for additional regulators of apoptosis, we screened a 
number of bcl-2 family members and other apoptosis executers as well. Pro-survival genes such 
as Bcl-2 and Bcl-xL and pro-apoptosis genes such as bax, bid and bim proteins were found to be 
not changing. (fig 4.5.8. B). Survivin a member of inhibitor of Apoptosis (IOA) family of 
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antiapoptotic protein and has a dual role for cancer; anti-apoptosis and cell division [212-214]. 
We showed that survivin expression is downregulated with both ATAD2 siRNA1 and SiRNA3 
transfection in Hep3b and HepG2 cells. 
 
Figure 4.5.9 Expression levels of Survival kinases after ATAD2 KD in Hep3b and HepG2 cells in A. p38 stress 
kinases in B.  
 
We also checked key apoptosis and survival pathway genes such as AKT, JNK, ERK, p38 
and NFK-B genes. We failed to find a significant change in neither total AKT nor phosphorylated 
form of AKT and total ERK1/2 kinase and phospho ERK1/2 kinases. These kinases are generally 
involved in survival of cells. JNK kinase and NFK-B were not changing as well (figure 4.5.9 A). 
On the other hand, we showed total levels of p38 kinase and its active phosphorylated forms are 
upregulated after ATAD2 knockdown in Hep3b, HepG2 and Huh7 cells (figure 4.5.9 B). These 
results showed us that ATAD2 is upstream of p38 kinase. 
Apoptosis is a part of a differentiation process, and occurs in vivo as well. To test the 
hypothesis that liver cancer cells are forced to differentiate after ATAD2 knockdown and thus 
may eventually lead cells to go to apoptosis, we checked a panel of markers of liver cell 
differentiation. We previously described the markers for the expression of hepatocyte lineage 
markers, epithelial and mesenchymal markers. We checked the expression of these markers and 
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unfortunately neither the hepatocyte lineage markers HNF-1α, HNF-4α, anti-trypsin1 and ZO-1 
nor E-cadherin and vimentin being epithelial-mesenchymal markers, did not change after 
ATAD2 knockdown at the conditions that we see apoptosis (Figure 4.5.10 A). 
  We also checked the expression of main tumor suppressors to explore the role of ATAD2 
in liver cancer cells. After ATAD2 knockdown, we did not see any significant change of 
p15Ink4b, p16Ink4a and p21Cip1 and also phosphorylated serine15 p53 and BP53 protein using 
western blot. Neither of these tumor suppressors nor damage markers was found to be changed 
(Figure 4.5.10. B). 
 
Figure 4.5.10 Epithelial and Liver specific markers after ATAD2 knockdown in A. and tumor suppressor 
genes in B.  
 
4.5.6 Survivin did not rescue loss of ATAD2 induced apoptosis in liver cancer cells 
As stated earlier, survivin has a dual role; it may act as an anti-apoptotic protein and has a 
role in cell division. In the conditions that we see apoptosis, there is a decrease of expression of 
survivin protein. So to dissect the role of survivin protein for liver cancer, we made recombinant 
GFP-fused survivin overexpressing stable colonies in Hep3b cells and also GFP overexpressing 
colonies as control. We confirmed the overexpression of survivin using western blot (figure 
4.5.11.A). Then we performed ATAD2 knockdown in these clones to see whether survivin can 
rescue cells from loss of ATAD2 induced apoptosis. Unfortunately survivin did not rescue cells 
from apoptosis, to show the result, only one of the colonies was given as a figure here (figure 
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4.5.11. B).   
 
 
Figure 4.5.11 Survivin failed to rescue loss of ATAD2 induced apoptosis in Hep3b cells. A, Survivin western 
showing overexpression of surviving in Hep3b clones B. Survivin overexpressing Hep3b cells still going to 
apoptosis. 
 
4.5.7 RNAi targeting of ATAD2 inhibited cell proliferation and colony formation of non-
liver cells 
To evaluate the effect of ATAD2 depletion on the proliferation of hela cells, we used 
BrdU labeling and colony formation assays of Hela cells and MRC5 cells. Hela cells were 
transfected with 4 different siRNAs and the decrease of ATAD2 protein was shown by western 
blotting (figure 4.5.13.B). After transfection cells were subjected to short term BrdU staining 
using FACS analysis. We detected significant decrease of BrdU incorporation specifically with 
siRNA1 transfection. BrdU incorporation is robustly decreased from 22% for siCTRL to 5% at 
day 3 with G1 arrest reaching as high as 70% of cells for siRNA1 with respect to 58% for control 
siRNA transfected cells (figure 4.5.12.A). We confirmed this finding via colony formation 
experiment. siRNA1 and siRNA3 transfection reduced colony numbers significantly with respect 
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to siCTRL and treatment of cells with low dose 0,1uM, medium dose 0,5uM or high dose 1uM 
TSA synergized with knockdown and decreased significantly colony number(p< 0,01). Figure 
4.5.12 B and C showed the decrease of colony formation either alone or together with TSA 
treatment. These data showed that ATAD2 knockdown decreased the cell growth and the colony 
formation capacity non-liver cancer cells as well. 
 
Figure 4.5.12 ATAD2 knockdown inhibited growth and colony formation of Hela cells. A. BrdU FACS analysis 
of Hela cells after ATAD2 KD. B. and C. Colony formation assay performed after ATAD2 KD and TSA treatment 
of HCC cells potentiates the effect of KD. 
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We checked key regulators of Rb and p53 pathways to understand the mechanism of 
decreased the cell proliferation in Hela cells. Loss of ATAD2 protein in Hela cells increased p53 
protein levels and its main target p21Cip1 protein levels with 3 of the ATAD2 siRNAs (Figure 
4.5.13A and B). To our surprise, this was not expected. Because hela cells were infected with 
Human papilloma virus and p53 and Rb pathways were shown to be inactive. To explain the 
increase of p53 protein levels after ATAD2 loss, we hypothesized that ATAD2 may bind to E6 
and E7 oncoproteins and regulate their expression as well. We checked E6 and E7 protein levels 
 
Figure 4.5.13 Key cell cycle regulatory protein expression after ATAD2 KD in Hela cells  
using western blotting. As shown in the figure E6 levels did not change significantly and E7 
antibody was not good enough or undetectable. Downstream of p53/ p21Cip1 pathway is Rb 
protein. We detected a decrease in phosphorylated levels of Rb but not with total levels of Rb 
protein. E2F protein levels were also decreased and this lead to decrease of cylin E and Cyclin A 
protein levels (figure 4.5.13.middle panel). ATAD2 was shown to be co-activator with C-myc 
oncogene protein. So we checked c-myc protein levels with the same lysates and c-myc was 
decreased. To repeat the experiments and to see the effect of other siRNAs as well, we repeated 
the westerns with all siRNAs (figure 4.5.13.B). 
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4.5.8  Loss of ATAD2 induced senescence in MRC5 cells  
ATAD2 gene was down in senescence associated gene list therefore we expected loss of 
ATAD2 would induce senescence in liver cells. To see the effect of ATAD2 loss in normal cells 
we changed our model to MRC5, human normal lung fibroblast cells. MRC5 cells reached to full 
senescence at around population doubling 70, so we do not expect these cells to show significant 
senescence rates at PDL 30. Successful knockdown of ATAD2 protein in MRC5 PDL 30 was 
shown by western blotting (figure 4.5.14.B). We performed senescence assay after transfection 
and showed that loss of ATAD2 induced senescence with siRNA1 and siRNA4 at day 3 (figure 
4.5.14.A). We repeated these experiments with immortal MRC5 cells and obtained the same 
results as shown in figure 4.5.14.A lower panel. Not only normal MRC5 cells but also immortal 
MRC5 cells showed senescence after loss of ATAD2 protein showing that it is inducing 
premature senescence. Short term BRDU analysis together with PI staining showed that after 
ATAD2 loss, BrdU incorporation did not change for presenescent MRC5 (PDL 32) most 
probably because the cells arrested at G2/M phase of the cell cycle at day 3 for all the siRNA1 
and siRNA 4 tested (figure 4.5.14.D and E).  To confirm these results we performed colony 
formation experiment in presenescent MRC5 cells. Colony numbers significantly decreased for 
both siRNA1 and siRNA3 (figure 4.5.14. C). We also performed p53 western to see if senescence 
is p53 dependent whereas only siRNA2 increased p53 protein levels slightly (figure 4.5.14.B). 
These results showed that ATAD2 protein did not induce apoptosis but senescence in these cells. 
 
4.5.9 RNAi knockdown of ATAD2 using tet-inducible lentivirus system 
To determine the tumor suppression effect of ATAD2 loss by RNAi and to image in vivo, 
we developed a tetracycline regulatable lentiviral vector expressing shRNA cassette against 
ATAD2 transcript (figure 4.5.15.A). Using this vector we infected Hep3b, Huh7 and Hela cells. 
We also used a control vector expressing scrambled sequence. When induced by doxocycline, 
shRNA is expressed and cells started to express RFP protein, therefore we could trace the cells in 
vitro and in vivo. We induced the Huh7, Hep3b and Hela cells stably expressing ATAD2 shRNA 
and shCTRL and preparing RIPA lysates we showed the knockdown of ATAD2 protein (figure 
4.5.15.B). Increasing dose of Doxocycline showed the efficient knockdown of ATAD2 in Huh7 
and Hep3b cells (Figure 4.5.15. C). Indirect immunofluorescence was also used to follow knock- 
 
 117 
 
Figure 4.5.14 ATAD2 KD in MRC5 cells induce senescence in MRC5 mortal and immortal cells in A. B. 
ATAD2 KD showed in MRC5 cells C. Colony formation capacity decreased D. and E. BrdU incorporation did not 
change significantly. 
 
down of ATAD2 protein in Huh7 cells (figure 4.5.15.D). Huh7 cells were heterogenous in terms 
of efficiency of knock-down. Almost half of the cells were successfully downregulated ATAD2 
protein, whereas control shRNA expressing cells were homogenously positive. ATAD2 
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knockdown is showed using staining of ATAD2 with green color and loss of ATAD2 is observed 
in red fluorescence protein and thus ShRNA expressing ATAD2 cells (figure 4.5.15.D). Caron et 
al showed that ATAD2 is binding to H4K5Ac histones, to see if ATAD2 knockdown 
destabilizing or havening any effect on levels of H4K5Ac, we stained cells with H4K5Ac 
antibody. Costaining did not show any effect on H4K5Ac levels with knockdown of ATAD2 
(figure 4.5.15.E). 
 
Figure 4.5.15 shRNA lentiviral vectors downregulated ATAD2 levels when induced by doxycycline. A. 
Lentiviral vector and advantages B. and C. ATAD2 KD after infection and induction D. and E. ATAD2 KD and 
H4K5Acetyl staining after induction and loss of ATAD2. 
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4.5.10    Downregulation of ATAD2 expression by tet-inducible RNAi suppressed 
tumorigenecity of HCC cells in vivo 
  
Figure 4.5.16 Xenograft models and imagining of shATAD2 and ShCTRL hep3b and huh7 cells in A and C 
sequentially B. cell cycle regulating genes in shATAD2 tumors and D. New subclones of Hep3b shATAD2 cells. 
Using this system, we injected 10x106 shCTRL and shATAD2 cells into the right and left 
side of the 6 mice for both Huh7 and Hep3b cells. We fed 3 mice with doxycycline in drinking 
water to induce the expression of shATAD2 and shCTRL. We measured size of tumors every 3 
or 4 days, and plotted the graph as in the figure 4.5.16.A. and C.  Results clearly showed that 
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Huh7 injected tumors were not responsive to knockdown of ATAD2 (figure4.5.16.C). Whereas 
we detected a suppression of tumorigenecity of hep3b cells expressing shATAD2 with respect to 
shCTRL when induced with doxycycline. Before mice were executed, we performed in vivo 
imaging of xenografts using Xenogen Ivis Kinetics in vivo imaging system. RFP expressing 
tumors were visualized and photographs were taken as red color (figure 4.5.16.B). We executed 
the mice and extracted the tumors and performed western analysis to see the specificity of the 
knockdown and mechanism of tumor shrinkage. Westernblot analysis was performed to see 
ATAD2 protein levels between shATAD2 and ShCTRL tumors. ATAD2 protein levels were 
significantly decreased for mice 1 and 2. For the three mice, we also checked apoptosis via 
caspase3 and key tumor suppressors. We showed that caspase 3 was not activated but p21 levels 
were significantly increased with a corresponding decrease in E2F1 and cyclin E and A proteins. 
Survivin protein is also found to be decreased for these tumors (figure 4.5.16.B).  
We increased the number of mice from 4 to 10 animals, however during that time these 
cells somehow lost the expression of shATAD2 as followed by RFP and ATAD2 western. We 
then subcloned Hep3b cells and obtained two subclones that downregulated the expression of 
ATAD2 protein when induced. We named these clones Hep3b shATAD2 clone 6 and shATAD2 
clone 17. We plan to increase animal numbers to 10 using these two subclones (figure 4.5.16.D).  
 
4.5.11 Loss of ATAD2 increased histone acetylation and increased p300 histone 
acetyltransferase levels 
There is fine balance between activity of histone deacytylases (HDACs) and histone 
acetyltransferases (HATs) in cells. Today we know that HDAC are overexpressed in several 
cancer and HDAC inhibitors like trichostatin (TSA) and sodium butyrate inhibits histone 
deactylation and increases histone acetylation levels. HDAC inhibitors are also used to treat 
cancer. Several articles showed that this leads to growth arrest and/or apoptosis. Therefore we 
investigated whether ATAD2 loss increased histone acetylation. We used nuclear extract 
preparation to check the levels of global histone acetylation after loss of ATAD2 protein. Using 
both pan Acetyl H3 and pan Acetyl H4 antibodies, and further using specisific residues we 
showed that global H3 levels but not H4 acetylation were significantly increased after loss of 
ATAD2 in Hep3b cells but not with Huh7 cells (figure4.5.17. A and B). We also used TSA 
treatment as a positive control. Levels of histone 3 and histone 4 acetylations reached to 
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maximum levels after TSA treatment. We checked specifically a few acetylated residues and 
showed that H3K18 Acetyl and H4K5Ac are upregulated for Hep3b and HepG2 cells but not 
with Huh7 cells (figure 4.5.17.A).  
 
Figure 4.5.17 ATAD2 KD leads to increase in global histone acetylation increase A. specific histone acetylation 
western and B. total H4 and H3 acetylation levels and C. and D. confirmation of global H3 and H4 acetylation 
increase as shown by FACS E. TSA treatment of Hep3b and Huh7 induced apoptosis but not with snu387 and 
snu475 cell lines. 
 
We further confirmed the results with FACS analysis using the same antibodies. This 
experiment showed that cells are at low H3 acetylation levels and significantly reached to high 
acetylation levels after siRNA1 and SiRNA3 transfection (figure 4.5.17. C). Apoptotic cells were 
 122 
also acetylated as shown in figure 4.5.17.C. H4 acetylation was also increased from low and 
medium level to high levels after transfection with siRNA1 and SiRNA3 (figure 4.5.17. D).  
Since histone acetylation increase can induce apoptosis, as a proof to ATAD2 induced 
histone acetylation increase, we treated Hep3b and Huh7 cells with TSA and observed their 
phenotypes. Hep3b and Huh7 cells but not Snu387 and Snu475 cells induced apoptosis. Using 
FACS analysis we quantified the apoptosis rates of cells (figure 4.5.17.E). 
 
4.5.12 ATAD2 knockdown induced HAT expression in Liver Cancer cells 
To search for the responsible enzyme increase in acetylation for ATAD2, using 
differentially expressed HATs and HDACs in our microarray data, and we searched HATs 
downregulated in HCC or HDACs upregulated in HCC. We find 7 targets and using 
immunoblotting we stained p300, HAT1, PCAF and HDAC1, 2, 4 and 5 enzymes. Among these 
enzymes, only P300 correlated with our data (Figure 4.5.18). 
 
Figure 4.5.18 Key histone acetyltransferase and deacytylases expression after ATAD2 Knockdown 
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CHAPTER 5.   DISCUSSION 
 
5.1 Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular 
carcinoma cells 
Most of the Wnt ligands and receptors are involved in different cellular processes by 
initiating canonical or noncanonical Wnt signals [196]. Canonical and noncanonical Wnt 
pathways function antagonistically [198-199, 206]. Thereby this information links β-catenin in 
extremely complex cellular processes some of which are only mediated by canonical Wnt 
pathway. Liver development and adult liver homeostatasis can be accounted in these complex 
events and canonical Wnt signaling cascade contributes to both liver regeneration and liver 
“zonation” by regulating certain liver-specific metabolic programs [215]. Besides, it is important 
for the activation of liver stem or progenitor cells, as well as HCC-initiating cells [216-219]. 
Canonical Wnt signaling is not frequently mutationally activated in HCC, except in 
hepatoblastoma [220]. It is highly limited in a cluster of HCCs with different etiological 
background including low p53 mutation rate, negative HBV status and chromosomal stability, as 
mentioned earlier along with lower histological grade and better patient survival. Surprisingly, β-
catenin mutations are infrequent in more advanced and poorly differentiated HCCs, suggesting 
the association with poor prognosis [61, 63]. These data suggests that although known as an 
active player in HCC malignancy, canonical Wnt signaling is not required and also repressed for 
advanced HCCs. To sum up, constitutive activate canonical Wnt pathway by β-catenin mutation 
may be required HCC induction and development implicated with differentiation-dependent 
events. HCC-derived cell lines were used to show this role for further experiments. 
Firstly, classification of 11 HCC cell lines into "well-differentiated" and "poorly 
differentiated" subtypes using hepatocyte lineage, epithelial and mesenchymal cell markers, and 
in vitro migration assays. 
While well-differentiated HCC cell lines possess many common features with hepatocytes 
including expression and E-cadherin, and epithelial morphology, poorly differentiated cell lines 
express different mesenchymal markers strongly and generally lack the expression of hepatocyte 
lineage and epithelial markers. Their in vitro behaviors were discriminative as well. Poorly 
differentiated cell lines were found to be moving more in the wounding assay compared to well-
differentiated cell lines, they were more motile (Table 4.1.1). Previously, a global expression 
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profiling study categorized HCC cell lines in Group I and Group II [219]. Group I was perfectly 
correlated with well-differentiated cells and Group II with poorly differentiated cells. Induction 
of oncofetal promoters with increased expression of AFP and IGF-II were affliated to Group I, 
whereas invasion and metastac genes were affiliated to Group II. Our classification of cells into 
well differentiated and poorly differentiation was also positively correlated with epithelial and 
mesenchymal HCC cells respectively. [54]. As a result of EMT process, mesenchymal cancer 
cells are produced with high invasive and metastatic capabilities [221]. This is also correlated 
with the data we obtained with higher motility of poorly differentiated subtype reported here. 
Thus, when considered these two types of cell lines are alike well-differentiated and poorly 
differentiated HCC tumors, respectively. The mutual relationship between the status of Wnt 
pathway and HCC differentiation status is showed here using this. 
The same type of expression analysis of Wnt ligands and Frizzled receptors were reported 
for mouse hepatocytes, but analysis of Wnt signaling components in liver or hepatocytes was ill 
known [222]. Canonical receptors Fzd7 and Fzd9, as well as noncanonical Fzd2, Fzd3, Fzd4 and 
Fzd6 were found to be expressed for mouse hepatocytes. For HCC cell lines, we reproduced the 
same analysis with the exception of Fzd9 with weak expression. Additionally, we observed 
increased expression of canonical Fzd1 and Fzd5 in most HCC cell lines. The expression 
frequency of these receptors was not linked to HCC cell differentiation status. Canonical Wnt1 
and Wnt2, and noncanonical Wnt4, Wnt5a, Wnt5b and Wnt11 were expressed for mouse 
hepatocytes. All or the most of the HCC cells were equipped with canonical Wnt3 and wnt10b 
ligands but they lost the expression of canonical Wnt1 and Wnt2. Wnt8b was expressed only in 
well-differentiated cell lines. Noncanonical Wnt4, Wnt5a and Wnt5b ligands were expressed 
mutually exclusively in the poorly differentiated cell lines, but not in well-differentiated cell 
lines. Most of the poorly differentiated cell lines also expressed noncanonical Wnt7b. Wnt3, 
Wnt4, Wnt5a, Fzd3, Fzd6 and Fzd7 have been previously implicated in HCC tumors [223-225]. 
Overexpression of Wnt10b in HCC [226] and increased levels of Wnt5a transcripts in chronic 
hepatitis, cirrhosis and HCC [227] was announced previously. C-terminally mutated HBV X 
protein upregulating Wnt5a expression in HCC cells [227] suggests the role of wnt5a in the 
clinical relevance of HBV at least in HBV-related liver diseases. Thus noncanonical Wnts may be 
used as to predict HCC prognosis. 
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In this study we also showed that well-differentiated cell lines showed active canonical 
Wnt signaling at variable degrees with high signaling activity was associated with β-catenin and 
Axin1 mutations in two well differentiated cell lines. For the other two well differentiated cell 
lines we also showed some activity but the functional significance is not known [5]. 
Stem cell and cancer cell self-renewal in other cancer types has been shown to have 
canonical Wnt signaling activity and thus  the presence of canonical wnt signalling activity in 
well-differentiated-HCC cell lines such as HepG2, Huh7 and PLC/PRF/5 may be linked with 
HCC stem cells [228]. 
Our third observation was poorly differentiated cell lines do not have canonical Wnt 
signaling activity in six out of seven poorly differentiated cell lines. Even a poorly differentiated 
cell 475 cell line with deleterious Axin1 mutation (SNU475) lacked canonical activity. Thus this 
suggests the presence of an active repression of activity in these cells. Transient or Tet-regulated 
expression of mutant β-catenin failed to induce canonical Wnt signaling activity in two different 
poorly differentiated cell lines. Using confocal imaging we linked this weak activity to poor 
nuclear accumulation of β-catenin in SNU449.cl8 cell line. 
Wnt5a act as an antagonist and regulator of β-catenin levels in other cell types [216-217]. 
Hereby we also showed that Wnt5a-expressing plasmid can significantly inhibit canonical Wnt 
signaling in HCC cells. The mechanism of Wnt5a antagonism is not known yet. In breast cancer 
cells, nuclear beta-catenin and expression of target genes were observed when wnt5a is lost 
[229]. The results that ectopically and endogenously expressed N-terminally truncated forms of 
β-catenin suggest that Wnt5a is acting downstream to β-catenin. Wnt5a can inhibit canonical Wnt 
signaling either by proteasomal degradation [230], or, by downregulating TCF activity without 
influencing β-catenin levels [198] in kidney epithelial cells. such models can very well be applied 
to our findings. Knockdown of noncanonical Wnt ligands in poorly differentiated HCC cell lines 
may help to elucidate the mechanisms of lack of canonical wnt signalling in liver cancer. 
Wnt5a can be a tumor suppressor or oncogenic depending on cellular context. Wnt5a 
plays an oncogenic role in melanoma, gastric, pancreas, prostate cancer, but as a tumor 
suppressor role in HCC, neuroblastoma, leukemia, colon, and thyroid cancers [206]. It may have 
a role in tumor progression by inducing EMT. Furthermore, the Wnt5A/Protein kinase C pathway 
was shown to activate invasion in melanoma cells via of an EMT [68]. Similarly pancreas cancer 
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cells expressed CUTL1 that also upregulates Wnt5a and induced migration, proliferation and 
invasiveness [231].  
To sum up we showed that canonical Wnt activity is active in well-differentiated, but 
repressed in poorly differentiated HCC cell lines may also implicate the association of β-catenin 
mutations with well-differentiated, but not in poorly differentiated tumors and that a dual 
function of Wnt signaling cancer initiation and tumor progression. 
 
5.2  Selective monoclonal antibodies directed against C-terminal domain of  β−Catenin 
We used immunofluorescence and immunohistochemistry studies using a panel of tumor 
cells to further characterize the antibodies that we have developed in our laboratory and their 
selective affinity to the different cellular and functional forms of beta-catenin. When we consider 
the fact that beta-catenin protein can be found in three different subcellular localizations with 
different modes of regulation in complex with several different types of proteins and interaction 
partners, the use of antibodies showing selective affinity to dissect different subcellular 
localizations and functionally active beta-catenin gains a significant amount of importance. This 
complexity of beta-catenin is partially due to the different interaction partners which also depend 
on the presence of beta-catenin in different subcellular portions of the cells. In figure 1.3, we 
mapped the sites of interaction of several different β-Catenin binding proteins along the beta-
catenin protein. Our Mabs, 4C9 and 9E10 clones were directed on the very C-terminal end, 
partially overlapping on the last 10 aminoasid residues of the β-catenin protein. We were able to 
find 10 different proteins which can localize this part of β-catenin in the literature. Together with 
well known interactors of β-catenin such as TBP, Chibby, Theashirt, CBP/p300, 6 different PDZ 
domain proteins (Lin-7, TIP1, S-SCAM, MAGI-1, NHERF-1, NHERF-2) can also bind this 
region (figure 1.3). Thus there is a competition for binding this region.  In order for 4C9 and 
9E10 Mabs to bind their epitopes, this part of the protein should be free of PDZ proteins and be 
conformationally available. Compared to commercial antibody, confocal microscopy analysis 
showed that our hybridomas successfully reacted against β-catenin in the nucleus and cytoplasm 
whereas membrane staining was more intense with commercial anti-β-Catenin antibody in APC 
mutated colorectal carcinoma cell lines; SW480 and SW837 and beta-catenin mutant cell line 
Snu398 cell lines. As a result the selective immunoreactivity of our hybridomas towards 
cytoplasmic and nuclear β-Catenin but not to membrane bound form of β-Catenin can be 
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explained due to the availability of the last 10 aminoasid residues of β-Catenin in cytoplasmic 
and nuclear pools of β-Catenin protein. For example, PDZ binding proteins are known to anchor 
their binding partners in close proximity of plasma membrane and are expected to interact with 
membrane bound form of beta-catenin but not with the nuclear pool of beta-catenin. This data 
explains why we can detect nuclear and cytoplasmic beta-catenin with our hybridomas directed 
against this PDZ domain but not with commercial antibody. The strong selective 
immunoreactivity of our antibodies is also proven by ∆N-β-Catenin expressing inducible clone of 
HCC cell line Snu449-c8. In the presence accumulating mutant β-Catenin, both antibodies 
showed the increased immunoreactivity only to cytoplasmic and nuclear β-Catenin whereas 
commercial antibody failed to show such specific increased immunoreactivity.  
Unfortunately, we failed to show such specific immunoreactivity in tumor samples of different 
organs. In most of the cases except colon carcinoma samples, our antibodies reacted well against 
membrane bound form of β-Catenin. We can explain such a discrepancy by the lack of 
deparaffinization procedure in immunofluorescence techniques. The denaturation protocol for 
paraffin embedded tissue samples may help the membrane bound β-Catenin protein readily 
available compared to cytoplasmic and nuclear form of β-Catenin.  
Activating mutations (APC and beta-catenin mutations and/or constitutive activation by 
Wnt ligands) in the Wnt/β-Catenin pathway elements lead to accumulation of β-Catenin in the 
cytoplasm as well as in the nucleus where it interacts with TCF/LEF family of transcription 
factors and activates transcription of the Wnt responsive genes. The specific immunoreactivity of 
active beta-catenin staining by these antibodies makes them more valuable due to their 
recognition of  β-Catenin with diverse functions. Our tissue staining data showed that these 
antibodies have the capacity to detect β-Catenin pools which has oncogenic roles in different 
cancer types. 9E10 antibody staining in different types of tumor tissues showed that only a subset 
of colon carcinoma tissues are nuclear positive. In the literature similar findings were associated 
with a subset of tumors harboring APC or beta-catenin mutations leading to accumulation of 
oncogenic beta-catenin. In correlation with this data, breast and endometrium cancer tissue 
samples which are known to be APC and beta-catenin mutation negative were found to be 
nuclear negative. Nuclear positivity detected by these antibodies (4C9 and 9E10) would be an 
indicative of presence of APC and activating beta-catenin mutations in the tissue samples. In 
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conclusion, these anti β-catenin antibodies not only showed a great potential to detect different 
cellular functions, as well as tumor-associated aberrations of β-catenin protein in the clinical 
studies but also they may serve as an important tool to decipher several interacting partners of 
beta-catenin to decipher their role in contribution to carcinogenesis.   
 
5.3 Screening of human kinome and Phosphatome 
 In order to identify novel pro-senescence targets, we performed siRNA screening for 
kinases and phosphatases. We determined a set of kinases and phosphatases for siRNA screening 
using differentially expressed genes obtained from microarray data with isogenic senescent and 
immortal HCC cells, as well as cirrhosis and HCC tissues. From a list of 518 kinase and 223 
phosphatases, we identified126 kinase genes and 28 phosphatase genes that are upregulated in 
immortal HCC cells. Using a sensitive method to quantify cell viability after transfection, we 
screened all kinase and phosphatase genes. Thus we have identified kinases or phosphatases that 
might have significant role in HCC cell survival. Genes showing least viability after 
sulphordamine-B assay identified as essential kinases or phosphatases whose knock-down 
induced cellular senescence, apoptosis and growth arrest. 
 Three different siRNA sequences were used to eliminate the off-target effect; therefore 
our assay is specific to identify the role of each gene. 
 Among all the kinases tested, 6% of all kinases (8/126) and 17% (5/28) were found to be 
essential for cell survival. Among these kinases, CDK1, CDK2, PcTaire2, CHK2, and PLK1 
were already implicated in cell cycle and mitosis. MYLK, CAMK2d, and CAMK1a are also 
implicated in cell signaling and survival. 
 The effect of knock-down of phosphatases could be investigated under two different 
groups, one group of phosphatases whose knock-down decreased the cell survival and the other 
group whose knock-down help cells to increase cell survival. The knock-down of these 
phosphatases might derepress the oncogenic enzymes or pathways, thus activate survival of cells. 
The second group could be explained by their antagonistic role against kinases which are 
oncogenic and upstream of these kinases in the same pathway or cross-talk of pathways which 
are quite common for kinase signaling pathways.  
 We also developed in vivo screening method using xenograft models in nude mice. Using 
the same sequences against kinases validated in vitro we can test the effect of knock-down using 
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this xenograft models. We failed to image these tumors in vivo using Alexa labelled RAFT-RGD 
and Alexa- labelled Transferrin dyes. This might be cell type dependent, because liver cells 
express transferrin receptors. Therefore other cell lines can be tested for transferrin receptor 
expression.  
 
5.4       Histone methylation and Role of histone modifying enzymes in liver cancer 
In this study, for the first time, we showed and mapped the global methylation status of 
each histone methylation residues for immortal and senescent liver cells. These marks are good 
candidates to predict disease prognosis and reveals potential therapeutic targets for HCC. We also 
characterized histone modifying enzymes that play a significant role and aberrantly expressed in 
liver cancer cells. By using knock-down and overexpression studies, we tried to dissect the role 
of these histone modifying enzymes in liver cancer. We made a preliminary screen using 
lentiviruses targeting 6 different histone modifying enzymes, but we failed to show any 
phenotype after knock-down using RNAi.  
Among these enzymes, we further screened these enzymes whose inhibition would induce 
cell senescence in liver cancer and investigate their role in senescence. On the transcriptional 
level, we failed to show any affect on expression of tumor suppressor proteins such as p21, p16 
and p15 in two different cell lines. This may be explained by the redundancy of enzymes working 
in the same residues and dynamic regulation of these modifications. 
We further characterized the role of suv420H1 gene in liver cancer. By ectopic 
overexpression studies, we showed that suv420H1 enzyme is responsible for trimethylation of 
H4K20 residue and aberrant nuclei containing cells are formed after transient transfection. We 
checked the DNA damage after transient overexpression but we failed to show a role of 
suv420H1 in induction of DNA damage. Since H4K20me3 is involved in gene silencing, we 
asked whether induction of SUV420H1 enzyme in liver cancer would restore the imprinting of 
H19 gene. Overexpression of SUV420H1 did not restore the imprinting of H19 gene in liver 
cancer cells. However the restore of monoallelic expression might require combinatory 
involvement of epigenetic changes like histone methylation and DNA methylation on the 
promoter and imprinting control center of H19 gene. 
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5.5 Role of ATAD2 in hepatocellular carcinoma  
ATAD2 has been suggested as a driver gene for genomic amplification at chromosome 
8q23 in HCC many years ago, based on comparative genomic expression analysis [232]. Despite 
this provocative observation published eight years ago, the role of ATAD2 in HCC remains 
totally unknown. We performed preliminary experiments in relation with its potential role in 
senescence bypass and HCC malignancy. Firstly, we showed that ATAD2 protein expression is 
low or undetectable in normal liver as well as in isolated human hepatocytes. In contrast, its 
expression was upregulated in HCC cell lines. Similarly, experiments with tumor tissue arrays 
indicated that it was frequently overexpressed in a subset of advanced HCC tumors. We also 
showed that ATAD2 protein is overexpressed in liver cancer samples with an increased of 
positivity of advanced tumors.  Downregulation of ATAD2 expression by specific siRNAs in 
normal fibroblasts (MRC5) and HeLa cells was associated with an increased in senescence-
associated beta-galactosidase (SABG) activity and decreased BrdU incorporation into cellular 
DNA (Fig. 2A). In addition, both cell lines displayed decreased colony forming ability following 
ATAD2 inactivation (Fig. 2B). These effects were accompanied with both p53 and p21Cip1 
accumulation in HeLa cells (Fig, 2C), strongly suggesting that ATAD2 may help cancer cells to 
bypass senescence arrest by neutralizing p21Cip1-mediated inhibition of pRb phosphorylation. 
Interestingly, ATAD2 downregulation in p53- and pRb-deficient Hep3B cells resulted in massive 
apoptotic response (Fig. 2D), strongly suggesting that it may participate to several tumor survival 
mechanisms. Our preliminary findings provide proof-of-principle that the inhibition of ATAD2 
may represent a promising approach for HCC therapy. Based on our preliminary data, our goal is 
to substantiate the potential oncogenic role of ATAD2 gene in HCC.  
We also showed that ATAD2 knockdown increased global histone acetylation levels 
significantly contributing to activation of apoptosis related genes. Correlated with this finding 
p300 histone acetyltransferase levels were upregulated in two cell lines tested. Further support 
came from the treatment of these cell lines with TSA. TSA treatment of HCC cells induced 
apoptosis with increased levels of global acetylation.  
As ATAD2 is an acetylated histone-binding protein, we also tested the combinatory anti-
tumor effects of histone deacetylase inhibitors together with ATAD2 inactivation by RNA 
interference. Treatment of Hela cells with different doses of TSA after ATAD2 siRNA 
transfection, decreased the colony formation capacity of these cells.  
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CHAPTER 6. FUTURE PERSPECTIVES 
 
Histone modifying enzymes acting on the same residues can be targeted at the same time 
to eliminate the redundancy problem. As performed for protein kinases, histone methylation 
enzymes can be screened or targeted with small molecule inhibitors acting on a family of 
enzymes having the same active region.  
In relation with a potential oncogenic role of ATAD2 in HCC, we need to elucidate the 
oncogenic role of ATAD2 by testing the potential role of ATAD2 in senescence bypass. 
Overexpression of ATAD2 in mortal cells like MRC5 cells may be performed and cells will then 
be challenged to replicative senescence by in vitro passaging or to oncogene-induced senescence 
by retroviral expression of H-RasV12 or DNA Damage models.  
To identify the ATAD2 regulated genes in liver cancer, global gene expression analysis or 
high throughput sequencing (CHIP-seq) can be performed. The testing of ATAD2 protein as a 
potential tumor marker can be performed, the number of sections of several numbers of cirrhotic 
and cancer samples can be stained and prognostic potential of ATAD2 protein can be shown.  
For kinase and phosphatases identified in vitro using siRNA screening should be validated 
in vivo and the specific role of each enzyme should be also investigated using overexpression and 
knock-down studies. The pathways in which these kinases are acting can also be targeted with 
specific inhibitors.    
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Abstract
Background: -catenin mutations that constitutively activate the canonical Wnt signaling have been observed in a
subset of hepatocellular carcinomas (HCCs). These mutations are associated with chromosomal stability, low histological
grade, low tumor invasion and better patient survival. We hypothesized that canonical Wnt signaling is selectively
activated in well-differentiated, but repressed in poorly differentiated HCCs. To this aim, we characterized differentiation
status of HCC cell lines and compared their expression status of Wnt pathway genes, and explored their activity of
canonical Wnt signaling.
Results: We classified human HCC cell lines into "well-differentiated" and "poorly differentiated" subtypes, based on the
expression of hepatocyte lineage, epithelial and mesenchymal markers. Poorly differentiated cell lines lost epithelial and
hepatocyte lineage markers, and overexpressed mesenchymal markers. Also, they were highly motile and invasive. We
compared the expression of 45 Wnt pathway genes between two subtypes. TCF1 and TCF4 factors, and LRP5 and LRP6
co-receptors were ubiquitously expressed. Likewise, six Frizzled receptors, and canonical Wnt3 ligand were expressed
in both subtypes. In contrast, canonical ligand Wnt8b and noncanonical ligands Wnt4, Wnt5a, Wnt5b and Wnt7b were
expressed selectively in well- and poorly differentiated cell lines, respectively. Canonical Wnt signaling activity, as tested
by a TCF reporter assay was detected in 80% of well-differentiated, contrary to 14% of poorly differentiated cell lines.
TCF activity generated by ectopic mutant -catenin was weak in poorly differentiated SNU449 cell line, suggesting a
repressive mechanism. We tested Wnt5a as a candidate antagonist. It strongly inhibited canonical Wnt signaling that is
activated by mutant -catenin in HCC cell lines.
Conclusion: Differential expression of Wnt ligands in HCC cells is associated with selective activation of canonical Wnt
signaling in well-differentiated, and its repression in poorly differentiated cell lines. One potential mechanism of
repression involved Wnt5a, acting as an antagonist of canonical Wnt signaling. Our observations support the hypothesis
that Wnt pathway is selectively activated or repressed depending on differentiation status of HCC cells. We propose
that canonical and noncanonical Wnt pathways have complementary roles in HCC, where the canonical signaling
contributes to tumor initiation, and noncanonical signaling to tumor progression.
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Background
Hepatocellular carcinoma (HCC) is an epithelial cancer
that originates from hepatocytes or their progenitors. It is
the fifth most frequent neoplasm worldwide (>500,000
deaths/year), and its incidence is steadily increasing in the
West [1]. Hepatocellular carcinoma is graded into four
stages as well-differentiated, moderately differentiated,
poorly differentiated and undifferentiated tumors, respec-
tively. HCC arises as a very well differentiated cancer and
proliferates with a stepwise process of dedifferentiation.
Indeed, well-differentiated histology is exclusively seen in
early stage and is rare in advanced HCC. Well-differenti-
ated and moderately differentiated HCC cells are morpho-
logically similar to hepatocytes, and are distinguished
only by their smaller size and architectural organization as
irregular trabecular or pseudoglandular patterns. In con-
trast, poorly differentiated and undifferentiated HCC cells
are characterized with scanty cytoplasms and pleomor-
phism [2]. Like in other epithelial tumors, in HCC the
progenitors evolve during tumor progression and become
more and more autonomous. In this process, the tumor
cells change their morphology and behavior; they loose
cuboidal shape and polarity, and become more independ-
ent from neighboring tissues. Finally, they acquire the
capacity to invade the underlying tissue and form distant
metastases. These morphological changes are usually
associated with progressive loss of biochemical and mor-
phological features of hepatocytes, hence the process is
qualified as "dedifferentiation" [3]. Portal venous inva-
sion is significantly associated with poorly differentiated
and undifferentiated HCCs and the tumor invasiveness is
the most crucial factor in determining the long-term out-
come for the patient [4].
Molecular changes involved in HCC dedifferentiation and
invasiveness are known only partially. Epithelial markers
such as hepatocyte nuclear factors and E-cadherin were
reported to be down-regulated in HCC [3,5] and their loss
is closely related to tumor invasion and metastasis [5]. In
contrast, mesenchymal cell markers such as snail [6], twist
[7] and vimentin [8] display positive correlation with
HCC invasiveness and/or metastasis. These changes have
been considered to represent the epithelial-mesenchymal
transition (EMT) in HCC, based on in vitro studies [9-15].
Hepatocyte nuclear factor-4 (Hnf-4) is essential for
morphological and functional differentiation of hepato-
cytes [16,17], and its expression is downregulated during
HCC progression in mice [18]. HCC dedifferentiation
process is associated with a progressive accumulation of
genomic changes including chromosomal gains and
losses, as well as p53 mutations [19]. A rare exception to
this picture is the status of the CTNNB1 gene that encodes
-catenin, a key component of the Wnt/-catenin (canon-
ical Wnt) signaling pathway.
Independent studies showed that -catenin mutations are
associated with a subset of low grade (well-differentiated)
HCCs with a favorable prognosis and chromosome stabil-
ity [20-25]. Among 366 unifocal HCCs studied by Hsu et
al. [20], -catenin mutations were associated with grade I
histogoly. Another study with similarly high number of
tumors (n = 372) also indicated that mutant nuclear -cat-
enin correlated positively with non-invasive tumor and
inversely with portal vein tumor thrombi [23]. In addi-
tion, -catenin mutations were associated with signifi-
cantly better 5-year patient survival in these large cohorts.
Direct study of canonical Wnt signaling activity in primary
tumors is not possible. However, this can be studied indi-
rectly by using target genes [22]. Using glutamine syn-
thetase (encoded by canonical Wnt signaling target GLUL
gene) as a sensitive and specific marker, Audard et al. [22]
showed that 36% HCCs displayed canonical Wnt activa-
tion. These tumors exhibited significant features associ-
ated with well-differentiated morphology. The association
of -catenin mutation and nuclear translocation with
well-differentiated tumor grade was also reported during
hepatocellular carcinogenesis, using several transgenic
mouse models [26]. Activation of -catenin was most fre-
quent in liver tumors from c-myc and c-myc/TGF-1
transgenic mice. However, it was very rare in faster grow-
ing and histologically more aggressive HCCs developed in
c-myc/TGF- mice. Taken together, these studies suggest
that nuclear translocation of -catenin and activation of
canonical Wnt signaling are early events in liver carcino-
genesis, mostly affecting well-differentiated HCCs.
Mutations of -catenin gene initially identified in colorec-
tal cancers, cause constitutive activation of canonical Wnt
signaling, as a result of aberrant -catenin protein accu-
mulation. Inactivating mutations of APC gene in colorec-
tal cancer and AXIN1 in HCC also activate canonical Wnt
signaling by the same mechanism. Therefore, tumors dis-
playing -catenin, APC or AXIN1 mutation are considered
to display active or constitutive canonical Wnt signaling
[27] Activation of canonical Wnt signaling appears to be a
common event for colorectal cancer, as opposed to HCC
with mutations limited to a subset of these cancers. Inter-
estingly, transgenic mice expressing oncogenic -catenin
in hepatocytes develop only hepatomegaly [28,29], in
contrast to intestinal polyposis and microadenoma when
expressed in intestinal cells [30].
Taken together, published data indicate that Wnt pathway
and -catenin mutations may play a complex role in HCC.
Close association of -catenin mutation with low tumor
grade suggests that canonical Wnt signaling has a dual role
in HCC cells, depending on their differentiation state. As
an initial attempt to characterize differentiation-depend-
ent functions of Wnt pathway and canonical Wnt signal-
ing in HCC, we used a panel of HCC-derived cell lines. We
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first performed gene expression and in vitro cell migration
analyses to classify HCC cell lines into two distinct sub-
types. The first subtype that we named here as "well-differ-
entiated" was formed by epithelial cell lines with limited
motility and invasiveness. Mesenchymal-like cell lines
that have lost their epithelial-, hepatocyte-like features
clustered into a second subtype named as "poorly differ-
entiated". Next, we compared these two subtypes for the
expression of 45 Wnt pathway genes, as well as for the
activity of canonical Wnt signaling. Our findings provided
evidence for the constitutive activation of canonical Wnt
signaling in well-differentiated, but not in poorly differen-
tiated cell lines. We also report the upregulation canonical
Wnt3 ligand in the majority of HCC cell lines. Canonical
Wnt8b was selectively expressed in well-differentiated cell
lines. In contrast, noncanonical Wnt4, Wnt5a, Wnt5b and
Wnt7b ligands were expressed selectively in poorly differ-
entiated HCC cell lines. In addition, ectopic expression of
noncanonical Wnt5a inhibited canonical Wnt signaling
in two different cell lines. Our findings support the differ-
ential involvement of canonical and noncanonical Wnt
signaling in HCC, depending on tumor cell differentia-
tion state.
Results
Classification of hepatocellular carcinoma cell lines into 
"well-differentiated" and "poorly differentiated" subtypes
Fuchs et al. [12] have recently classified HCC cell lines
into "epithelial" and "mesenchymal" types based on E-
cadherin and vimentin expression. We performed a simi-
lar analysis using our cell line panel. Initially, we analyzed
15 cell lines (Figure 1). The expression of -fetoprotein
(AFP) was limited to six cell lines (Huh7, Hep40, HepG2,
Hep3B, Hep3B-TR, PLC/PRF/5); the other cell lines being
either not expressing (SNU182, SNU387, SNU398,
SNU423, SNU449, SK-Hep1, Mahlavu, FOCUS) or
weakly expressing (SNU475). All AFP-positive (AFP+) cell
lines also expressed E-cadherin, whereas only 3/9 (33%)
of AFP- cell lines expressed this epithelial marker. Mesen-
chymal cell markers including vimentin, slug, snail, twist-
1 and twist-2 were also positive in most AFP- cell lines.
These markers also displayed weakly positive expression
in some AFP+ cell lines. For confirmation, we performed
immunocytochemical analysis of vimentin protein
expression in five AFP+ and five AFP- cell lines (Figure 2).
We observed strong and homogenous immunostaining
with all five AFP- cell lines. In contrast AFP+ cell lines were
either negative or displayed heterogeneously positive
immunoreactivity. These findings suggested that all AFP+
HCC cell lines were epithelial-like based on E-cadherin
expression, but they also expressed some mesenchymal
cell markers at variable degrees. In contrast, AFP- cell lines
were usually negative for E-cadherin, and most of them
were strongly positive for mesenchymal cell markers. The
expression patterns of these mesenchymal markers
showed marked heterogeneity. For example, SNU182 was
positive for all five markers tested, whereas FOCUS was
positive only for vimentin expression.
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell linesFigure 1
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell lines. 
Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH was used as a con-
trol for expression analyses shown here and in figures 4 to 7.
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We selected four AFP+, and seven AFP- cell lines for fur-
ther analysis. HNF-4 and its downstream target HNF-1
are best known hepatocyte-associated epithelial cell mark-
ers [3]. These two genes that are involved in liver develop-
ment and hepatocyte specification have previously been
identified as specific markers for HCC cells with well-dif-
ferentiated function and morphology [31]. The expression
of these HNFs displayed perfect correlation with the
expression of AFP (Figure 3a): four AFP+ cell lines (Huh7,
Hep3B, HepG2, Hep40) were also highly positive for both
HNF-4 and HNF-1. In contrast, seven AFP- cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) did not express these factors. SNU449,
another AFP- cell line displayed only weak HNF-4
expression. Epithelial cells including hepatocytes show
low motility, in contrast to mesenchymal cells that display
high motility and invasive behavior. To test whether epi-
thelial and mesenchymal gene expression patterns of
HCC cells correlated with their in vitro motility, we used
wound-healing assay. After 24 hours of wounding, AFP-
HCC cells (Mahlavu, SNU449, SNU475, SNU182) moved
through the wound, whereas AFP+ HCC cells (Huh7,
Hep3B, Hep G2, Hep40) cells did not (Figure 3b; Hep40
and SNU182 data not shown). A quantitative analysis of
this data confirmed that poorly differentiated cell lines
display higher motility (Figure 3c).
Based on expression analysis, together with in vitro motil-
ity and previously published invasiveness data, we classi-
fied our panel of HCC cell lines into two subtypes (Table
1). We qualified HepG2, Huh7, Hep3B and Hep40 as
"well-differentiated" HCC cell lines, because they express
AFP, E-cadherin, HNF-4 and HNF-1, and they display
low motility and/or low invasiveness. Most of these fea-
tures are confined to "well-differentiated" HCC tumors
([2,18,32,33]. We qualified the remaining seven cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) as "poorly-differentiated" HCC cell lines,
based on the lack of expression of both hepatocyte lineage
and epithelial cell markers analyzed here. In addition,
these poorly differentiated cell lines shared many features
with mesenchymal cells including the expression of mes-
enchymal markers (vimentin, slug, snail, twist-1, and
twist-2), high motility and invasiveness. These expression
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell linesFigure 2
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell lines. 
Cells grown on coverslips were subjected to immunoperoxidase assay using anti-vimentin antibody (brown), and counter-
stained with hematoxylin (blue).
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and migratory features are associated with tumor dediffer-
entiation and confined to poorly differentiated HCCs [6-
8,14,34].
Expression TCF/LEF family of transcription factors
Following the identification of well-differentiated and
poorly differentiated HCC cell lines, we analyzed the
expression of 45 Wnt pathway genes by RT-PCR assay. We
first investigated the expression profile of TCF/LEF factors.
The TCF-1 and TCF-4 were highly expressed in all HCC
cell lines, while TCF-3 expression was limited to a subset
of cell lines (Figure 4). LEF-1 transcript expression was
weak, except for SNU398 cells. These findings indicated
that at least two different nuclear factors mediating canon-
ical Wnt signaling were expressed in any of HCC cell lines
tested.
Expression of Frizzled receptors and LRP co-receptors
Next we analyzed the expression of 10 Frizzled receptors
and their two co-receptors. Two canonical (Fzd1, Fzd5)
and three noncanonical (Fzd3, Fzd4, Fzd6) Frizzled recep-
tors were expressed in all cell lines tested. Also, Fzd2, Fzd7
and Fzd8 were expressed in most cell lines independent of
their differentiation status (Figure 5-top). Lrp-5 and Lrp-6
co-receptors also were consistently expressed in all cell
lines (Figure 5-bottom). These findings indicated that
HCC cell lines were equipped with the expression of sev-
eral canonical and noncanonial Wnt signaling receptors,
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motilityFigure 3
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motility. 
(a)Selective expression of HNF-4 and HNF-1 in AFP+ HCC cell lines. Total RNAs were extracted from cells and used for 
RT-PCR analysis of HNF-4 and HNF-1 expression. GAPDH RT-PCR was used as a loading control. (b. c) Differential motil-
ity of AFP+ and AFP- HCC cell lines. Cells were cultured in six-well culture plates, and a single linear wound was made with a 
pipette tip in confluent monolayer cells. The distances between wound edges were measured at fixed points in each dish 
according to standardized template. After 24 hours migration, cell migration into the wound was visualized using phase con-
trast microscopy at ×20 magnification (b). The number of cells migrating beyond the wound edge was counted (c). Assays in 
six replicates, error bars; SD. SNU475 cells are larger cells giving rise to visual overestimation of migrating cell number in the 
picture shown in b.
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so that each HCC cell line was likely to respond to both
canonical and noncanonical Wnt signals.
Differential expression of canonical and noncanonical 
Wnt ligands
In humans, there are 19 known genes encoding canonical
and noncanonical Wnt ligands [35]. We studied the
expression profile of the complete list of human Wnt lig-
ands (Figures 6 and 7). From the group of eight known
canonical Wnt ligands, only Wnt3 was strongly and uni-
formly expressed in all cell lines tested. Wnt10b was also
strongly expressed, but not in all cell lines (Figure 6). We
observed selective expression of canonical Wnt8b in well
differentiated cell lins. In contrast, among seven nonca-
nonical Wnt ligands, Wnt4, Wnt5a, Wnt5b and Wnt7b
were expressed in almost all poorly differentiated cell
lines tested. This contrasted with their poor expression in
well differentiated cell lines (Figure 7-top). Signaling spe-
cificity of four other Wnt ligands have not yet been clearly
established [35]. Among these ligands, Wnt9a expression
was detectable in nearly all cell lines tested. In contrast,
Wnt9b and Wnt2b expressions were associated to well dif-
ferentiated and poorly differentiated cell lines, respec-
tively (Figure 7-bottom).
Our comprehensive analysis of Wnt signaling molecules
in HCC cell lines revealed several features. First, with the
exception of Wnt ligands, most of the major components
of Wnt signaling pathway were expressed redundantly in
HCC cell lines, independent of their differentiation status.
In contrast, Wnt ligand expression displayed two types of
selectivity. First, out of eight known canonical only Wnt3
and Wnt10b displayed strong expression in most cell
lines, independent of differentiation status. Second, out of
seven noncanonical Wnt ligands, four were expressed in
HCC cell lines with a high selectivity for poorly differenti-
ated ones. Well-diffferentiated cell lines displayed selec-
tive expression of Wnt8b. These findings may have several
Table 1: Well-differentiated and poorly differentiated HCC cell lines according to hepatocyte lineage, epithelial and mesenchymal 
markers, and in vitro motility and invasiveness assays
Cell Lines Fetal 
Hepatocyte 
Marker
Epithelial & Hepatocyte 
Markers
Mesenchymal markers Motility Invasivene
ss
AFP HNF4a HNF1a E-cadherin vimentin slug Snail Twist-1 Twist-2
Well-
differentiated
HepG2 High High High Low (-) Low Low Low High Low Low [14]
Huh7 High High High High Low (±) Low Low (-) Low Low [14]
Hep3B High High High High Low High Low (-) (-) Low Low ([74]
Hep40 High High High Low High (-) High High Low Low n.t.
Poorly 
differentiated
SNU398 (-) (-) (-) Low High Low High High High Low n.t.
SNU475 (±) (-) (-) (-) High High High High Low High n.t.
SNU449 (-) Low (-) (±) High Low Low High High High n.t.
SNU387 (-) (-) (-) (-) Low High High (-) (±) n.t. n.t.
FOCUS (-) (-) (-) Low High Low (-) (-) Low n.t. n.t.
Mahlavu (-) (-) (-) (±) High Low (-) High Low High High [74]
SNU182 (-) (-) (±) High high High High High High High n.t.
(-); not detected; ±; traces; n.t.; not tested.
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implications. Most, in not all HCC cell lines were
equipped with an autocrine/paracrine canonical Wnt sig-
naling system, as reported previously for breast and ovar-
ian cancer cell lines [36]. In contrast, because of selective
expression of noncanonical Wnt ligands, only poorly dif-
ferentiated cell lines could serve from an autrocrine non-
canonical Wnt signaling system. In addition, poorly
differentiated HCC cells could also provide noncanonical
Wnt signals to other cells by a paracrine mechanism.
Finally, noncanonical Wnt ligands such as Wnt5a might
inhibit canonical Wnt signaling in HCC cells, as previ-
ously reported in other cell types [37-39].
Autocrine canonical Wnt signaling in well differentiated 
hepatocellular carcinoma cell lines
Canonical Wnt signaling activates TCF/LEF-dependent
transcription, which can be monitored by reporters con-
taining TCF/LEF-responsive elements [27,40]. We sur-
veyed canonical Wnt signaling in HCC cell lines using
TCF/LEF reporter pGL3-OT plasmid, as described previ-
ously [41]. First, we compared TCF/LEF (TCF) activity in
three cell lines with known mutations in canonical Wnt
signaling pathway (Figure 8a). Well-differentiated HepG2
cell line displays -catenin mutation. Poorly-differenti-
ated SNU398 and SNU475 cell lines display -catenin and
AXIN1 mutations, respectively [42,43]. Normalized TCF
activity was the highest in HepG2 cells. Compared to
HepG2, SNU398 cells displayed 50% less activity. More
interestingly, despite a homozygous deletion leading to a
loss of Axin1 expression (data not shown; [42,43], there
was no detectable TCF activity in SNU475 cells. This con-
trasted sharply with another well-differentiated AXIN1
mutant HCC cell line, namely PLC/PRF/5 (Alexander)
that displayed high TCF activity [42] (additional data not
shown).
Next, we compared TCF activity of eight other cell lines
that displayed wild-type -catenin and AXIN1 status [41-
43]. Hep40 cells that harbor a missense AXIN1 mutation/
polymorphism (R454H) was included in this group, since
functional significance of this mutation is unknown [41].
We detected weak, but significant (3-4 fold) TCF activity
in well-differentiated Huh7 and Hep3B cell lines. On the
other hand, all five poorly differentiated cell lines, as well
as well-differentiated Hep40 cells displayed no detectable
activity under our experimental conditions (Figure 8b).
Taken together, we collected TCF activity data from 12
HCC cell lines. Independent of -catenin or AXIN1 status,
TCF activity was detected in four out of five (80%) well-
differentiated cell lines, whereas only one out of seven
(14%) poorly differentiated cell lines had constitutive
TCF activity [P < 0.046 (one-tailed), 0.071(two-tailed);
Fisher Exact Probability Test]. This data supports the
hypothesis that well-differentiated HCC cells display an
autocrine/paracrine canonical Wnt signaling, probably
because they co-express Wnt3 and several canonical Friz-
zled receptors. However, the great majority of poorly dif-
ferentiated cell lines failed to generate canonical Wnt
signaling activity, although they similarly co-expressed
Wnt3 and canonical Frizzled receptors.
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell linesFigure 4
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell lines. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay of four members of TCF/LEF family. See Figure 
1 for GAPDH loading control.
Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
Page 8 of 20
(page number not for citation purposes)
Canonical Wnt signaling is repressed in poorly 
differentiated hepatocellular carcinoma cells
The lack of canonical Wnt activity in poorly differentiated
cells could be due to either lack of sufficient Wnt ligand
activity. Alternatively, canonical Wnt signaling could be
repressed in these cell lines. A number of proteins down-
stream to -catenin such as Axin2, HTLE family, hAES,
Chibby, CTBP and ICAT are known to display inhibitory
activity on canonical Wnt signaling [44]. We compared
the expression of genes encoding these inhibitory pro-
teins, but found no correlation with TCF activity or differ-
entiation state (Figure 9).
Next, we compared TCF activity in Huh7, SNU449 and
SNU182 cell lines following transient expression of a
mutant (S33Y)--catenin (Figure 10). Transfection with
S33Y--catenin resulted in an increase in total -catenin
protein in Huh7 and SNU449. This increase was less evi-
dent in SNU182 cells (Figure 10a). Well-differentiated
Huh7 cells responded to S33Y--catenin expression by a
strong activation of TCF/LEF reporter (130 folds). Under
the same experimental conditions, the response of
SNU449 cells was minimal (5 folds). More importantly,
SNU182 cells were totally unresponsive (Figure 10b).
These important differences between well-differentiated
Huh7 and two different poorly differentiated cell lines
(SNU449 and SNU182) are apparently not due to differ-
ences in transient transfection efficiencies, since the meas-
ured activities have been corrected for such differences
(see material and methods section).
In order to confirm the data on weakened response in
poorly differentiated cell lines, we generated a clone from
SNU449 cells (SNU449-cl8) with Tet repressor controlled
expression of N-terminally truncated -catenin (aa 98-
781). N-terminally truncated -catenin forms are fre-
quently detected in cancer cells including HCC cells. They
lack Ser/Thr phosphorylation sites (aa Ser23, Ser29,
Ser33, Ser37, Thr41, Ser45) that are critically involved in
its ubiquitin-mediated degradation, and they accumulate
in the cell nucleus leading to oncogenic activation canon-
ical Wnt signaling [27]. As shown in figure 11a, SNU449-
cl8 cells expressed only wild-type -catenin in the pres-
ence of tetracycline (Tet-on conditions), while expressing
both wild-type and truncated -catenin at comparable lev-
els in Tet-off conditions. The induced expression of trun-
cated -catenin resulted in only a weak activation (3-4
fold) of TCF reporter activity, similar to data obtained by
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell linesFigure 5
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell lines. Frizzled 
receptors involved in canonical and noncanonical Wnt signaling were tested for expression by RT-PCR assay (Top). The 
expression of LRP co-receptors was analyzed similarly (bottom). Total RNAs were extracted from cell lines and used to detect 
gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.
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transient transfection experiments (Figure 11b). This low
level of activation was similar to that seen in well-differen-
tiated HCC cells in the absence of -catenin or Axin-1
mutation (Fig. 8b), and strongly suggests that canonical
Wnt signaling is actively repressed in this poorly differen-
tiated HCC cell line. For comparison, well-differentiated
HepG2 cells expressing wild-type and a similar N-termi-
nally truncated -catenin (25-140 aa) activated TCF
reporter gene by more than 60-fold (Figure 8a). In other
words, although both Tet-off SNU449-cl8 and HepG2
cells displayed a heterozygous truncating -catenin muta-
tion, TCF activation was 15-fold less in poorly differenti-
ated SNU449 background. To test whether this repression
was related to cellular localization of -catenin, we per-
formed immunofluorescence detection using confocal
microscopy (Figure 11c). Wild-type -catenin was local-
ized at the cell membrane with weak nuclear localization.
The induction of truncated -catenin in Tet-off SNU449-
cl8 cells did not change this distribution significantly. We
observed only weak cytoplasmic accumulation, with
slight increases in both membrane and nuclear localiza-
tion. In sharp contrast with these observations, in colorec-
tal cancer cells (APC-mutated), used as a positive control
[45], we detected strong nuclear accumulation of -cat-
enin by the same technique.
WNT5A inhibits canonical Wnt signaling in HCC cells
Presently, the mechanism of repression of canonical Wnt
signaling in poorly differentiated HCC cells is unknown,
but it is associated with a lack of nuclear accumulation of
-catenin. Among noncanonical Wnt ligands, Wnt5a is
best known for its antagonistic effect on canonical Wnt
signaling [46]. Therefore, we tested the effect of ectopic
Wnt5a expression on mutant--catenin-induced TCF
activity in Huh7 cell line. In the absence of Wnt5a, TCF
activity was induced more than 160-fold by mutant -cat-
enin in this cell line. Co-expression of Wnt5a resulted in
three-fold repression of TCF activity (Figure 12a). To con-
firm our observations, we also tested the effects of Wnt5a
on TCF activity induced by endogenous mutant -catenin
using HepG2 cell line. The expression of Wnt5a in this cell
line caused a significant inhibition of TCF activation
mediated by endogenous -catenin (P < 0.05; Figure 12b).
We concluded that Wnt5a that is selectively expressed in
poorly differentiated HCC cell lines, and probably simi-
larly acting noncanonical Wnt ligands are involved, at
least partly, in the repression of canonical Wnt signaling
in these cells.
Discussion
Since the initial description of -catenin mutations in
HCCs in 1998 [33], Wnt signaling became a center of
interest for these tumors. A large set of Wnt ligands and a
large array of receptors are implicated in different cell
processes by initiating canonical, but also noncanonical
Wnt signals [35]. The antagonism between canonical and
noncanonical Wnt pathways has also been reported
[37,38,46]. Thus, both -catenin and Wnt signaling are
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell linesFigure 6
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell lines. Canonical Wnt ligands were 
tested for expression by RT-PCR assay. Total RNAs were extracted from cell lines and used to detect gene expression by RT-
PCR assay. See Figure 1 for GAPDH loading control.
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involved in highly complex cellular events of which only
some are mediated by canonical Wnt pathway. This com-
plexity is also observed during liver development and as
well as in adult liver homeostatic events. Canonical Wnt
signaling contributes to liver growth and regeneration,
but also to liver "zonation" by controlling some liver-spe-
cific metabolic programs. ([47]). In addition, it contrib-
utes to the activation of liver stem or progenitor cells, as
well as HCC-initiating cells [48-51].
Mutational activation of canonical Wnt signaling is not a
frequent event in HCC, in contrast to hepatoblastoma dis-
playing very high rates [52]. Mutations of -catenin were
restricted to a group of HCCs associated with low p53
mutation rate, negative HBV status and chromosomal sta-
bility, as stated earlier. These mutations were also associ-
ated with lower histological grade and better patient
survival. Unexpectedly, -catenin mutations are rare in
more advanced and poorly differentiated HCCs [20,23].
Therefore, although considered to play an active role in
HCC malignancy, the activation of canonical Wnt signal-
ing may not be necessary for, or even repressed in
advanced HCCs. Thus, -catenin mutation and constitu-
tive activation of canonical Wnt signaling may be differen-
tiation-dependent events with mechanistic implications
in HCC initiation and progression. We attempted to
address this issue by using HCC-derived cell lines.
We first classified 11 HCC cell lines into "well-differenti-
ated" and "poorly differentiated" subtypes using hepato-
cyte lineage, epithelial and mesenchymal cell markers,
and in vitro migration assays. Well-differentiated HCC
cell lines shared many features with hepatocytes such as
expression of HNF-1, HNF-4, and E-cadherin, and epi-
thelial morphology. Poorly differentiated cell lines were
usually deficient in the expression of hepatocyte lineage
and epithelial markers, but they expressed different mes-
enchymal markers strongly. These two types of HCC cell
lines were also distinguished from each other by their in
vitro behaviors. Poorly differentiated cell lines were usu-
ally more motile and more invasive than well-differenti-
ated cell lines (Table 1). A global expression profiling
study classified HCC cell lines in Group I and Group II
[51]. Our well-differentiated and poorly differentiated cell
line subtypes showed perfect correlation with Group I and
Group II, respectively. Well-differentiated Group I was
characterized by the activation of oncofetal promoters
leading to increased expression of AFP and IGF-II,
whereas poorly differentiated Group II was characterized
by overexpression of genes involved in metastasis and
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma cell linesFigure 7
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma 
cell lines. Noncanonical and unclassified Wnt ligands were tested for expression by RT-PCR assay. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.
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invasion. Our well-differentiated and poorly differenti-
ated subtypes were also in perfect correlation with respec-
tively epithelial and mesenchymal HCC cell line types
that have been identified very recently [12]. Mesenchymal
cancer cells are considered as the products of EMT that is
believed to be a key mechanism for the acquisition of
invasive and metastatic capabilities by tumor cells [53].
Higher motility of poorly differentiated HCC cell lines
reported here is in line with this concept. Thus, our two
classes of cell lines share many similarities with well-dif-
ferentiated and poorly differentiated HCC tumors. We
used this model to compare the status of Wnt pathway
according to HCC differentiation status.
A comprehensive analysis of Wnt signaling components
in liver or hepatocytes is lacking. However, the expression
of Wnt ligands and Frizzled receptors in mouse hepato-
cytes has been published [54]. Mouse hepatocytes
expressed canonical receptors Fzd7 and Fzd9, as well as
noncanonical Fzd2, Fzd3, Fzd4 and Fzd6. We observed
highly similar pattern of expression in HCC cell lines with
the exception of Fzd9 that showed weak expression. In
addition, we detected increased expression of canonical
Fzd1 and Fzd5 in most HCC cell lines. The expression fre-
quency of these receptors was not associated with HCC
cell differentiation status. Mouse hepatocytes expressed
canonical Wnt1 and Wnt2, and noncanonical Wnt4,
Wnt5a, Wnt5b and Wnt11. All or most HCC cell lines
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differentiated hepatocellular carcinoma cell linesigur  8
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differenti-
ated hepatocellular carcinoma cell lines. (a) Comparative analysis of the canonical Wnt signaling in hepatoma cell lines 
with known mutations of -catenin or Axin-1 genes. TCF reporter assay shows that well-differentiated HepG2 cells display 
high signaling activity. In contrast, canonical Wnt signaling is attenuated in poorly differentiated SNU398, and undetectable in 
poorly differentiated SNU475 cell line. Assays in triplicate, error bars; SD. (b) Comparative analysis of the canonical Wnt sign-
aling in HCC cell lines with wild-type -catenin and Axin-1 genes. Huh7 and Hep3B cell lines (both well-differentiated) display 
weak but significantly increased TCF reporter activity. Other cell lines (all poorly differentiated, except Hep40) display no 
detectable TCF reporter activity. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) 
plasmids, respectively. Assays in triplicate, error bars; S. D. Cells were transfected with the reporter gene pGL3-OT (OT) har-
boring LEF-1/TCF binding sites for -catenin and the corresponding pGL3-OF (OF) without these sites.
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have lost the expression of canonical Wnt1 and Wnt2, but
they displayed increased expression of canonical Wnt3
and Wnt10b ligands. Another canonical ligand, Wnt8b
was expressed selectively in well-differentiated cell lines.
In contrast, noncanonical Wnt4, Wnt5a and Wnt5b lig-
ands were expressed in the majority of poorly differenti-
ated cell lines, but not in most of well-differentiated cell
lines. In addition, most HCC cell lines (poorly differenti-
ated cell lines in particular) also displayed increased
expression of noncanonical Wnt7b. Among Wnt ligands
and Frizzled receptors that we found to be expressed or
upregulated in HCC cell lines, Wnt3, Wnt4, Wnt5a, Fzd3,
Fzd6 and Fzd7 have been previously reported to be over-
expressed also in primary HCC tumors [55-57]. Overex-
pression of Wnt10b was also reported in HCC cels [58].
Increased levels of Wnt5a transcripts were detected in
chronic hepatitis, cirrhosis and HCC [59]. A C-terminally
mutated HBV X protein was shown to upregulate Wnt5a
expression in HCC cells [60]. Thus, Wnt5a upregulation
observed in clinical samples might be related to HBV at
least in HBV-related liver diseases. Based on our observa-
tions that associate noncanonical Wnt ligand expression
to poorly differentiated HCC cell lines, it will be interest-
ing to test the predictive value of noncanonical Wnt
expression for HCC prognosis.
Another important finding of this study is the differential
activity of canonical Wnt signaling in different HCC sub-
types. Well-differentiated cell lines displayed active
canonical Wnt signaling at variable degrees. In addition to
strong signaling activity associated to -catenin and Axin1
mutations in two well differentiated cell lines, we also
observed autocrine canonical Wnt signaling in two other
well differentiated cell lines, as reported for some other
cancer cell lines [36]. The functional significance of auto-
crine canonical Wnt signaling in these cell lines is not
known.
However, small molecule antagonists of Tcf4/beta-catenin
complex were shown to inhibit TCF reporter activity and
down-regulate the endogenous Tcf4/-catenin target
genes c-Myc, cyclin D1, and survivin in Huh7 cells [61].
This observation strongly suggests that the autocrine
canonical Wnt signaling is functional in well-differenti-
ated HCC cell lines. Canonical Wnt signaling has been
linked to both stem cell and cancer cell self-renewal in
other cancer types. It was proposed that some adult can-
cers derive from stem/progenitor cells and that canonical
Wnt signaling in stem and progenitor cells can be sub-
verted in cancer cells to allow malignant proliferation
[62]. Indeed, well-differentiated-HCC cell lines identified
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cellsFigure 9
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cells. Total 
RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH RT-PCR was used as a 
loading control.
Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
Page 13 of 20
(page number not for citation purposes)
here such as HepG2, Huh7 and PLC/PRF/5 have been
reported to harbor HCC stem cells [63]
Our third noteworthy observation was the lack of detecta-
ble canonical Wnt signaling activity in six out of seven
poorly differentiated cell lines. Even a poorly differenti-
ated cell line with a deleterious Axin1 mutation
(SNU475) lacked detectable signaling activity. Thus, most
probably, the canonical Wnt signaling was not only inac-
tive, but also repressed in poorly differentiated HCC cell
lines. In confirmation of this expectation, transient or Tet-
regulated expression of mutant -catenin failed to gener-
ate significant canonical Wnt signaling activity in two dif-
ferent poorly differentiated cell lines. Furthermore, we
linked this weak activity to poor nuclear accumulation of
-catenin protein in SNU449.cl8 cell line. Thus, unlike
well-differentiated cell lines, poorly differentiated HCC
cells displayed strong resistance to canonical Wnt signal
activation.
The mechanisms of resistance to canonical Wnt signal
activation in poorly differentiated HCC cells are presently
unknown. We provide here one potential mechanism.
Wnt5a has been previously implicated in canonical Wnt
signaling as an antagonist and regulator of -catenin lev-
els in other cell types [48,49]. Using both ectopic and
endogenous mutant -catenin expression systems in two
different cell lines, we demonstrated that co-transfections
with Wnt5a-expressing plasmid can significantly inhibit
canonical Wnt signaling in HCC cells. The mechanism of
Wnt5a antagonism on canonical Wnt signaling in HCC
cells is not known. In breast cancer cells, the loss of Wnt5a
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in poorly differenti-ated hepatoc llular carcinoma cellsFigur 10
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in 
poorly differentiated hepatocellular carcinoma cells. (a) Well-differentiated Huh7, and poorly differentiated SNU449 
and SNU182 cell lines have been co-transfected with either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) or 
empty pCI-neo plasmid (S33Y--catenin -), and cellular -catenin levels at post-transfection 48 h were tested by immunoblot-
ting. Calnexin was used as a loading control. (b) Cell lines were treated as described, then pCI-neo-mutant -catenin (S33Y)-
transfected cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) 
and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections included pGL-OT or pGL-OF, 
in addition to pCI-neo plasmids in both (a) and (b).
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signaling resulted in stabilization of nuclear beta-catenin
and expression of Wnt/beta-catenin target genes [64].
However, both ectopically and endogenously expressed
mutant -catenins used in our experiments were N-termi-
nally truncated devoid of their Ser/Thr phosphorylation
motifs. Thus, Wnt5a appears to inhibit canonical Wnt sig-
naling in HCC cells, downstream to -catenin, independ-
ent of its glycogen synthase 3-- and bTrCO-dependent
degradation. Wnt5a has been shown to inhibit canonical
Wnt signaling either by bTrCP-independent proteasomal
degradation [65], or, by downregulating -catenin-
induced reporter gene expression without influencing -
catenin levels [37] in kidney epithelial cells. Wnt5a may
use similar mechanisms in Huh7 and HepG2 cells. Fur-
ther studies with downregulation of noncanonical Wnt
ligands in poorly differentiated HCC cell lines may help
to better define the implications of such ligands in liver
cancer biology.
The role of Wnt5a in cancer is complex. It may play
tumor-promoting or tumor-suppressing functions
depending on cellular context. Wnt5a has been described
as a tumor promoter in melanoma, gastric, pancreas, pros-
tate cancer, but as a tumor suppressor in HCC, neuroblas-
toma, leukemia, colon, and thyroid cancers [46]. The
inability of Wnt5a to transform cells or signal through the
canonical -catenin pathway pointed that it cannot pro-
mote tumorigenesis by upregulation of canonical Wnt sig-
naling, unlike canonical Wnt ligands [66]. Our results
suggest that Wnt5a, upregulated in poorly differentiated
highly motile mesenchymal-like HCC cells may play a
role in tumor progression by inducing EMT. Upregulation
of Wnt5a expression during EMT has been reported [67].
Furthermore, the Wnt5A/Protein kinase C pathway was
shown to mediate motility in melanoma cells via of an
EMT [68]. Similarly, CUTL1-upregulated Wnt5a signifi-
cantly enhanced migration, proliferation and invasiveness
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated SNU449Figure 11
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated 
SNU449.cl8 cells. SNU449 cells were stably transfected with Tet-responsive N--catenin expression vector to obtain 
SNU448.cl8 cells. (a) Induced expression of N-terminally truncated N--catenin protein in the Tet-Off conditions, as tested 
by western blot assay. Total cell lysates were extracted from cells and subjected to western blot assay using anti--catenin anti-
body. (b) TCF activity is only weakly induced in Tet-off conditions, as tested by duplicate experiments. (c) SNU449.cl8 cells at 
Tet-On state express wild-type endogenous -catenin protein principally located at cell membrane. Under Tet-Off conditions 
the staining pattern remains almost identical despite N--catenin expression. Note lack of nuclear accumulation. SW480 cells 
used as positive control display strong nuclear -catenin staining. Cells were grown on coverslips, subjected to indirect immun-
ofluorescence assay using anti--catenin antibody (red), counterstained with DAPI (blue) and examined by confocal micros-
copy.
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in pancreas cancer cellls [69]. These effects were accompa-
nied by a marked modulation of marker genes associated
with EMT. Wnt5a may promote EMT in HCC cells by a
similar mechanism.
The expression status of Wnt5a in HCC is not well known.
To our knowledge, only one report addressed this issue
[59]. Compared to normal tissue, Wnt5a mRNA expres-
sion was strongly induced in HCC, as well as in chronic
hepatitis and cirrhosis. However, immunostaining of
Wnt5a protein showed a bell-shaped pattern: low to
undetectable levels were present in normal tissue and in
tumor samples, whereas strong immunostaining was seen
in chronic hepatitis, cirrhosis and dysplastic liver cells.
The reasons of the discrepancy between transcript and
protein expression in HCC tissues are not known pres-
ently. However, it appears that peritumoral liver tissues
express high levels of Wnt5a protein that could trigger
noncanonical Wnt signaling in adjacent tumor cells. It
will be important to further investigate the role of Wnt5a
in HCC tumor progression.
Taken together, our studies demonstrate that canonical
Wnt activity is active in well-differentiated, but repressed
in poorly differentiated HCC cell lines. This correlates
with in vivo tumor studies indicating that -catenin muta-
tions are prevelant in well-differentiated, but not in
poorly differentiated tumors. In addition, we showed that
poorly differentiated cell lines express noncanonical Wnt
ligands such as Wnt5a acting as an antagonist of canonical
Wnt signaling. Thus, it appears that HCC cells may acti-
vate or repress their canonical Wnt signaling, using auto-
crine/paracrine systems based on selective use of
canonical and noncanonical Wnt ligands.
We hypothesize that the active canonical Wnt signaling
observed in well-differentiated HCC cells contributes to
tumor initiation, but not necessarily to tumor progres-
sion. Instead, noncanonical Wnt signaling may be used by
poorly differentiated HCC tumors to promote cell motil-
ity and invasion. Selective use of canonical and nonca-
nonical Wnt signaling at different stages may be a key
mechanism involved in hepatocellular carcinogenesis.
Recent studies showed that canonical Wnt signaling con-
tributes to the self-renewal and expansion of HCC-initiat-
ing cells with stem/progenitor cell features [50,70].
However, the lack of HCC development in -catenin
transgenic mice strongly suggests that canonical Wnt sign-
aling activation has limited tumorigenic potential in liver
tissue. Indeed, recent studies showed that canonical Wnt
signaling plays a major role in the specification of mature
hepatocytes for perivenous-specific gene expression
([71,72]. Such a hepatocyte differentiation function of
canonical Wnt signaling may not be compatible with cel-
lular dedifferentiation that goes along with HCC develop-
ment. Therefore, alternative pathways such as Wnt5a-
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cellsFigure 12
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cells. (a) Huh7 cells were co-transfected with 
either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) along with pShuttle-IRES-WNT5a or empty pShuttle-IRES 
vector. 48 hours post transfection; cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals 
detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections 
included pGL-OT or pGL-OF, in addition to pCI-neo-S33Y--catenin and pIRES plasmids. (b) HepG2 experiments were per-
formed under similar conditions, except that pCI-neo-mutant -catenin (S33Y) plasmid was omitted.
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mediated noncanonical Wnt signaling may be necessary
for sustained growth and progression of HCC tumors.
Melanoma may serve as a demonstrated model to our
hypothesis. Similar to HCC, canonical Wnt signaling acti-
vation is an early event and nuclear -catenin accumula-
tion is associated with better patient survival in
melanoma. Nuclear -catenin is lost in more aggressive
melanomas that express Wnt5a that promotes EMT, cell
motility and metastasis[46]. Chien et al. [73] have
recently demonstrated that canonical Wnt signaling
induces growth inhibition and differentiation in
melanoma cells, whereas Wnt5a can antagonize some of
these effects. These findings clearly establish a dual func-
tion of Wnt signaling in melanoma. In light of these
recent developments, our findings call for further investi-
gations on respective roles of canonical and noncanonical
Wnt signaling in HCC.
Conclusion
Our observations support the hypothesis that Wnt path-
way is selectively activated or repressed depending on dif-
ferentiation status of HCC cells. We propose that
canonical and noncanonical Wnt pathways have comple-
mentary roles in HCC, where the canonical signaling con-
tributes to tumor initiation, and noncanonical signaling
to tumor progression.
Methods
Cell lines
Hepatocellular carcinoma cell lines Huh7, Hep40,
Hep3B, Hep3B-TR, FOCUS, Mahlavu, SNU182, SNU 387,
SNU 398, SNU423, SNU 449, SNU 475, PLC/PRF/5, SK-
Hep-1, hepatoblastoma cell line HepG2 and colorectal
cancer cell line SW480 were cultivated as described previ-
ously [41].
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Total RNAs were extracted from cultured cells using
NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren, Ger-
many) according to the manufacturer's protocol. The
cDNAs were prepared from total RNA (2 g) using Rever-
tAid First Strand cDNA Synthesis Kit (MBI-Fermentas, Vil-
nius, Lithuania). A negative control without reverse
transcriptase (1 l ddH2O instead) was also prepared for
each sample. All PCR reactions were carried out using 1 l
cDNA from the reverse transcription mix, for 35 cycles
except GAPDH, which was amplified for 24 cycles. Nega-
tive controls without reverse transcriptase were included
for each set of primers (primer sequence information is
available upon request). PCR products were analyzed on
a 2% (w/v) agarose gel.
Wound-healing assay
Cells were cultured in six-well culture plates in RPMI 1640
or DMEM with 10% FBS. A single linear wound was made
with a p200 pipette tip in confluent monolayer cells. The
distances between wound edges were measured at fixed
points in each dish according to standardized template.
Debris were removed by washing the cells twice with PBS
and then cells were incubated in RPMI 1640 or DMEM
with 2% FBS. After 24 hours migration, cells were fixed
with methanol and stained with 0.2% crystal violet. Cell
migration into the wound was visualized using phase con-
trast microscopy (x20 magnification). The number of cells
migrating beyond the wound edge was quantified micro-
scopically in the randomly selected fields for each tripli-
cate well.
Immunocytochemistry
Cells were grown on coverslips, fixed in 4% formalde-
hyde, permeated with 0.5% saponin/0.1% Triton X-100,
and stained with mouse monoclonal anti-human vimen-
tin antibody (Dako) using Envision kit (Dako), developed
with diaminobenzidine, and counterstained with hema-
toxylin.
Confocal microscopy
Cells were grown on slides in 6 well plates and were fixed
in 3.5% paraformaldehyde (PFA) for 15 minutes, and per-
mealized using 0,25% Triton-X-100 for 10 min. Non spe-
cific protein binding was blocked by 30 minutes of
incubation with 5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) at room temperature.
Cells were then incubated 2 hours with monoclonal anti-
-catenin antibody M5.2 (1:200 dilution) in 1% BSA in
PBS at room temperature in a moist chamber. Immun-
ofluorescence staining was obtained by incubating for 1
hour with Alexa Fluor® 594 F(ab')2 fragment of rabbit
anti-mouse IgG (H+L) (Invitrogen) (dilution 1:750).
Cells were counterstained with DAPI (dilution 1:750),
slides were mounted using ProLong® Gold antifade rea-
gent (Invitrogen) and examined under Zeiss LSM 510
Meta laser scanning confocal microscope (MPI Freibourg,
Germany) using 488 nm and 543 nm laser excitation
lines, and photographed.
Plasmids
The pShuttle-IRES-Wnt5a expression plasmid was con-
structed by subcloning of an EcoRI-cut Wnt5a cDNA frag-
ment from plasmid pGEMTz-Wnt5a vector (a gift from R.
Kemler) into BglII site of the pShuttle-IRES-hrGFP-1 vec-
tor (Stratagene, USA). pCI-Neo-mutant -catenin (S33Y)
expression plasmid, and pGL3-OT and pGL3-OF reporter
plasmids were kindly provided by B. Vogelstein. Other
plasmids were pCI-Neo (Promega) and pEGFP-N2 (Clon-
tech, Palo Alto, CA). The pAUCT-N--catenin plasmid
expressing N-terminally truncated -catenin (aa 98-781)
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under the control of Tet repressor was constructed using
pAUCT-CCW vector (gift from Ali Fattaey, USA). A cDNA
fragment of XhoI-NotI digestion from pCI-Neo-mutant -
catenin (S33Y) plasmid was inserted into XhoI-NotI site
of pAUCT-CCW vector.
Transfections
Endogenous TCF/LEF-dependent transcriptional activity
was tested by using pGL3-OT and pGL3-OF reporter plas-
mids, as described previously [41], except that cells were
transfected using Lipofectamin 2000 reagent (Invitrogen),
following instructions provide by the supplier. Mutant -
catenin-induced TCF/LEF-dependent transcriptional
activity was tested after co-transfection of cells with pCI-
Neo-mutant -catenin (S33Y) expression plasmid (1.75
g/well) together with the reporter plasmids. pCI-Neo
(1.75 g/well) was used as negative control. The effect of
Wnt5a expression on TCF/LEF-dependent transcriptional
activity was tested using Huh7 and HepG2 cell lines.
Huh7 cell line was co-transfected with pCI-Neo-mutant -
catenin (S33Y) expression plasmid (1 g/well) together
with either pShuttle-IRES-Wnt5a (0.75 g/well) or the
empty vector pShuttle-IRES-hrGFP-1 (0.75 g/well) and
pGL3-OT/pGL3-OF reporter plasmids (0.75 g/well for
each). At 48 h following transfection, luciferase assay was
performed by using Luciferase Reporter Gene Assay, con-
stant light signal kit (Roche Diagnostics GmbH., Man-
nheim, Germany). Luciferase activity was read with The
Reporter® Microplate Luminometer (Turner BioSystems
Inc., Sunnyvale, CA) and data was normalized according
to transfection efficiency obtained with each transfection,
as described previously [41]. HepG2 cell line was co-trans-
fected with either pShuttle-IRES-Wnt5a (0.5 g/well) or
the empty vector pShuttle-IRES-hrGFP-1 (0.5 g/well)
and pGL3-OT/pGL3-OF reporter plasmids (0.5 g/well
for each), with an internal control (0.05 g/well pRL-TK
Renilla luciferase vector) in a 12-well plate, using Lipo-
fectamine 2000 Transfection Reagent. Forty-eight hours
post-transfection, the cells were washed with PBS, and
lysed in passive lysis buffer (Dual Luciferase kit;
Promega). The cell lysates were transferred into an Opti-
Plate 96-well plate (Perkin-Elmer) and assayed in a 1420-
Multilabel counter luminometer, VICTOR3 (Perkin-
Elmer) using the Dual-Luciferase kit (Promega). Relative
TOP-FLASH luciferase units were measured and normal-
ized against Renilla luciferase activity and further normal-
ized luciferase activity against FOP-FLASH activity. All
transfection experiments were performed in triplicate and
data were expressed as mean of triplicate values (±S. D.)
and p values were calculated. TCF/LEF activity was
reported as the ratio of normalized luciferase activities
obtained with pGL-OT and pGL-OF plasmids, respectively
(mean ± S. D.).
Generation of mutant -catenin expressing SNU449-cl8 
cell line
SNU449 cell line clone ectopically expressing N-termi-
nally truncated (aa 98-781) -catenin, under the control
of Tet repressor was generated by stable transfection with
pAUCT-N--catenin plasmid. Briefly, SNU449 cells were
plated onto 6-well plate and transfected with 2 g of plas-
mid DNA using Lipofectamin 2000 reagent (Invitrogen).
24 hours post transfection, cells were transferred to 90
mm dishes and subjected to G418 (0.6 g/ml) selection in
the presence of tetracycline (1 g/ml) until resistant cell
colonies became visible. Several clones were tested by
Western blot for the expression of N-terminally truncated
(aa 98-781) -catenin after withdrawing tetracycline from
the culture medium to induce the expression of the trans-
gene. Only one clone (SNU449-cl8) displayed Tet-
dependent expression of mutant -catenin, and it was
used for further studies.
Western blotting
Detergent-soluble cell lysates were prepared at 48 h post-
transfection and used for western blot analysis, as
described previously [41]. Antibodies to -catenin (Santa
Cruz Biotechnology, Inc., CA) and calnexin (Sigma) were
obtained commercially. ECL kit (Amersham Life Science,
Inc., Piscataway, NJ) was used for detection of antigen-
antibody complexes. Equal protein loading was verified
by Western blot assay with calnexin antibody.
Statistical analysis
The statistical significance of the active TCF reporter activ-
ity between well-differentiated and poorly differentiated
HCC cell lines was tested by Fisher Exact Probability Test
using an on-line tool http://faculty.vassar.edu/lowry/Vas
sarStats.html.
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Abstract
Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, ‘‘normal-like’’, and ERBB2+ subgroups
were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly
understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity.
Methodology/Principal Findings: A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on
their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as
senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All SCP cell lines expressed estrogen receptor (ER).
Loss of ER expression combined with the accumulation of p21Cip1 correlated with senescence in these cell lines. p21Cip1
knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast,
tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared
the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells
produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells.
In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/
CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+myoepithelial-
like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and ‘‘normal-like’’ tumors, and ICP cell
lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice.
Conclusions/Significance: Luminal A and ‘‘normal-like’’ breast cancer cell lines were able to generate luminal-like and
myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/
progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is
directly correlated with stem/progenitor phenotypes and poor differentiation potential.
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Introduction
Human breast tumors are heterogeneous, both in their
pathology and in their molecular profiles. Gene expression
analyses classify breast tumors into distinct subtypes, such as
luminal A, luminal B, ERBB2-positive (ERBB2+) and basal-like
[1,2,3]. The prognosis and therapeutic response of each subtype is
different. Luminal A cancers are mostly estrogen receptor-a-
positive (ER+) and sensitive to anti-estrogen therapy, with the best
metastasis-free and overall survival rates. Luminal B tumors have
an incomplete anti-estrogen response and lower survival rates.
Basal-like and ERBB2+ tumors are ER- and display the worst
survival rates [2,3]. The patterns of genetic changes such as
chromosomal aberrations and gene mutations observed in breast
tumors indicate that breast tumorigenesis does not follow a
stepwise linear progression from well-differentiated to poorly
differentiated tumors with cumulative genetic aberrations [4]. This
suggests that different breast tumor subtypes do not represent
different stages of tumor progression, but rather represent the cells
from which they initiate [4]. The mammary gland is composed of
differentiated luminal and myoepithelial cells that are generated
from multi-lineage, luminal-restricted, and myoepithelial-restrict-
ed progenitors originating from a hypothetical breast epithelial
stem cell. Thus, different types of breast cancers might originate
from such stem or progenitor cells at a given stage of commitment
and differentiation, as observed in hematological malignancies
[4,5]. Without compromising the author’s hypothesis, it is also
possible that the molecular heterogeneity of breast cancer is due to
subtle differences in the ability of tumor-initiating cells to generate
differentiated progeny.
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Epithelial cells isolated from mammary gland cells undergo two
successive senescence states in cell culture, termed ‘‘stasis’’ and
‘‘agonescence’’ [6,7]. In contrast to normal mammary epithelial
cells, established breast cancer cells are immortal by definition.
They may owe this phenotype of immortalization to genetic and
epigenetic inactivation of senescence checkpoints and reactivation
of telomerase reverse transcriptase expression [7]. Either in
relation to these changes or independently, breast cancer cells
may also present a stem/progenitor phenotype that is less
subjected or resistant to senescence barriers. However, the
abundance of non-tumorigenic and differentiated cells both in
breast tumors and cell lines strongly suggests that replicative
immortality cannot be assigned to all cells within a tumor or a
cancer cell line, and that spontaneous senescence after a limited
number of population doublings (PD) is likely to occur. If this
hypothesis is correct, then the rate of generation of senescent
progeny may reflect the potential of a cancer stem/progenitor cell
to produce terminally differentiated progeny. We tested this
hypothesis using a panel of luminal and basal-like breast cancer
cell lines (Table S1). Although a single cell line is not representative
of breast tumor heterogeneity, a panel of cell lines might
reproduce the heterogeneity that is observed in primary breast
tumors, albeit with some limitations [5,8]. Therefore, we hoped
that in vitro studies with a panel of cell lines might help to better
understand breast tumor heterogeneity.
Our senescence tests allowed us to classify breast cancer cell
lines as senescent cell progenitor (SCP) and immortal cell
progenitor (ICP) subtypes. We also show that senescent progeny
are observed exclusively in ER-positive cells, as a result of ER
inactivation, partly mediated with p21Cip1 protein. The ability to
produce senescent progeny was associated with the ability to
produce luminal-like and myoepithelial-like progeny from stem/
progenitor-like cells. In contrast, most of the cell lines lacking
senescent progeny were also unable to generate differentiated
progeny. Finally, we show that SCP-subtype cells cluster with
luminal A and ‘‘normal-like’’ breast tumor types and are less
tumorigenic, whereas ICP-subtype cell lines cluster with luminal B
and basal-like tumor types and are more tumorigenic.
Materials and Methods
Ethics Statement
We used archival tumor samples remaining from a previous
study by BB and IGY described in Gur-Dedeoglu et al. [9], for
which the use of the tissue material was approved by the Research
Ethics Committee of Ankara Numune Research and Teaching
Hospital (decision date: 04/07/2007). The tumor samples in this
study were used anonymously. All animals received care according
to the Guide for the Care and Use of Laboratory Animals. All
animal experiments have been pre-approved by the Bilkent
University Animal Ethics Committee (Decision No: 2006/1;
Decision date: 10/5/2006).
Clinical samples and cell lines
Freshly frozen tumor specimens were collected at Ankara
Numune Hospital. Breast cancer cell lines used in this study were
obtained from ATCC (http://www.atcc.org) and listed in Table
S1. Cell line authenticity was verified by short tandem repeat
profiling, as recommended by ATCC (Dataset S1). Isogenic clones
from the T47D (n= 20) cell line were obtained from single cell-
derived colonies. Briefly, cells were plated in 96-well plates to
obtain single colonies in fewer than 70% of the wells. Isolated
colonies were then transferred to progressively larger wells, and to
T25 flasks. Clones were subcultivated weekly at 1:4 dilution ratios,
and maintained in culture for 25–30 passages to reach .60 PD
before testing.
Primary antibodies
The following antibodies were used: anti-CD44 (559046; BD
Pharmingen), anti-CD24 (sc53660; Santa Cruz,), anti-ASMA
(ab7817; Abcam), anti-CK19 (sc6278; Santa Cruz,), anti-p21Cip1
(OP64; Calbiochem), anti-p16Ink4a (NA29, Calbiochem), anti-ERa
(sc8002; Santa Cruz).
Low-density clonogenic assays
Cells were seeded as low-density on coverslips in six-well plates
(500–2000 cells, according to plating efficiency) and allowed to
grow in DMEM supplemented with 10% fetal calf serum (FCS),
with medium change every three days, until they formed colonies
of a few hundred cells. Depending on the cell line, this took one to
two weeks. For bromodeoxyuridine (BrdU) incorporation assays,
cells were labeled for 24 h prior to immunocytochemistry, as
described previously [10].
Immunocytochemistry
For simple immunoperoxidase assays, cells were fixed with cold
methanol for five minutes, then blocked with 10% FCS in
phosphate-buffered saline (PBS) for 1 hour. This was followed by
incubation with a primary antibody for 1 h. Cells were then washed
with PBS three times and subjected to immunostaining using the
Dako-Envision-dual-link system and the liquid diaminobenzidine
(DAB) substrate chromogen system (Dako, CA, USA), according to
the manufacturer’s instructions. Hematoxylin was used as a
counter-stain when the visualization of cells was necessary. For
SABG-immunoperoxidase co-staining studies, unfixed cells were
first subjected to SABG assay, and then fixed prior to immuno-
staining assays. Hematoxylin counter-staining was omitted for co-
staining experiments, unless cells were negative for SABG staining.
Immunoblot analyses
Cell pellets were incubated in an NP-40 lysis buffer containing
50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% Nonidet P-40,
and a protease inhibitor cocktail (Roche) for 30 minutes in a cold
room. Cell lysates were then cleared by centrifugation, and a
Bradford assay was performed to quantify their protein concen-
tration. 30 mg of protein was denatured and resolved by SDS-
PAGE using 10% or 12% gels. The proteins were then transferred
to the PVDF or nitrocellulose membranes. Membranes were
treated for 1 h with a blocking solution of TRIS-buffered saline
containing 0.1% Tween-20 and 5% non-fat milk powder (TBS-T)
and probed with a primary antibody for 1 h. Next, membranes
were washed three times with TBS-T and incubated with an HRP-
conjugated secondary antibody for 1 h. Immunocomplexes were
then detected by an ECL-plus (Amersham) kit on the membrane.
a-tubulin was used as an internal control.
SABG assay and BrdU/SABG co-staining
SABG activity was detected as described [11], except that cells
were counterstained with eosin or nuclear fast red following SABG
staining. For BrdU/SABG co-staining, cells were first labeled with
BrdU (10 mg/ml) for 24 h in a freshly added culture medium as
described [10]. Next, cells were subjected to a SABG assay, fixed
in 70% methanol, and subjected to BrdU immunostaining.
Estrogen and tamoxifen treatment
Cells were seeded under low-density clonogenic conditions onto
coverslips in six-well plates, and cultivated in a standard culture
Senescence in Breast Cancer
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medium for seven to eight days. Then, cells were fed with phenol
red-free DMEM (Gibco) supplemented with 5% charcoal-stripped
FCS for 48 h, followed by two successive 48 h treatments with
1029 M estrogen (E2; 17b-estradiol; Sigma), 1026 to 1029 M 4-
hydroxytamoxifen (4OHT; Sigma) or an ethanol vehicle, under
the same conditions. Colonies were then subjected to a SABG
assay. Each experimental condition was conducted in triplicate
and experiments were repeated three times.
Generation of estrogen receptor-overexpressing clones
T47D-iso23 cells were transfected with the expression vector
pCMV- ERa [12] or an empty vector, using FuGENE-6 (Roche).
ER overexpressing and control clones were selected with 500 mg/
ml G418 for three weeks. Isolated single cell-derived colonies were
picked and expanded in the presence of G418.
Lentiviral infection and generation of p21Cip1 knockdown
clones
We used mission shRNA plasmid pLKO.1,-puro-p21
(NM_000389.2-640s1c1, Sigma) for p21cip1 knockdown experi-
ments. The Control vector shRNA-pGIPz-SCR-puro and a helper
packaging mix (Invitrogen) were also used. HEK293T was co-
transfected with the appropriate vector and packaging mix, using
the CalPhos Mammalian Transfection Kit (Clontech) and
following the manufacturer’s instructions. After 48 h of culture,
virus-containing culture media were collected, filtered, and used to
infect T47D-iso23 cells. After 4 h of infection, stable cells were
selected with 1 mg/ml puromycin for seven days.
Nude mice tumorigenicity and in vivo senescence assays
T47D and MDA-MB-231 cells (56106) were injected subcuta-
neously into CD-1 nude mice (Charles River). Females (n = 5 for
each cell line) and males (n = 4 for each cell line) were used.
Tumor sizes were measured up to 47 days post-injection. In
addition, four tumors from each cell line were analyzed for the
presence of senescent cells by SABG staining, as described
previously [10].
Cluster analysis
The two-channel microarray data containing 8102 cDNA
genes/clones generated by Sorlie et al. [2] were downloaded from
the Stanford Microarray Database (SMD) (http://genome-www.
stanford.edu/MicroArray/). In the downloading process, the ‘‘log
(base 2) of R/G Normalized Ratio (median)’’ parameter was used
for data filtering. We have median-centered expression values for
each array. We selected arrays and genes with greater than 75%
good data (representing the amount of data passing the spot
criteria). Sixty-eight tissue samples were obtained according to this
criterion and annotated with the subtypes described by the
authors, found in the ‘‘Supplementary Information’’ of the data set
in SMD. The expression values of ‘‘500 gene signature,’’ defined
by the authors, were extracted from the data. Gene expression
profiles of 31 breast cancer cell lines performed by Charafe-
Jauffret et al. [13], using the whole-genome cDNA microarray
Affymetrix HGU-133 plus 2, was obtained from the ‘‘Supplemen-
tary Table’’ of the article. The authors filtered genes with low and
poorly measured expression, and with low expression variation,
retaining 15, 293 genes. After log transformation of the data, we
median normalized the data arrays in R language, using the
Bioconductor biostatistical package (www.r-project.org/ and
www.bioconductor.org/). The ‘‘500 gene signature’’ tumor data
[2] and the normalized breast-cancer cell line data [13] were
combined with respect to probe IDs using a set of customized perl
routines (source codes are available upon request). A set of 175
genes was common. ‘‘Median center’’ normalization of genes was
done for the merged data set for the total samples. We performed
unsupervised hierarchical clustering with the 99 samples (the 31
breast cell line [13] and 68 breast tumor [2] samples) by the pair-
wise complete-linkage hierarchical clustering parameter, using the
Gene-Pattern program. The Pearson correlation method was used
for distance measurements. Clustering was visualized by java
treeview, again using Gene-Pattern (http://www.broad.mit.edu/
cancer/software/genepattern/).
Statistical analyses
Significant differences were evaluated using unpaired Student’s
t test for compared samples sizes of 10 or higher. Otherwise, one-
tailed Fisher’s exact test was used with 262 tables; P,0.05 was
considered statistically significant. On the graphical representation
of the data, y-axis error bars indicate the standard deviation for
each point on the graph.
Results
Classification of breast cancer cell lines as senescent-cell
progenitor and immortal-cell progenitor subtypes
Clonogenic assays have been successfully used to test the
generation and self-renewal abilities of phenotypically distinct
progeny of mammary stem/progenitor cells [14]. We previously
applied this technique to test the ability of cancer cells to produce
progeny with replication-dependent senescence arrest [10]. Cells
were plated under low-density clonogenic conditions and cultivat-
ed for one to two weeks until individual cells performed eight to
ten PDs and generated isolated colonies composed of several
hundred cells. This method permits tracing progeny generated by
a few hundred cells under the same experimental conditions. We
explored a panel of 12 breast cancer cell lines, composed of
luminal (n = 7) and basal (n = 5) subtypes (Table S1). Cell lines
formed two groups, according to the presence of senescent cells in
isolated colonies. One group of cell lines generated colonies with
high rates of senescence, while others did not produce appreciable
amounts of senescent cells. Representative pictures of colonies
subjected to the SABG assay are shown in Fig. 1A. The percent of
SABG+ progeny was calculated by manual counting of at least 10
different colonies for each cell line. Colonies derived from five cell
lines generated SABG+ cells at high rates (means: 5-40%)
Senescence rates were negligible (means ,5%) in the progeny of
the remaining seven cell lines. The first group, the senescent cell
progenitor subtype, included T47D, BT-474, ZR-75-1, MCF-7,
and CAMA-1 cell lines. The second group, the immortal cell
progenitor subtype, included MDA-MB-453, BT-20, SK-BR-3,
MDA-MB-468, HCC1937, MDA-MB-231 and MDA-MB-157
(Fig. 1B).
In order to verify whether the occurrence of senescent cells in the
SCP group was intrinsic to each cell line or due to the presence of a
side population, we generated clones from the T47D (n=20) cell
line, and subjected them to the SABG assay at different intervals. All
clones acted similarly to the parental T47D cell line with similar rates
of SABG+ progeny. No clone gained the ICP phenotype. More
importantly, none of the clones tested over a long period of time
(.60 PDs) entered full senescence (data not shown), unlike normal
mammary epithelial cells that undergo two stages of senescence
arrest over a period of ,20 PDs [7]. The SABG assay can provide
false-positive responses, especially when cells remain under conflu-
ence for a long period [15]. Although all our tests used low-density
clonogenic conditions, we wanted to confirm the senescence arrest
by a long-term (24 h) BrdU labeling assay under mitogenic
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conditions, as senescent cells in permanent cell cycle arrest cannot
incorporate BrdU under these conditions [16]. Co-staining of cells
for SABG and BrdU from CAMA-1, T47D, and T47D-iso23
colonies provided clear indication that the great majority of SABG+
senescent cells were BrdU-, whereas non-senescent BrdU+ cells were
usually SABG- (Fig. 1C). These findings indicated that SABG+
senescent cells were at the terminal differentiation stage with an
irreversible loss of DNA synthesis ability. Our observations also
indicated that SABG and BrdU tests could be used alternatively to
identify senescent (SABG+/BrdU-) and immortal (SABG-/BrdU+)
cells under our experimental conditions.
Senescent cell progenitor phenotype association with
p21Cip1 expression
p16Ink4a and p21Cip1 (in a p53-dependent manner or indepen-
dently) have been shown to be mediators of senescence arrest in
different cells, including mammary epithelial cells [6,15,17,18,19].
We therefore analyzed the expression of p16Ink4a and p21Cip1 in
the cell line panel. Heterogeneously positive nuclear p21Cip1
immunoreactivity was observed in four of the five SCP cell lines,
but not in any of the seven ICP cell lines (Fig. 2A). The association
of p21Cip1 expression with the SCP subtype was statistically
significant (P=0.01). We also compared the expression of p16Ink4a.
Three of five SCP cell lines displayed heterogeneously positive
immunostaining, whereas three of seven ICP cell lines displayed
homogenously positive staining (Fig. S1). The difference of
p16Ink4a expression between the two groups was not significant
(P=1). These observations indicated that the SCP phenotype was
associated with p21Cip expression in breast cancer cell lines.
To test whether p21Cip1 was directly involved in the senescence
observed in SCP cells, we first performed p21Cip1/SABG staining
in T47D-iso23 cells (hereafter termed T47D). p21Cip1, but not
p16Ink4a staining, was associated with SABG staining (Fig. S2).
Next, we generated two derivative cell lines following infection of
T47D with lentiviral vectors encoding p21Cip1 shRNA (T47D-
p21sh) or a scrambled control (T47D-scr). Following the
Figure 1. Classification of breast cancer cell lines as senescent cell progenitor and immortal cell progenitor subtypes. (A) Examples of
SABG staining for senescence of breast cancer cell line colonies obtained after plating at low-density clonogenic conditions. Breast cancer cell lines
(Table S1) were plated to obtain a few hundred colonies with 1–2 weeks of cell culturing and were subjected to SABG assay, followed by
counterstaining with nuclear fast red. T47D, ZR-75-1, MCF-7, CAMA-1 and BT-474 generated heterogeneous colonies composed of with SABG+ and
SABG- cells (shown here), but also fully negative and/or fully positive colonies. All other cell lines produced only SABG- colonies (,5% SABG+ cells).
Scale bar: 50 mm. (B) Classification of breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes by
quantification of the ability to generate senescent progeny. Cell lines with a mean of SABG+ cells higher than 5% were termed SCP, and the other cell
lines as ICP. Colonies that were generated and stained as described in (A) were counted manually to calculate % SABG+ cells. At least 10 colonies
were counted for each cell line. Error bars represent mean 6 SD. (C) SABG+ senescent cells displayed terminal growth arrest. CAMA-1, T47D and
T47D-iso23 colonies were generated as described in (A), labeled with BrdU for 24 h in the presence of freshly added culture medium, and subjected
to SABG/BrdU double-staining. SABG+ cells are BrdU-, and vice versa. T47D-iso23 is a clone derived from T47D. Note that parental T47D and T47D-
iso23 clones displayed similar staining features.
doi:10.1371/journal.pone.0011288.g001
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demonstration of p21Cip1 knockdown in T47D-p21sh cells by
western blot assay (Fig. 2B), both cell lines were plated under low-
density plating conditions, colonies were grown for 10 days, and
subjected to SABG and BrdU staining. It was not possible to
quantify SABG+ cells in T47D-p21sh cells because they formed
tight clusters in culture (data not shown). We therefore used BrdU
staining as an alternative method for senescent cell quantification
(Fig. 2C). Randomly selected colonies were counted for the
number of BrdU+ and BrdU- cells (Fig. 2D). The T47D-scr cell
line generated BrdU+ progeny at a rate of 48620% per colony
(n = 18). Under the same conditions, T47D-p21sh cells displayed
BrdU+ progeny at a rate of 65612% per colony (n= 18), with a
significant (P= 0.0043) increase in the number of cells escaping
terminal arrest (Fig. 2E). These results indicated that p21Cip1 was
responsible, at least partly, for inducing the senescence observed in
the progeny of T47D cells.
The control of senescent cell progeny generation by an
estrogen receptor
As stated above, p21Cip1 is a downstream target of p53 for
senescence, but T47D cells do not express wild-type p53 (Table S1).
Estrogen inhibits p21Cip1 expression [20] by c-Myc-mediated
repression [21], MYC gene being a direct target of ER complex
[22]. We therefore tested whether ER could be involved in the
senescence observed in T47D cells. The data shown in Fig. 3A
indicates that T47D cells displayed nuclear ER immunoreactivity in
their great majority, but some progeny was ER-. More interestingly,
these ER- cells tended to be SABG+, suggesting that senescence
occurred in T47D cells as a result of ER loss. Next, we tested
whether experimentally modifying ER activity in T47D cells had
any effect on senescence response. After plating at low-density
clonogenic conditions, cells were grown in a regular cell culture
medium that contained weakly estrogenic phenol red [23] for seven
days in order to obtain visible colonies. The culture medium was
then changed with phenol-free DMEM complemented with
charcoal-treated FCS, grown for two more days, and then cultivated
for four more days in the presence of E2 (1029 M), OHT (1029 M
to 1026 M), or an ethanol vehicle as control. Colonies were
subjected to SABG staining (Fig. 3B). Total and SABG+ cells were
counted from 20 randomly selected colonies for each treatment
(Fig. 3C). Colonies grown in a phenol-free charcoal-treated control
medium complemented with an ethanol vehicle only displayed
31613% SABG+ cells. Complementing this medium with 1029 M
Figure 2. Growth arrest observed in senescent cell progenitors was inhibited by p21Cip1 silencing. (A) Four of five senescent SCP cell
lines (top four from left) generated colonies with heterogeneous expression of p21Cip1; in contrast none of seven ICP cell lines generated p21Cip1 cells.
Colonies were immunostained for p21Cip1, with hematoxylin used as counterstain. Scale bar: 50 mm. (B–E) p21Cip1 silencing inhibited the production
of the terminally arrested progeny of SCP cells. (B) shRNA-mediated inhibition of p21Cip1 expression. T47D cells were infected with lentiviral vectors
encoding p21Cip1 shRNA or scrambled shRNA to generate T47D-p21sh and T47D-scr stable cell lines, and tested for p21Cip1 knockdown by western
blotting. (C–E) The ability to generate growth-arrested cells was inhibited by p21Cip1 knockdown. Colonies were generated from respective cell lines,
labeled with BrdU for 24 h, immunostained for BrdU, and slightly counterstained with hematoxylin to visualize BrdU+ and negative cells. Scale bar:
50 mm. (C). Individual colonies were manually counted for quantification of % BrdU cells. Each bar represents one colony (D). The silencing of p21Cip1
caused a significant increase (P = 0.0043) in % ratios of BrdU+ cells (E). Mean % BrdU+ cells (6 SD) values were calculated from data presented in (D).
Error bars represent mean 6 SD. Tub.; a-tubulin.
doi:10.1371/journal.pone.0011288.g002
Senescence in Breast Cancer
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11288
E2 generated colonies with 17618% SABG+ cells. Senescence
inhibition by E2 was nearly 50% and statistically significant when
compared to the ethanol-complemented control cells (P= 0.0093).
In contrast to E2, OHT provoked a dose-dependent increase in the
proportion of SABG+ cells. At the maximum dose used (1026 M
OHT), 90613% of colony-forming cells displayed a SABG+ signal
(Fig. 3D), indicating that tamoxifen-mediated inactivation of ER
can induce almost a complete senescence response in these cells
(P,0.0001). The increase in senescence rate was also significant
with 1027 M OHT (P= 0.0002).
Our findings strongly suggested that the senescence observed in
the SCP T47D cell line was due to a loss of expression and/or
function of ER in a subpopulation of the progeny of these cells.
For confirmation, we constructed ER-overexpressing stable clones
from T47D cells. The thhree clones with the highest ER
expression were selected. In addition, three clones with endoge-
nous expressions of ER were selected from stable clones obtained
with an empty vector (Fig. 4A). Progeny obtained from these six
clones were tested by BrdU assay (Fig. S3). Randomly selected
colonies (n = 10) from each clone were evaluated for total and
BrdU+ number of cells (Fig. 4B). Consistently higher levels of
BrdU+ cells were observed with clones ectopically expressing the
ER protein (Fig. 4C). Overexpression of ER resulted in a
significant increase in the BrdU+ progeny (P= 0.034). The
protective effect of ER overexpression was not as important as
the senescence-promoting effects of ER inhibition. This was not
unexpected, since the parental cells used for the ER overexpres-
sion studies were already expressing high levels of endogenous ER
(Fig. 4A), displaying a baseline anti-senescence activity due to the
serum estrogen and phenol red found in the cell culture medium.
The close relationship between ER and senescence in the ER+
T47D cell line, and the highly effective treatment of ER+ breast
tumors with tamoxifen, which induced senescence in our
experimental model, suggested that senescence induction might
be a relevant mechanism involved in anti-estrogen treatments. As
fresh tumor tissues cannot be obtained from tamoxifen-treated
patients for obvious ethical reasons, we analyzed untreated ER+
breast tumor samples for evidence of spontaneously occurring in
vivo senescence. We screened a panel of 12 snap-frozen ER+
breast tumor tissues from 11 patients for senescence by an SABG
Figure 3. Generation of senescent cell progeny was controlled by the estrogen receptor-a. (A) SCP cells (T47D) expressed nuclear ER.
Colonies were co-stained for senescence by SABG and for ER expression by immunoperoxidase. The MDA-MB-231 cell line was used as a negative
control. (B–D) The production of senescent progeny in SCP cells was inhibited by estrogen (E2), but enhanced by tamoxifen (4OHT) treatment. After
plating in low-density clonogenic conditions, T47D cells were grown in standard cell culture medium for seven days, followed by phenol-free DMEM
complemented with charcoal-treated fetal calf serum for two days, and then cultivated for four days in the presence of E2, OHT, or an ethanol vehicle
(control). Colonies were subjected to SABG staining (B). Total and SABG+ and SABG- cells were counted from 20 randomly selected colonies (C), and
mean % SABG+ cells (6 SD) values were calculated (D). Error bars represent mean6 SD. The inhibition of senescence by E2 and its activation by OHT
was statistically significant when compared to ethanol-complemented control cells (P values 0.0093, 0.0002 and,0.0001 for 1029 M E2, 1027 M OHT
and 1026 M OHT, respectively).
doi:10.1371/journal.pone.0011288.g003
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assay. The mean age of the patients was 58612 yrs, with a mixed
menopause status (Table S2). Two tumors (17%) displayed
SABG+ cells that were scattered within the tumor area (Fig. S4).
Thus, ER+ breast tumors also produced senescent progeny in vivo,
but at a lower rate.
Senescent cell progenitor and immortal cell progenitor
subtypes’ abilities to differentiate into luminal and
myoepithelial cell types
The cellular specificity of ER expression in the mammary
epithelial cell hierarchy is poorly understood. Previous data
suggests that normal ER+ cells may represent either relatively
differentiated luminal cells with limited progenitor capacity or
primitive progenitors with stem cell properties in the luminal cell
compartment [4,24,25]. Based on the close association between
senescence (which can be considered a manifestation of terminal
differentiation) and loss of ER positivity, we hypothesized that
ER+ SCP cells may differ from ER- ICP cells by their
differentiation potential. We surveyed a few hundred single-cell-
derived colonies from each of the 12 cell lines for production of
stem/progenitor-like, luminal-like, and myoepithelial-like cells.
We used CD44 as a positive stem/progenitor cell marker [26,27],
CD24, ER, and CK19 as luminal lineage markers [27,28,29], and
ASMA as a myoepithelial lineage marker [29].
Representative examples of marker studies by immunoperox-
idase staining in SCP and ICP cell lines are shown in Fig. 5. All
five SCP cell lines displayed a heterogeneous pattern of positivity
for CD44; some colonies were fully positive, some fully negative,
and others were composed of both positive and negative cells.
CD44/CD24 double immunofluorescence studies with the T47D
cell line indicated that SCP cells produce also CD44+/CD24-
stem/progenitor cells, as expected (data not shown). In sharp
contrast, five of the seven ICP cell lines generated only fully
positive CD44 colonies, indicating they do not produce CD44-
cells. One cell line was totally CD44-. Only one cell line displayed
Figure 4. Overexpression of estrogen receptor-a inhibited the production of terminally arrested progeny. (A) ER-overexpressing (ER-5,
ER-7, ER-26) and control (C-8, C-10, C-11) clones were established from T47D cells and tested for ER expression by western blotting using decreasing
amounts of total proteins. Calnexin was used as loading control. (B–C). Colonies were generated, labeled with BrdU for 24 h and immunostained for
BrdU (shown in Fig. S3). Individual colonies were manually counted for quantification of % BrdU cells (B), and mean % BrdU+ cells values were
calculated (C). Error bars represent mean6 SD. ER overexpression caused a significant increase in % ratio of BrdU+ cells (*three ER clones versus three
controls; P = 0.034).
doi:10.1371/journal.pone.0011288.g004
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a pattern similar to that of SCP cell lines. A comparison of the two
subtypes indicated that the ability to generate both CD44+ and
CD44- progeny was significantly associated with the SCP
phenotype (P= 0.0046). All five SCP cell lines displayed
heterogeneous, but mostly positive ER immunostaining, whereas
all seven ICP cell lines never generated ER+ cells. The expression
of ER was also significantly associated with the SCP subtype
(P= 0.0012), as well as the ability to produce ASMA+ progeny
(P= 0.0046). The ICP cell lines did not generate ASMA+ cells,
while four out of five SCP cell lines generated rare ASMA+ cells
under low-density clonogenic conditions. Interestingly, the abun-
dance of ASMA+ cells was much higher in the two SCP cell lines
that were tested at high cell density (Fig. S5). This suggests that
either the production of ASMA+ cells is enhanced at high cell
density, or these myoepithelial-like cells display limited survival
under long-term culture conditions. We did not find a strong
association between the expression of CD24 and CK19 markers
and cell subtype. All five SCP cell lines and three ICP cell lines
Figure 5. Senescent cell progenitor and immortal cell progenitor subtypes greatly differed in their ability to differentiate into
luminal and myoepithelial lineage cells. Senescent cell progenitor and immortal cell progenitor subtype cell lines were studied by
immunoperoxidase staining using CD44 and markers for luminal epithelial (CD24, CK19, ER) and myoepithelial (ASMA) lineages. Insets: magnified
views of positive cells. Both subtypes have CD44+ cells. Senescent cell progenitor cell lines produced both progenitor-like (CD44+; CD242), as well as
ER+ luminal-like and ASMA+ myoepithelial-like cells (except ZR-75-1 for myoepithelial-like cells). Immortal cell progenitor cell lines were defective for
generation of ER+ luminal-like or ASMA+ myoepithelial-like cells. Moreover, five of seven cell lines could not generate CD44- cells. The expression of
CD24 and CK19 markers did not differ significantly between the two subgroups, except that some immortal cell progenitor subtype cell lines did not
express CD24 or CK19.
doi:10.1371/journal.pone.0011288.g005
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generated heterogeneously staining colonies for CD24 expression.
Similarly, all five SCP cell lines, as well as three ICP cell lines,
expressed CK19, but homogenously.
Typical features of senescent progenitor and immortal
progenitor breast cancer cell lines
As summarized in Fig. 6, SCP and ICP subtype cell lines
displayed several subtype-specific features. All SCP cell lines
produced differentiated and senescent cells, in addition to putative
CD44+/CD242 stem/progenitor cells. Indeed, all of them
produced ER+ and CD24+ luminal-like cells and most of them
(n = 4/5) also produced ASMA+ myoepithelial-like cells. In
contrast, five of the seven ICP cell lines never produced CD44-
cells, suggesting they cannot generate differentiated progeny under
the experimental conditions tested. In confirmation of this
hypothesis, four ICP cell lines only produced CD44+/CD242/
ER-/CK19-/ASMA- stem/progenitor-like, but never differentiat-
ed cells. Furthermore, all seven ICP cell lines were unable to
produce ASMA+ myoepithelial-like, ER+ luminal-like or SABG+
senescent cells. CD24 and CD19 luminal lineage markers were
expressed in three cell lines, one of which was fully positive for the
CD44 stem/progenitor marker.
SCP and ICP subtype cell lines correlate with distinct
breast tumor subtypes
Distinct cell-type features associated with SCP and ICP subtypes
suggest that they may be phenocopies of molecularly defined
breast tumor subtypes [1,2,3,30]. As the prognosis and therapeutic
response of each subtype is different [2,3], we questioned whether
we could assign SCP and ICP cell lines to known molecular
subtypes of breast tumors. Using cell line and primary tumor gene
expression datasets, we conducted a hierarchical clustering
analysis. The ‘‘intrinsic gene set’’ data generated by Sorlie et al.
[2] to classify breast tumors into five molecular subtypes was used
to filter cell line data generated by Charafe-Jauffret et al. [13]. A
set of 175 genes was common between the two data sets. Sixty-
eight tumors and 31 cell lines were subjected to pair-wise
complete-linkage hierarchical clustering and distance measure-
ments. This tumor–cell line combined analysis produced two
major clusters. One cluster was composed of basal and luminal B
subtype tumors and five of six ICP cell lines. The other cluster
included luminal A, ERBB2+, and ‘‘normal-like’’ subtype tumors
and all five SCP subtype cells. Four cell lines clustered with the
luminal A tumor subclass. Finally. one cell line clustered with the
‘‘normal-like’’ subclass (Fig. 7A). A full list of clustered tumors and
cell lines is provided in Fig. S6.
Luminal A tumors clustering with our SCP subtype cell lines
displayed the longest tumor-free, distant metastasis-free, and
overall survival rates. In contrast, basal and luminal B tumors
clustering with our ICP subtype cell lines had the worst prognosis,
with shorter tumor-free, distant metastasis-free, and overall
survival times [2]. Our cluster analysis suggested that the ability
to generate differentiated and senescent progeny characterized
breast cancers with poor tumorigenicity, and that resistance to
differentiation and senescence was indicative of more aggressive
tumorigenicity. We compared in vivo intrinsic tumorigenic
behaviors of the SCP cell line T47D and the ICP cell line
MDA-MB-231 in female (n = 5 for each cell line) and male (n = 4
for each cell line) CD1 nude mice Fig. 7B). MDA-MB-231 cells
displayed higher tumorigenicity than T47D cells. In total, we
observed progressively growing tumors in five of nine animals
injected with MDA-MB-231. In contrast, T47D formed smaller
and regressing tumors in nine of nine animals (P,0.03).
Interestingly, the difference in tumorigenicity between these two
cell lines was more pronounced in male animals (P,0.05 after 20
days post-injection). To test whether the difference in tumorige-
nicity between MDA-MB-231 and T47D cells was correlated with
spontaneous in vivo senescence, we analyzed four tumors from
each cell line. Two T47D tumors displayed positive SABG
staining, whereas no positive staining was observed with all four
MDA-MB-231 tumors (Fig. S7).
Discussion
In recent years, phenotypic heterogeneity of breast cancers has
been correlated with genetic and molecular heterogeneity [1,3].
Breast cancer subtypes may represent cancers originating from
different progenitor cells. Molecular and phenotypic heterogeneity
and associated clinical manifestations of breast tumor subtypes
have been related to the type of hypothetical tumor progenitor
cells originating from a hypothetical mammary epithelial stem cell
or from downstream progenitor cells [4,5]. This hypothesis has
not been fully validated, mainly because a hierarchical map of
cells involved in mammary epitheliogenesis has not yet been
established.
To better understand phenotypic differences between breast
cancer subtypes, we applied senescence as a surrogate marker for
the potential to generate terminally differentiated progeny. We
completed these studies with markers for breast stem/progenitor
and differentiated luminal and myoepithelial lineage cells. The use
of low-density clonogenic conditions allowed us to follow the fate
Figure 6. Typical features of senescent progenitor and
immortal progenitor breast cancer cell lines.
doi:10.1371/journal.pone.0011288.g006
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of a large number of progeny for each cell line studied. From these
approaches, we draw several important conclusions. First, breast
cancer cell lines form two distinct groups: SCP and ICP subtypes.
The SCP cell lines produce non-senescent and senescent progeny,
whereas the ICP cell lines produce only non-senescent progeny.
Second, SCP and ICP cell lines are exclusively ER+ and ER- cell
lines, respectively. Senescence occurs as a result of ER loss
associated with p21Cip1 induction in SCP cells. Inversely,
experimental activation of ER by E2 protects from senescence,
whereas its inactivation by tamoxifen aggravates it. Thus,
senescence in ER-dependent cells appears to result from the loss
of survival signals generated by transcriptional activity of ER. A
similar type of senescence has been reported for lymphoma,
osteosarcoma, and hepatocellular carcinoma tumors upon c-MYC
inactivation [31]. Third, SCP cells generate ER+, CD24+, or
CK19+ luminal-like, as well as ASMA+ myoepithelial-like
progeny. These findings strongly suggest that most, if not all,
SCP cells have the capacity to give rise to two major types of
differentiated cells that are found in normal mammary epithelium.
In sharp contrast, ICP cells never produce ER+ luminal-like or
Figure 7. Senescence cell progenitor and immortal cell progenitor subtype cell lines correlate with distinct breast tumor subtypes.
(A) Unsupervised hierarchical clustering of breast tumor and cell line gene expression data were obtained from Sorlie et al [2] and Charafe-Jauffret et
al [25]. Dendrogram displaying the relative organization of tumor and cell line data demonstrated that ICP cell lines cluster with basal and luminal A
tumors in the same branch, except for MDA-MB-453. In contrast, SCP cell lines clustered with luminal A (BT-474, CAMA-1, MCF-7, T47D) and ‘‘normal-
like’’ tumors (ZR-75-1). No data was available for MDA-MB-468. A dendrogram with sample IDs was provided in Fig. S6. The ‘‘intrinsic gene set’’ data
generated by Sorlie et al. [2] was used to filter cell line data generated by Charafe-Jauffret et al. [13]. A set of 175 genes was common between the
two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise complete-linkage hierarchical clustering and distance measurements.
(B) Immortal cell progenitor MDA-MB-231 was more tumorigenic than the SCP type T47D cell line. Female (n = 5 per cell line) and male (n = 4 per cell
line) CD1nudemice received 56106 cells by subcutaneous injection and observed up to 47 days for tumor formation. Chart displays mean tumor sizes
(6 S.D.) generated by MDA-MB-231 and T47D cell lines, respectively in female (top) and mala (bottom) mice. T47D cells formed smaller tumors that
regressed and completely resolved within 30 days. Tumors formed by MDA-MB-231 were larger in size and did not show total resolution. Note that
this cell line was more tumorigenic in male mice.
doi:10.1371/journal.pone.0011288.g007
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ASMA+ myoepithelial-like cells. Indeed, some ICP cells generate
only CD44+ stem/progenitor-like cells and never CD442,
CD24+, CK19+, ER+, or ASMA+ cells. These findings indicate
that ICP cells have limited differentiation ability, at least under in
vitro conditions. The differentiation ability of ICP cells appears to
be lost completely or partially, so that they do not differentiate
fully while they self-renew as stem/progenitor-like cells. Fourth,
SCP cell lines form the same molecular cluster with luminal A and
‘‘normal-like’’ breast tumors. This suggests that SCP cell lines are
phenocopies of these relatively benign and/or anti-estrogen-
responsive tumors. The poor tumorigenicity of SCP cells in nude
mice correlates with better tumor-free and metastasis-free survival
of patients with luminal A type tumors. In contrast, ICP cell lines
cluster with luminal B and basal-like breast tumor subtypes, and
they are more tumorigenic, as expected for luminal B and basal-
like tumor cells. It is presently unknown whether breast tumor
subtypes that cluster with SCP or ICP cell lines are also composed
of either differentiating or mostly self-renewing stem/progenitor
cells. Recent studies reported that breast tumors may contain only
CD44+, or only CD24+ cells, as well as mixed cell populations,
and that CD44+ tumor cells express many stem-cell markers
[27,32]. In addition, an association between basal-like breast
cancer and the presence of CD44+/CD242 cells has been
established [32].
The mechanisms of the differentiation block observed in ICP
cell lines are not known. One might argue that cell lines that
produce only CD44+, but never differentiation marker-positive
cells, cannot be defined as stem/progenitor cells. However, such
cell lines are not completely inert to differentiation stimuli, and
may undergo differentiation under special conditions. For
example, MDA-MB-231 and MDA-MB-468 cells (identified as
ICP cell lines here) can be induced to differentiate into ER+ cells
by Wnt5a treatment, and MDA-MB-231 cells then become
sensitive to tamoxifen [33].
Most of the findings reported here are derived from in vitro
studies performed with established cancer cell lines. Presently, it is
unknown to what extent these findings are also relevant for breast
tumors. We provide here some promising data that supports in
vivo relevance of our conclusions. First, our cluster analyses
associated SCP cell types with luminal A and ‘‘normal-like’’ breast
tumors, whereas ICP cell types shared similar gene expression
profiles with luminal B and basal-like breast tumors. Second, ICP-
type MDA-MB-231 cells were more tumorigenic than SCP-type
T47D cells. T47D cells formed smaller tumors in some animals,
and all tumors displayed regression between 10 and 15 days post-
injection. Accordingly, we observed positive SABG staining in two
out of four T47D tumors, but not in MDA-MB-231 tumors.
Obviously, ICP-like and SCP-like tumors in affected women may
or may not display similar tumorigenic potentials, depending on
the women’s hormonal status and treatment conditions. However,
as most SCP-like luminal A or ER+ tumors are successfully treated
with tamoxifen [34], their less aggressive behavior could be related
to their highly effective senescence response to tamoxifen
treatment, as shown here with T47D cells under in vitro
conditions (Fig. 3). It will be interesting to examine whether the
success of anti-estrogenic treatments is indeed associated with
senescence induction in breast tumors. If this is the case,
senescence-inducing treatments could be considered for breast
cancer.
In conclusion, our analyses reveal that the in vitro ability to
generate senescent progeny permits discrimination between cells
that share molecular and tumorigenic similarities with luminal A
subtype breast tumors from cells related to basal/luminal B
subtype tumors. We also provide in vitro evidence for classifying
breast cancers into two major groups based on the ability to
generate differentiated progeny. Less-tumorigenic SCP cell lines
generate both luminal- and myoepithelial-like cells. In contrast,
more-tumorigenic ICP cell lines are defective in their ability to
generate differentiated progeny. Our findings may have prognostic
relevance and serve as a basis for therapeutically inducing
differentiation and senescence in breast cancer.
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Figure S3 Effect of estrogen receptor-overexpression on the
production of BrdU-negative terminally arrested cell progeny. ER-
overexpressing (ER-5, ER-7, ER-26) and control (C-8, C-10, C-
11) stable clones were established from T47D cells. Following
transfection with ER expression and control vectors, colonies were
generated from respective cell lines, labeled with BrdU for 24 h,
immunostained for BrdU (brown), and slightly counterstained with
hematoxylin to visualize BrdU+ and BrdU- cells.
Found at: doi:10.1371/journal.pone.0011288.s006 (6.57 MB TIF)
Figure S4 Detection of SABG+ senescent cells in estrogen
receptor-positive breast tumors. Snap-frozen tumors were used to
obtain 6 m thick sections and used directly to detect SABG+ cells.
H&E: hematoxylin-eosin staining.
Found at: doi:10.1371/journal.pone.0011288.s007 (9.45 MB TIF)
Figure S5 ASMA+ myoepithelial-like cells are produced fre-
quently in senescent cell progenitor T47D and MCF-7 cell lines
under confluent conditions. ASMA was tested by immunoperox-
idase.
Found at: doi:10.1371/journal.pone.0011288.s008 (4.08 MB TIF)
Figure S6 Unsupervised hierarchical clustering of breast tumor
and cell line gene expression data that is described in Fig. 7A.
Dendrogram shown here includes tumor and cell line sample IDs.
Found at: doi:10.1371/journal.pone.0011288.s009 (1.05 MB TIF)
Figure S7 Tumors derived from T47D but not from MDA-MB-
231 display SABG (+) senescent cells. Two of four T47D tumors
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displayed SABG+ cells. All four MDA-MB-231 tumors lacked
SABG+ cells.
Found at: doi:10.1371/journal.pone.0011288.s010 (7.97 MB TIF)
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a b s t r a c t
Cellular senescence is a process leading to terminal growth arrest with characteristic mor-
phological features. This process is mediated by telomere-dependent, oncogene-induced
and ROS-induced pathways, but persistent DNA damage is the most common cause. Senes-
cence arrest is mediated by p16INK4a- and p21Cip1-dependent pathways both leading to ret-
inoblastoma protein (pRb) activation. p53 plays a relay role between DNA damage sensing
and p21Cip1 activation. pRb arrests the cell cycle by recruiting proliferation genes to facul-
tative heterochromatin for permanent silencing. Replicative senescence that occurs in
hepatocytes in culture and in liver cirrhosis is associated with lack of telomerase activity
and results in telomere shortening. Hepatocellular carcinoma (HCC) cells display inactivat-
ing mutations of p53 and epigenetic silencing of p16INK4a. Moreover, they re-express telo-
merase reverse transcriptase required for telomere maintenance. Thus, senescence bypass
and cellular immortality is likely to contribute signiﬁcantly to HCC development. Onco-
gene-induced senescence in premalignant lesions and reversible immortality of cancer
cells including HCC offer new potentials for tumor prevention and treatment.
 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Senescence is an evolutionary term meaning ‘‘the pro-
cess of becoming old”; the phase from full maturity to
death characterized by accumulation of metabolic prod-
ucts and decreased probability of reproduction or survival
[1]. The term ‘‘cellular senescence” was initially used by
Hayﬂick and colleagues to deﬁne cells that ceased to divide
in culture [2]. Today, cellular senescence is recognized as a
response of proliferating somatic cells to stress and dam-
age from exogenous and endogenous sources. It is charac-
terized by permanent cell cycle arrest. Senescent cells also
display altered morphology and an altered pattern of gene
expression, and can be recognized by the presence of
senescence markers such as senescence-associated
b-galactosidase (SABG), p16INK4A, senescence-associated
DNA-damage foci and senescence-associated heterochro-
matin foci (for a review see Ref. [3]). This cellular response
has both beneﬁcial (anti-cancer) and probably deleterious
(such as tissue aging) effects on the organism. Most of
our knowledge of cellular senescence is derived from
in vitro studies performed with ﬁbroblasts, and some epi-
thelial cells such as mammary epithelial cells. Animal
models are increasingly being used to study cellular senes-
cence in vivo. Telomerase-deﬁcient mouse models lacking
RNA subunit (TERC/) have been very useful in demon-
strating the critical role of telomeres in organ aging and tu-
mor susceptibility [4]. Other mouse models including
tumor suppressor gene-deﬁcient and oncogene-expressing
mice were also used extensively.
Compared to other tissues and cancer models, the role
of senescence in liver cells and its implications in hepato-
cellular carcinogenesis have been less explored. One of
0304-3835/$ - see front matter  2008 Elsevier Ireland Ltd. All rights reserved.
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the main obstacles is the lack of adequate in vitro systems.
As hepatocytes can not divide in cell culture, the study of
their replicative senescence mechanisms is not easy. Nev-
ertheless, these cells are able to quit their quiescent state
in vivo and proliferate massively in response to partial
hepatectomy or liver injury [5]. This capacity can be ex-
plored to study in vivo senescence of hepatocytes using ro-
dent models. Studies with clinical samples indicate that
hepatocyte senescence occurs in vivo in patients with
chronic hepatitis, cirrhosis and HCC [6–8]. In contrast to
the paucity of studies directly addressing cellular senes-
cence, the critical role of telomere shortening (as a feature
associated with replicative senescence) in cirrhosis and
HCC development is well established [9]. Telomeres in nor-
mal liver show a consistent but slow shortening during
aging. In contrast, hepatocyte DNA telomere shortening is
accelerated in patients with chronic liver disease with
shortest telomeres described in cirrhotic liver and HCC.
Telomerase-deﬁcient mice have also been used elegantly
to demonstrate the critical roles of telomerase and telo-
meres in liver regeneration and experimentally induced
cirrhosis [10,11]. A major accomplishment in recent years
was the demonstration of critical role played by senes-
cence for the clearance of ras-induced murine liver carci-
nomas following p53 restoration [12].
Despite a relatively important progress, the mecha-
nisms of hepatocellular senescence and the role of cellular
immortality in HCC remain ill-known issues. As one of the
rare tissues with ample clinical data on senescence-related
aberrations, liver may serve as an excellent model to fur-
ther explore the relevance of cellular senescence in human
biology. Moreover, a better understanding of senescence
and immortality in hepatic tissues may help to develop
new preventive and therapeutic approaches for severe li-
ver diseases such as cirrhosis and HCC. Here we will review
recent progress on senescence and immortality mecha-
nisms with a speciﬁc emphasis on hepatocellular
carcinogenesis.
2. Senescence pathways
Cellular senescence has long been considered as a
mechanism that limits the number of cell divisions (or
population doublings) in response to progressive telomere
shortening. Most human somatic cells are telomerase-deﬁ-
cient because of the repression of telomerase reverse
transcriptase (TERT) expression. Therefore, proliferating
somatic cells undergo progressive telomere DNA erosion
as a function of their number of cell divisions. This form
of senescence is now called as replicative or telomere-
dependent senescence (Fig. 1).
Human chromosome telomere ends are composed of
TTAGGG repeats (5–20 kb) in a DNA-protein complex
formed by six telomere-speciﬁc proteins, called ‘‘shelterin”
[13]. Telomeric DNA has a structure called ‘‘t-loop” which
is formed as a result of invasion of the single stranded G-
rich sequence into the double-stranded telomeric tract.
Since the 1930s, it has been known that telomeres, with
telomere-binding proteins, prevent genomic instability
and the loss of essential genetic information by ‘‘capping”
chromosome ends. They are also indispensable for proper
recombination and chromosomal segregation during cell
division. Telomeres become shorter with every cell divi-
sion in somatic cells, because of replication complex’s
inability to copy the ends of linear DNA, which also makes
them a ‘‘cell cycle counter” for the cell [14]. Telomeres are
added to the end of chromosomes with a complex contain-
ing the RNA template TERC and the reverse transcriptase
TERT [15]. Most somatic cells lack telomerase activity be-
cause the expression of TERT is repressed, in contrast to
TERC expression. The lack of sufﬁcient TERT expression in
somatic cells is the main cause of telomere shortening dur-
ing cell replication. This telomerase activity also helps to
maintain telomere integrity by telomere capping [15].
The loss of telomeres has long been considered to be the
critical signal for senescence induction. It is now well
known that telomere-dependent senescence is induced
by a change in the protected status of shortened telomeres,
whereby the loss of telomere DNA contributes to this
change [16]. The loss of telomere protection or any other
cause of telomere dysfunction results in inappropriate
chromosomal end-to-end fusions through non-homolo-
gous end joining or homologous recombination DNA repair
pathways [17]. These DNA repair pathways are used prin-
cipally to repair double-strand DNA breaks (DSBs). Thus, it
is highly likely that the open-ended telomere DNA is
sensed as a DSB by the cell machinery when telomere
structure becomes dysfunctional. Accordingly, dysfunc-
tional telomeres elicit a potent DSB type DNA damage re-
sponse by recruiting phosphorylated H2AX, 53BP1, NBS1
and MDC1 [18].
Telomere-dependent senescence is not the only form of
senescence. At least two other forms of telomere-indepen-
dent senescence are presently known: (1) oncogene-in-
duced senescence; and (2) reactive oxygen species (ROS)-
induced senescence (Fig. 1).
Oncogene-induced senescence had initially been identi-
ﬁed as a response to expression of Ras oncogene in normal
cells ([19], for a recent review see [20]). The expression of
oncogenic Ras in primary human or rodent cells results in
permanent G1 arrest. The arrest was accompanied by accu-
mulation of p53 and p16INK4a, and was phenotypically
indistinguishable from cellular senescence. This landmark
observation suggested that the onset of cellular senescence
does not simply reﬂect the accumulation of cell divisions,
but can be prematurely activated in response to an onco-
genic stimulus [19]. In 10 years following this important
discovery, telomere-independent forms of senescence have
become a new focus of extensive research leading to the
recognition of senescence as a common form of stress re-
sponse. Moreover, oncogene-induced senescence is now
recognized as a novel mechanism contributing to the ces-
sation of growth of premalignant or benign neoplasms to
prevent malignant cancer development [21]. In addition
to Ras, other oncogenes including Raf, Mos, Mek, Myc
and Cyclin E also induce senescence [20]. Conversely, the
loss of PTEN tumor suppressor gene also leads to senes-
cence [22]. Similar to telomere-dependent senescence,
oncogene-induced senescence is also primarily a DNA
damage response (Fig. 1). Experimental inactivation of
DNA damage response abrogates Ras-induced senescence
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and promotes cell transformation. DNA damage response
and oncogene-induced senescence are established follow-
ing DNA hyper-replication immediately after oncogene
expression. Senescent cells arrest with partly replicated
DNA, where DNA replication origins have ﬁred multiple
times, prematurely terminated DNA replication forks and
DNA double-strand breaks are present [23,24].
ROS-induced senescence, the other telomere-indepen-
dent senescence pathway is gaining importance (for a re-
cent review see Ref. [25]). Mitochondria are the major
intracellular sources of ROS which are mainly generated
at the respiratory chain. Therefore, ROS have been sus-
pected for many years as cellular metabolites involved in
organismal aging [26]. ROS are also generated in the cyto-
plasm by the NOX family of enzymes [27]. Experimental
induction of ROS accumulation in cells (for example by
mild H2O2 treatment or glutathione depletion) induces
senescence-like growth arrest in different cell types,
whereas anti-oxidant treatment can inhibit senescence
[25]. More importantly, ROS have been identiﬁed as critical
mediators of both telomere-dependent and oncogene-in-
duced senescence. Telomere-dependent senescence arrest
is accelerated in cells grown under high O2 conditions. In-
versely, cells grown under low O2 conditions display in-
creased lifespan ([28], see Ref. [25]). ROS also play a
critical role in Ras-induced senescence [29,30].
Currently, mechanisms of ROS-induced senescence are
not fully understood. It is generally accepted that oxidative
stress and ROS eventually cause DNA damage, whereby
DNA damage response may contribute to senescence
induction. The relationship between mitochondrial dys-
function, ROS, DNA damage and telomere-dependent
senescence has recently been demonstrated [31]. However,
ROS may also induce modiﬁcations in the cellular signaling
pathways resulting in senescence arrest. For example, ROS
induce senescence in hematopoietic stem cells by activat-
ing p38 MAPK [32].
Whether induced by telomere dysfunction, DNA repli-
cation stress following oncogene activation, or ROS accu-
mulation, DNA damage is one of the common steps in
the generation of senescence arrest via p53 activation
(Fig. 1). Upstream checkpoint kinases, such as ATM or
ATR are activated in response to DNA damage in the form
of double-stand breaks. These kinases phosphorylate
ATM/ATR/
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Fig. 1. DNA damage and p53 activation play a central role in different senescence pathways. DNA damage (often in the form of double-strand breaks)
activate upstream kinases (ATM and ATR) leading to p53 phosphorylation by CHK1 and CHK2 kinases. Phosphoryated p53 is released from MDM, and
stabilized in order to induce senescence arrest or apoptosis (not shown here).
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downstream factors including CHK1 and CHK2 that in turn
phosphorylate p53. Phosphorylation of p53 results in its
activation by the displacement of the MDM2 protein. Crit-
ical involvement of this p53 activating pathway has been
reported for both telomere-dependent [33], and onco-
gene-induced senescence [34].
Other mechanisms of senescence that are apparently
not driven by DNA damage should also be discussed here.
Of particular interest is the INK4 locus encoding two inhib-
itors of cyclin-dependent kinases (p16INK4a, p15INK4b), and
ARF, a p53 regulatory protein (for a review see Ref. [35]).
p16INK4a and p15INK4b connect some senescent initiating
signals to the retinoblastoma (Rb) pathway, independent
of p53 activation. These proteins are easily activated in cell
culture and induce senescence arrest. Cells that escape
senescence often display inactivation of p16INK4a, and
sometimes p15INKb and ARF either by homozygous deletion
or by shutting-down gene expression. A prominent role for
p16INK4a in senescence and tumor suppression in humans
has emerged, despite some confusion due to the fact that
a relatively small DNA segment encodes the 3 proteins of
the INK4 locus. p16INK4a is activated during telomere-
dependent and oncogene-induced senescence [19,36].
Moreover, its expression is induced in aging tissues [37].
The mechanisms of regulation of p16INK4a expression are
not well known. Although individual components of INK4
locus can respond independently to positively – (for exam-
ple to Ras) or negatively – (for example c-Myc) acting sig-
nals, the entire INK4 locus might be coordinately regulated
by epigenetic mechanisms (reviewed in Ref. [35]).
A very recent addition to the list of senescence mecha-
nisms is to be qualiﬁed as ‘‘senescence induced by secreted
proteins”. It was reported many years ago that TGF-b is a
mediator of oncogene-induced senescence [38]. This
mechanism of induction is of particular interest, because
it suggests that not only intrinsic cellular factors, but also
extracellular or secreted proteins can induce senescence.
Recent discovery of several other secreted proteins, includ-
ing IGFBP7 and IL6 as autocrine/paracrine mediators of
oncogene-induced senescence arrest, provide strong sup-
port for an extracellularly induced form of senescence
[39–41]. This new form of senescence regulation is remi-
niscent of the so called active apoptosis induction by death
ligands. Thus, an active form of cellular senescence in-
duced by ‘‘aging ligands” could be a major physiological
regulator of tissue/organism aging.
3. Cyclin-dependent inhibitors as commonmediators of
senescence arrest
We have already stated that senescence and apoptosis
share interesting similarities. Another similarity between
these cellular processes is the convergence of different
pathways in a common place to induce the same cell fate,
independent of the initial signal. Similarly to caspase acti-
vation, prior to apoptosis induction by different stimuli,
most if not all senescence pathways result in the activation
of cyclin-dependent kinase inhibitors (CDKIs) in order to
induce permanent cell cycle arrest. Senescent cells accu-
mulate at G1 phase of the cell cycle due to an inability to
enter into S phase in order to initiate DNA synthesis. The
transition of proliferating cells from G1 to S phase requires
the release of E2F factors from their inhibitory partner ret-
inoblastoma protein (pRb) following phosphorylation by
cyclin-dependent kinases (CDKs), in particular by CDK4/
CDK6 and CDK2 at this stage of the cycle [35]. The senes-
cence arrest is mediated by inhibition of pRb phosphoryla-
tion by CDK4 and CDK2. The activities of these enzymes are
controlled by different mechanisms, but the major proteins
involved in the control of senescence arrest are CDKIs. Al-
most all known CDKIs have been reported to be implicated
in senescence arrest, but three of them are best character-
ized: p16INK4a and p15INK4b which inhibit CDK4/CDK6, and
p21Cip1 which inhibits CDK2 (Fig. 2).
p21Cip1 is one of the main targets of p53 for the induc-
tion of cell cycle arrest following DNA damage [42]. Path-
ways that generate DNA damage response and p53
activation use p21Cip1 as a major mediator of cellular
senescence to control pRb protein [43]. Exceptionally,
p21Cip1 can be activated by p53-independent pathways to
induce senescence [44].
The Rb protein plays two important and complemen-
tary roles that are necessary to initiate and to permanently
maintain the cell cycle arrest in senescent cells. pRb pro-
teins ﬁrstly contribute to the exit from the cell cycle by
arresting cells at G1 phase, as expected [45]. In senescent
cells, this exit is complemented with a dramatic remodel-
ing of chromatin through the formation of domains of fac-
ultative heterochromatin called SAHF [46–48]. SAHF
contain modiﬁcations and associated proteins characteris-
tic of transcriptionally silent heterochromatin. Prolifera-
tion-promoting genes, such as E2F target genes are
recruited into SAHF in a pRb protein-dependent manner.
This recruitment is believed to contribute to irreversible
silencing of these proliferation-promoting genes [49].
4. Senescence of hepatocytes and chronic liver disease
Hepatocytes in the adult liver are quiescent cells, they
are renewed slowly, approximately once a year, as esti-
mated by telomere loss which is 50–120 bp per year in
healthy individuals [50,51]. However, the liver has an ex-
tremely powerful regenerative capacity, as demonstrated
experimentally in rodents, and as observed in patients
with chronic liver diseases [5]. This regenerative capacity
is due mostly to the ability of mature hepatocytes to prolif-
erate in response to a diminution of total liver mass either
experimentally, or following exposure to viral and non vir-
al hepatotoxic agents. In addition, the adult liver seems to
harbor hepatocyte-progenitor cells (<0.10% of total hepato-
cyte mass) that are able to restore liver hepatocyte popula-
tions [52]. However, hepatocytes, like any other somatic
cells, do not have unlimited replicative capacity, due to
the lack of telomerase activity that is needed to avoid telo-
mere shortening during successive cell divisions. This is
best exempliﬁed by decreased hepatocyte proliferation in
liver cirrhosis stage of chronic liver diseases [53], providing
in vivo evidence for the exhaustion of hepatocyte prolifer-
ation capacity. Senescence mechanisms in hepatocytes and
in liver tissue are not well known. However, a limited
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number of in vitro studies with hepatocytes, as well as
numerous descriptive in vivo studies in liver tissue provide
sufﬁcient evidence that hepatocytes can undergo senes-
cence type changes.
In vitro senescence in hepatocytes: as stated earlier,
limited proliferative capacity of somatic cells is controlled
by replicative senescence. The experimental study of repli-
cative senescence is done traditionally by serial culture of
primary cells. Initially observed in ﬁbroblasts, this phe-
nomenon has also been well understood in some epithelial
cells, mammary epithelial cells in particular [54]. On the
other hand, our knowledge of hepatocyte replicative senes-
cence is highly limited. In contrast to in vivo conditions,
mature hepatocytes are extremely resistant to cell prolifer-
ation in cell culture. Usually, more than 99.9% of adult liver
hepatocytes do not divide and can only be maintained in
culture for a few weeks at most. A small progenitor-type
cell population (so called small hepatocytes) has been
shown to proliferate in vitro, but they usually stop growing
at passages 5–7, with an ill-deﬁned senescence-like pheno-
type [55].
Fetal hepatocytes display better proliferation capacity
in culture. A few studies have shown that these fetal cells
enter replicative senescence, as shown by senescence-
associated b-galactosidase assay (SABG) at population dou-
bling (PD) 30–35 [55]. This is accompanied by progressive
shortening of telomeres down to 6 kbp, as these cells like
adult hepatocytes lack telomerase activity. However, it was
possible to immortalize these fetal hepatocytes by stable
expression of TERT [55]. Such immortalized cells have been
expanded beyond known senescence barriers (>300 PD).
In vivo senescence in liver tissue: in contrast to in vitro
studies, in vivo senescence of human hepatocytes is better
known. Indeed, the liver is one of the rare tissues where
in vivo evidence for senescence has been convincingly
and independently demonstrated by different investigators
[6–9]. Replicative senescence (as tested by SABG assay)
displayed a gradual increase from 10% in normal liver, to
84% in cirrhosis ([6,7]. It was also detected in 60% HCCs
[6]. It has also been demonstrated that telomere shorten-
ing in cirrhosis is restricted to hepatocytes and this hepa-
tocyte-speciﬁc shortening was correlated with SABG
staining [7].
Potential mechanisms of senescence in hepatocytes and
the liver: as presented in detail in the previous section,
multiple pathways of senescence have been described in
different experimental systems. Key molecules that are al-
ready involved in senescence arrest have also been sum-
marized. The published data on different senescence
pathways in the liver is fragmented and control mecha-
nisms involved in hepatocyte senescence are not com-
pletely understood. Therefore, existing data on
hepatocellular senescence together with potential mecha-
nisms that may be involved in this process will be
presented.
For reasons previously described, almost nothing is
known about molecular mechanisms involved in replica-
tive senescence and immortalization of hepatocytes in cul-
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ture. There are only a few demonstrations of hepatocyte
immortalization in vitro. Thus, ectopically expressed TERT
may induce hepatocyte immortalization. However, as the
published data using TERT immortalization is scarce, it is
highly likely that the immortalization of hepatocytes is
not an easy task even with a well-established protocol that
works with other epithelial cell types such as mammary
epithelial cells. The mechanisms of in vitro senescence
induction in hepatocytes are also mostly unknown. Rapid
induction of a senescence arrest in cultured hepatocytes
suggests that these cells display robust telomere-indepen-
dent senescence-inducing systems that are functional
in vitro. However, they remain to be discovered. It is highly
likely that, similar to other somatic cells, p53 and RB path-
ways in general, and some CDKIs in particular are also in-
volved in hepatocyte senescence, but the evidence is
lacking for the time being.
Telomere shortening during aging is slow (55–120 base
pairs per year) and stabilizes at mid age in healthy liver, so
that the loss of telomeric DNA does not reach a level to in-
duce telomere dysfunction and DNA damage response
[50,51]. Other forms of telomere-independent senescence
such as ROS-induced senescence may also be rare under
normal physiological conditions. On the other hand, telo-
mere loss is accelerated in chronic liver disease to reach
lowest levels in the cirrhotic liver [7,51]. Therefore, one
plausible mechanism involved in cirrhosis is probably telo-
mere-dependent senescence, or replicative senescence.
The relevance of replicative senescence to liver tissue aging
has been demonstrated experimentally using telomerase-
deﬁcient mice. Late generation telomerase-deﬁcient mice
display critically shortened telomeres and an impaired li-
ver growth response to partial hepatectomy. A subpopula-
tion of telomere-shortened hepatic cells displayed
impaired proliferative capacity that is associated with
SABG activity [11,56]. On the other hand, it has been re-
ported that mouse liver cells are highly resistant to exten-
sive telomere dysfunction. Conditional deletion of the
telomeric protein TRF2 in hepatocytes resulted in telomer-
ic accumulation of phospho-H2AX and frequent telomere
fusions, indicating loss of telomere protection. However,
there was no induction of p53 and liver function appeared
unaffected. The loss of TRF2 did not compromise liver
regeneration after partial hepatectomy. Liver regeneration
occurred without cell division involving endoreduplication
and cell growth, thereby circumventing the chromosome
segregation problems associated with telomere fusions.
Thus, it appears that hepatocytes display intrinsic resis-
tance to telomere dysfunction, although they are appar-
ently vulnerable to severe telomere loss [57].
Hepatocyte senescence that is observed in severe
chronic liver diseases such as cirrhosis may also be induced
by telomere-independent pathways. Chronic liver injury
observed under such conditions is accompanied with
inﬂammation, cell death, and oxidative stress [58–60].
Some of the etiological factors such as HCV and alcohol in-
duce mitochondrial dysfunction may result in ROS accu-
mulation [61,62]. Thus, ROS-induced senescence may also
occur during cirrhosis, although this has not yet been re-
ported. The status of DNA damage in chronic liver disease
is less well-known. 8-Hydroxydeoxyguanosine, an indica-
tor of DNA lesions produced by ROS, was reported to be in-
creased in chronic liver disease [63]. On the other hand, the
upregulation of DNA repair enzymes in cirrhosis has also
been reported [64]. Increased DNA repair activity in cirrho-
sis which may reﬂect increased DNA damages as a conse-
quence of chronic liver injury, but also inhibition of DNA
damage responses such as senescence were observed. Ta-
ken together, these observations suggest that the primary
cause of senescence in cirrhotic patients is telomere dys-
function and that ROS may also play additional roles.
Among senescence-related proteins, p16INK4a and
p21Cip1 expression was found to be high in cirrhosis, as
compared to normal liver and tumor tissues [65], suggest-
ing that these major senescence-inducing proteins accu-
mulate in the cirrhotic liver. Promoter methylation of
these CDKIs was also studied. Chronic liver disease sam-
ples displayed lower levels of methylation as compared
to HCCs [66]. Thus, the progression of chronic liver disease
towards cirrhosis is accompanied with a progressive acti-
vation of different CDKIs, as expected.
5. Senescence pathway aberrations and telomerase
reactivation in hepatocellular carcinoma
As stated earlier, p53 and retinoblastoma (Rb) pathways
play a critical role in senescence arrest as observed in dif-
ferent in vitro and in vivo models. Indirect evidence sug-
gests that these pathways may also be important in
hepatocellular senescence. The accumulation of p21 and
p16 in cirrhotic liver tissues has been reported indepen-
dently by different reports. On the other hand, HCC rarely
develops in liver tissues absent of chronic liver disease.
More than 80% of these cancers are observed in patients
with cirrhosis [9]. As the appearance of proliferating malig-
nant cells from this senescence stage requires the bypass of
senescence, the status of both p53 and RB pathways in HCC
is of great importance in terms of molecular aspects of
hepatocellular carcinogenesis.
HCC is one of the major tumors displaying frequent p53
mutations [67,68]. The overall p53 mutation frequency in
HCC is around 30%. Both the frequency and the spectrum
of p53 mutations show great variations between tumors
from different geographical areas of the World. A hotspot
mutation (codon 249 AGG? AGT) has been linked to
exposure to aﬂatoxins which are known to be potent
DNA damaging agents (for a review see Ref. [67]).
Although, it is unknown whether aﬂatoxins are able to
generate a DNA damage-dependent senescence response
in hepatocytes, their association with DNA damage and
p53 mutation provides indirect evidence for such an abil-
ity. Other p53 mutations described in HCCs from low aﬂa-
toxin areas may similarly be correlated with other DNA
damaging agents, such as ROS which are known to accu-
mulate in the livers of patients with chronic liver diseases,
including cirrhosis.
Another player of senescence arrest, the p16 gene is
rarely mutated in HCC, but its epigenetic silencing by pro-
moter methylation is highly frequent in this cancer. More
than 50% of HCCs display de novo methylation of the pro-
moter of CDKN2A gene, encoding p16 protein, resulting in
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loss of gene expression [67]. Major components of p53 and
Rb pathways in the same set of HCCs with different etiolo-
gies have been analyzed [69]. Retinoblastoma pathway
alterations (p16 INK4a, p15INK4b or RB1 genes) were present
in 83% of HCCs, whereas p53 pathway alterations (p53 or
ARF genes) were detected in only 31% of tumors. Altera-
tions in both Rb and p53 pathways were present in 30%
of HCCs. Thus, it appears that either the Rb and/or the
p53 pathway are affected in the great majority of HCCs,
and that both pathways are affected in at least one third
of these tumors. Unfortunately, p53 and p16INK4a aberra-
tions observed in HCC have not yet been studied in relation
to senescence aberrations. However, these observations
provide supporting evidence on the critical role of senes-
cence-controlling pathways in the development of HCC.
The lack of telomerase activity in normal and cirrhotic
liver correlates with progressive loss of telomere
sequences ending up with a senescence arrest. The
emergence of malignant hepatocytes from this senes-
cence-dominated cirrhotic milieu would require not only
the bypass of senescence, but also a way of survival despite
critically shortened telomeres. Additionally, the prolifera-
tive expansion of neoplastic cells in order to form
sustained tumor masses would require telomeres at a min-
imal length required to maintain intact chromosomal
structures.
Many studies showed that telomerase activity is a hall-
mark of all human cancers, including 80–90% of HCCs
[70–72]. It is currently unclear how the TERT expression
is repressed and released in normal hepatocytes and HCC
cells, respectively. The integration of HBV DNA sequences
into TERT gene provides evidence for a virus-induced
deregulation of TERT expression, but this appears to rarely
occur, as only four cases have been reported thus far [73–
75]. Hbx and PreS2 proteins may upregulate TERT expres-
sion [76,77]. The molecular mechanisms involved in TERT
suppression in somatic cells and its reactivation in cancer
cells are ill-known. The TERT promoter displays binding
sites for a dozen of transcriptional regulators: estrogen
receptor, Sp1, Myc and ER81 acting positively, and vitamin
D receptor, MZF-2, WT1, Mad, E2F1 and SMAD interacting
protein-1 (SIP1, also called ZEB-2 or ZFHX1B) acting nega-
tively [78]. Despite high telomerase activity, telomeres in
HCC were repeatedly found to be highly shortened
[65,79,80]. However, 30 telomere overhangs were found
to be increased in nearly 40% HCCs [80]. Moreover, the
expression of several telomeric proteins is increased in
HCC [80,81].
Another ill-known aspect of TERT activity in HCC cells is
the cellular origin of these malignant cells. It is presently
unclear whether HCC arises from mature hepatocytes
which lack telomerase activity, or stem/progenitor cell-like
cells that may already express TERT at sufﬁcient levels to
maintain telomere integrity. In the non-tumor area sur-
rounding the cancer tissue, telomerase activity could not
be detected, or was detected at very low levels.
The importance of telomerase activity in HCC
development has been studied experimentally using telo-
merase-deﬁcient mouse model. These mice show in-
creased susceptibility to adenoma development (tumor
initiation), but they are quite resistant to fully malignant
tumor development [82]. Likewise, telomerase deletion
limits the progression of p53-mutant HCCs with short telo-
meres [83]. These observations suggest that the aberra-
tions affecting telomerase activity and senescence
controlling genes such as p53 may cooperate during hepa-
tocellular carcinogenesis.
In summary, HCC is characterized by mutational inacti-
vation of p53, a major player in DNA damage-induced
senescence. In addition, p15INK4b, p16INK4a, p21Cip1 CDKIs
are often inactivated in this cancer mostly by epigenetic
mechanisms involving promoter methylation. These
changes may play a critical role in the bypass of senescence
that is observed in most cirrhosis cases, allowing some ini-
tiated cells to escape senescence control and proliferate. In
the absence of telomerase activity such cells would proba-
bly not survive due to telomere loss. However, since more
than 80% of HCCs display telomerase activity, it is highly
likely that the telomerase reactivation, together with the
inactivation of major CDKIs, plays a critical role in HCC
development by conferring premalignant or malignant
cells the ability to proliferate indeﬁnitely (Fig. 3). However,
cellular immortality is not sufﬁcient for full malignancy
[84]. Thus, senescence-related aberrations that are ob-
served in HCC cells, may confer a partial survival advan-
tage that would need to be complemented by other
genetic or epigenetic alterations.
6. Senescence as an anti-tumor mechanism in
hepatocellular carcinoma
Senescence in normal somatic cells and tissues is ex-
pected. How about cancer cells and tumors? Initial studies
using different cancer cell lines provided ample evidence
for the induction of senescence by different genetic as well
as chemical or biological treatments [85]. Thus, it appeared
that cancer cells, immortalized by deﬁnition, do have a
hidden senescence program that can be revealed by differ-
ent senescence-inducing stimuli. These studies provided
preliminary evidence for considering senescence induction
as an anti-cancer therapy. The in vivo relevance of these
observations and expectations became evident only very
recently. Senescence was observed in tumors or pre-neo-
plastic lesions. SABG activity as well as several other senes-
cence markers were detected in lung adenomas, but not in
adenocarcinomas observed in oncogenic Ras ‘‘knock-in”
mice [86]. Ras-driven mouse T-cell lymphomas entered
senescence after drug therapy, when apoptosis was
blocked [87]. The ﬁrst direct evidence of cellular senes-
cence in humans was reported for the melanocytic nevus
[88].
Senescence response of HCC cells was not the subject of
intensive study until very recently. Therefore the potential
role of senescence in these tumors is less well understood.
Treatment of HCC cell lines with 5-aza-2-deoxycytidine in-
duced the expression of p16INK4a, hypophosphorylation of
pRb and G1 arrest associated with positive SABG staining
[89]. Recent ﬁndings indicate that senescence induction
is a powerful mechanism of HCC regression. Xue et al. ex-
pressed H-ras oncogene and suppressed endogenous p53
expression in mouse hepatoblasts which produced massive
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HCCs upon implantation into livers of athymic mice [12].
However, these tumors regressed rapidly upon restoration
of p53 expression. Tumor regression was due to differenti-
ation and massive senescence induction, followed by im-
mune-mediated clearance of senescent cells. These
observations may indicate that oncogene-induced senes-
cence is also involved in HCC. On the other hand, HCCs in-
duced by tet-regulated c-Myc activation in mouse liver
cells differentiate into mature hepatocytes and biliary cells
or undergo senescence [90]. Thus, senescence induction
may also be relevant to oncogene inactivation in HCC. In
this regard, c-Myc down-regulation and senescence induc-
tion in several HCC cell lines as a response to TGF-b was
observed (S. Senturk, M. Ozturk, unpublished data).
So far, all the reported examples of senescence induc-
tion in HCC cells are in the form of a telomere-independent
permanent cell cycle arrest. Until recently, it was unknown
whether replicative senescence could also be induced in
immortal cancer cells. Ozturk et al. reported recently that
immortal HCC cells can revert spontaneously to a replica-
tive senescence phenotype [91]. Immortal HCC cells gener-
ated progeny that behaved, in vitro, similar to normal
somatic cells. Such senescence-programmed progeny
lacked telomerase activity due to TERT repression (proba-
bly mediated by SIP1 gene), and displayed progressive
telomere shortening in cell culture, resulting in senescence
arrest. It will be interesting to test whether such spontane-
ous reversal of replicative immortality is involved in well
known tumor dormancy and/or spontaneous tumor
regression.
7. Concluding remarks
Cellular senescence has gained great interest in recent
years following the demonstration that it also occurs
in vivo. It is also highly interesting that senescence can
be mediated by a large number of pathways and mole-
cules, as is the case for apoptosis. Recent ﬁndings that
implicate secreted molecules in senescence induction
strongly suggest that cellular senescence is not just a cellu-
lar event, but also a physiologically relevant process for the
whole organism. In terms of tumor biology, oncogene-in-
duced senescence that may serve as anti-tumor mecha-
nism in pre-neoplastic lesions underlines its clinical
relevance. On the other hand, induced or spontaneous
senescence that is observed in cancer cells is promising
to explore new approaches for tumor prevention and treat-
ment. The role of senescence bypass and cellular immortal-
ity in hepatocellular carcinogenesis is not well deﬁned.
But, many ﬁndings (inactivation of senescence-mediator
genes such as p53, p16INK4a and p15INK4b, as well as reacti-
vation of TERT) indicate that senescence mechanisms and
their aberrations are critically involved in HCC. We may
expect that this ﬁeld will attract more attention in coming
years for a better deﬁnition of senescence implications in
hepatocellular carcinogenesis.
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